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Chronic liver disease remains a significant cause of morbidity and mortality globally. 
Transplantation is the only effective treatment for end-stage disease but is limited by organ 
availability, surgical complications and risks of long term immunosuppression. Novel 
therapies for advanced disease are therefore required. The liver has a remarkable capacity 
to regenerate through division of mature hepatocytes, however in chronic or severe 
disease hepatocyte replication fails, senescence occurs and liver failure ensues. Ductular 
reactions (DRs), containing hepatic progenitor cells capable of repopulating the 
parenchyma, arise in chronic liver injury when hepatocyte regeneration is impaired. 
Enhancing this endogenous repair mechanism is a key therapeutic goal. Notch and Wnt are 
key signals required for liver regeneration, however to date they have principally been 
characterised in end-point disease and the temporal kinetics of these signalling pathways 
not known. 
I sought to identify if these signals control expansion of DRs after hepatocyte injury and 
whether they can be therapeutically manipulated. I examined the dynamics of Notch and 
Wnt activity using a genetic model of hepatocellular injury and ductular-mediated 
regeneration whereby induction of injury could be timed, synchronising the regenerative 
response. Using lineage tracing, small molecules, blocking antibodies and genetic loss of 
function experiments I defined distinct time-sensitive Notch and Wnt signatures where 
early regeneration is driven by Notch and the later response by Wnt. I demonstrated that 
inhibition of Notch1 and Notch3 but not Notch2 reduces the generation of DRs. I identified 
that DRs were a source of potent growth hormone IGF1 and this production was Wnt 
driven. Notch driven expression of IGF1-receptor within DRs identified this axis as a node 
for cooperation between Notch and Wnt signals. Blocking the IGF1 axis prevented DR 
expansion, which conversely could be enhanced by administration of recombinant IGF1.  
Here, I functionally defined complex temporal dynamics controlling of DRs and identified 





Chronic liver disease remains a significant cause of death and poor health worldwide. Liver 
transplantation is a treatment for advanced disease but there are insufficient organs 
available and significant risks of surgery and long term use of anti-rejection drugs. This 
means new types of treatment need to be developed. The liver has a remarkable ability to 
repair itself by replication of liver cells or hepatocytes, however in the case of severe or 
long-term damage this can become overwhelmed. The liver also contains a further type of 
cell called hepatic progenitor cells (HPCs) that can behave like ‘stem cells’ and contribute to 
liver regeneration when the hepatocytes fail. Understanding this process may help identify 
targets for drugs to enhance this method of liver repair. I focused my work on investigating 
chemical signalling pathways used by the developing liver to see if they controlled 
expansion of HPCs after injury. I identified that these pathways behave in a dynamic way, 
taking turns to control expansion. I also identified that these pathways can cooperate and 
took advantage of this to enhance the regenerative response. This work identifies targeting 
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1.1 Liver disease – the clinical problem 
Chronic liver disease is a significant cause of morbidity and mortality globally (1). In the 
United Kingdom disease incidence continues to rise with an approximately 50% increase 
between 1998 and 2009 (2). An evolutionary necessity in an organ whose principal roles 
include removal of toxins, the liver possesses a remarkable capacity to repair and 
regenerate itself. However in cases of severe or chronic injury these processes become 
overwhelmed and liver failure ensues. Transplantation is the only effective treatment for 
end-stage disease but is limited by organ availability, surgical complications and risks of 
rejection and long-term immunosuppression. Novel therapies for advanced disease are 
therefore required.  
1.2 Liver development 
An appreciation of liver development and the structure of the adult organ are helpful to 
understanding liver injury and repair. Anatomically the lobes of the adult liver are divided 
into lobules, a classical hexagonal arrangement of sheets or plates of hepatocytes radiating 
around a central draining vein (see Figure 1.1). Located along the lobule perimeter, the 
portal triad consists of a small portal vein, hepatic artery and bile duct. Blood flows from 
the portal tract through hepatic sinusoids towards the central vein. Highly specialised 
sinusoidal fenestrated endothelium permits contact between the basolateral surface of 
hepatocytes and the blood. Associated with the sinusoids are macrophages with key 
immune and repair functions and resting stellate cells, which maintain extracellular matrix 
but transform into activated myofibroblasts after injury and are responsible for scar 
deposition. Tight junctions between the apical surfaces of hepatocytes form bile canaliculi 
which drain newly synthesised bile into ducts lined with biliary epithelial cells also known as 
cholangiocytes. The area of interface between bile duct and canaliculus is termed the Canal 






Figure 1.1: Structure of the liver lobule: Sheets of plates of hepatocytes radiate around the 
central vein (CV). At the periphery of the lobule are the portal triads, consisting of a branch 
of the portal vein (PV), hepatic artery and a bile duct. The most peripheral hepatocytes, 
receiving the most oxygenated blood are termed zone 1 (Z1) hepatocytes. Those closest to 
the central vein are in zone 3 (Z3). Blood enters the liver from the portal vein and hepatic 
artery, flowing through sinusoids towards the central vein. Hepatocytes form sheets with 
their basolateral surface associated with sinusoidal fenestrated endothelium permitting 
contact between blood and hepatocytes. Closely associated with the sinusoids are 
numerous macrophages or Kupffer cells and in the space of Dissé separating hepatocytes 
from sinusoids are extracellular matrix components and stellate cells. The hepatocytes’ 
apical surface forms a bile canaliculus which drains newly synthesised bile into ducts lined 
by biliary epithelial cells or cholangiocytes. The junction between canaliculus and duct is 
termed the Canal of Hering. PV, portal vein; CV, central vein 
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The two mature liver epithelial cell types, hepatocytes and cholangiocytes share a common 
embryonic liver progenitor cell termed hepatoblast. These cells derive from three domains 
within the endoderm that migrate to fuse into a single prehepatic domain adjacent to the 
cardiogenic medosderm. At this stage the first molecular evidence of liver ‘specification’ 
occurs: the expression of albumin, transthyretin and alpha-fetoprotein (4, 5). Subsequently 
a liver diverticulum forms from the specified cells, now designated hepatoblasts, expressing 
the markers Dlk, E-cadherin and Liv2 (6-8). These cells proliferate and form a tissue bud 
within a basement membrane of laminin, collagen IV, nidogen, fibronectin and heparin 
sulfate proteoglycan (9). The hepatoblasts then migrate through the basement membrane, 
leaving the endoderm for the septum transversum. Here, under control of growth factors 
including hepatocyte growth factor (HGF) (10), continuing proliferation and liver expansion 
occurs.  
Ultimately the hepatoblasts make a fate decision: hepatocyte or cholangiocyte lineage (11). 
Cells adopting the cholangiocyte lineage align around branches of the portal vein to form a 
single layered ring called the ductal plate. Areas within the ductal plate become 
asymmetrical bi-layered arrangements which mature under the influence of SRY-related 
HMG box transcription factor 9 (SOX9) (12) to form luminal structures giving rise to bile 
ducts. Each ductal plate gives rise to an average of two bile ducts per portal tract (13) and it 
was initially proposed that the ductal plate cells that did not become bile ducts apoptose. 
Subsequently the ductal plate has been shown to also generate canals of Hering and 
hepatocytes of the periportal region (14). Cells adopting the hepatocyte lineage undergo a 
process of maturation involving a set of transcription factors, commonly referred to as liver-
enriched factors including hepatic nuclear factor (HNF)-1 alpha and HNF-4 alpha that form a 
network of auto-regulatory and cross-regulatory loops (15).  
Functions of all hepatocytes (e.g. gene expression and biochemical activities) are not 
equivalent and depends on their physical location within the lobule and this maturation 
continues in the first weeks after birth (16). From a metabolic perspective, rather than the 
anatomically defined lobular unit, the functional unit of the liver is the hepatic acinus. This 
represents all liver parenchyma supplied by a terminal branch of the portal vein and hepatic 
artery. Zone one (periportal) hepatocytes are located nearest to the entering vascular 
supply and thus receive the most oxygenated blood, zone 3 (pericentral) hepatocytes are 
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located closest to the central vein and therefore most sensitive to ischaemia. The metabolic 
functions of hepatocytes from each zone are distinct (17). For example zone 1 hepatocytes 
are specialised for oxidative functions such as gluconeogenesis, cholesterol synthesis and 
express urea cycle enzymes for the conversion of ammonia. Zone 3 cells are important for 
glycolysis, cytochrome P450-based drug detoxification, express glutamine synthase (GS) 
and utilise ammonia to generate glutamine (18). One key mechanism by which this 
functional zonation is maintained is via signalling molecules or morphogens (19). Wnt/beta-
catenin signalling was the first identified ‘zonation keeper’ (20). Further examples include 
members of the fibroblast growth factor (FGF) family (21), the transforming growth factor 
(TFG)-beta family (22), including bone morphogenetic proteins (BMPs), Notch (23-25), 
hepatocyte growth factor (HGF) (26, 27) and possibly Hedgehog signalling (28). Not 
surprisingly roles for these same morphogens have been implicated in liver development 
and regeneration. 
1.3 Liver regeneration – potential methods 
Two modes of liver regeneration have been demonstrated and are illustrated in Figure 1.2. 
In the first, for example after surgical removal of up to two-thirds of the liver (2/3 partial 
hepatectomy (PH)), the remaining hepatocytes and other liver cells are not injured and 
enlarge and divide to rapidly regenerate the liver in a process known as ‘compensatory 
hypertrophy’ (29, 30). Provided the ability of hepatocytes and cholangiocytes to divide 
remains intact, similar methods are also responsible for regeneration after a range of acute 
and chronic insults (31-33). There is evidence that the ability of mature hepatocytes to 
replicate declines in advanced disease. In rodent models there is reduction of hepatocyte 
DNA synthesis after partial hepatectomy in animals with cirrhosis (34, 35). In humans, 
cirrhosis is associated with expression of markers of cell cycle arrest in hepatocytes (36, 37) 





Figure 1.2: Methods of liver regeneration: (A) After hepatocyte injury, remaining 
hepatocytes reconstitute the liver mass by a combination of hypertrophy and proliferation. 
(B) In instances of severe or chronic injury, ultimately the regenerative capacity of 
hepatocytes becomes impaired. Facultative stem cells derived from the biliary 
compartment become activated, producing bipotential progenitor cells which are capable 
of expanding and differentiating into hepatocytes or cholangiocytes as required. (C) After 
severe biliary injury it is also likely that this process can happen in reverse, with 





The second regenerative strategy, proposed to contribute to regeneration after severe or 
chronic injury involves the activation of ‘stem cells’. The term ‘stem cell’ is probably not 
entirely appropriate in the liver. The strict definition of cells that are resident clonal 
precursors of both more stem cells of the same type, as well as a defined set of 
differentiated progeny, confirmed through in vivo transplantation and reconstitution assays 
(38-40) has not been met. There is no cell type visible routinely in the uninjured adult liver 
that has the functions of a fully committed tissue-specific stem cell akin to the cells of the 
intestinal crypts (41), the basal layer or the epidermis (42), bone marrow (43, 44) or bone 
(45). However, even in tissues with a clearly defined resident stem cell population such as 
skin and intestine, other populations of cells can act as stem cells, such as label retaining 
bulge cells in the hair follicle (46) and the label retaining +4 cell in the intestine (47-49). The 
+4 position intestinal stem cell is considered the prototype of a ‘facultative’ tissue stem cell, 
i.e. only active when required in very specific circumstances. These cells have subsequently 
been shown to have a bidirectional relationship with Lgr5+ classical intestinal stem cells 
(47). 
The term ‘facultative’ stem cell is also preferred when applied to the liver. Although here 
rather than a resident dedicated tissue stem cell that can be called upon to form multiple 
cell types should the need arise, the mature and apparently terminally differentiated 
hepatocyte and cholangiocyte epithelia serve to regenerate themselves and each other 
through what is probably a bipotent ‘progenitor’ intermediate (33). Investigators disagree 
whether this process represents transdifferentiation or ‘stem cell’-like activity and whether 
either mature epithelial type, or both, and whether all, or only a subset have this capacity. 
Descriptive studies support that progenitor mediated regeneration occurs in humans (50, 
51), and regeneration of hepatocytes from cells of biliary origin has been demonstrated in 
zebrafish (52, 53), the rat (54, 55) and the mouse (56-59). In these settings there is 
activation and expansion of ductular cells. Within this ductular expansion are cells known 
differentially as hepatic progenitor cells (HPCs), liver progenitor cells (LPCs), oval cells, or 
sometimes ductular hepatocytes in humans. For consistency I will use the term HPC 
throughout this thesis. As not all the cells in these ductular expansions are confirmed 
bipotent progenitors, the term ‘ductular reaction’ has been coined (60, 61), although 
technically speaking this term should include any associated inflammatory niche (62). These 
cells form ductular structures extending from the terminal biliary ductules, the interface 
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between hepatocytes and duct known as the canals of Hering (3, 63, 64). First described in 
the portal areas of rat livers after chemical injury, these cells express markers of 
hepatocytes (albumin) and biliary epithelial cells (cytokeratin 19) in a similar manner to 
foetal hepatoblasts (65-67). This led to speculation that these cells may be common 
precursors for both hepatocytes and biliary cells after injury in the adult although 
disagreement persists as to whether it is only this canal of Hering subset, or potentially all 
or at least more cholangiocytes that have this capacity as demonstrated by several 
independent studies (52, 68-70). The degree of contribution of biliary derived HPCs to 
hepatocyte regeneration is likely determined by the degree to which hepatocyte 
regeneration is impaired. Indeed the number of HPCs correlates with disease severity in 
human chronic liver diseases (71). Use of this second repair mechanism may be dependent 
on inhibition of hepatocyte proliferation following induction of p21 (59, 72) and thus animal 
models that do not replicate this feature of human disease will not demonstrate significant 
repopulation of the parenchyma by HPCs of biliary origin (33). The now strong evidence of 
the potential for cells of biliary origin to regenerate hepatocytes supports the study of HPCs 
as an in situ or ex vivo resource that can be targeted by novel therapies to enhance liver 
repair.  
1.4 Defining HPCs 
A limitation of studies using adult HPCs is their lack of unique cell surface markers, and lack 
of consensus regarding which combination of non-specific markers identifies those with 
repopulation capacity (36, 73). Historically HPCs were identified based on their morphology 
and location within tissue, as well as the co-expression of hepatocyte and biliary markers. 
This however is clearly not equivalent to demonstration of repopulation, is confounded by 
presence of markers that may be transiently or dynamically expressed and does not 
confirm cell of origin or hierarchy within the progenitor population. Clonogenic assays and 
in vitro differentiation protocols have been used to identify isolated putative HPCs (74), 
along with their ability to engraft and repopulate the parenchyma after transplantation 
(75). However biological function may be altered by the process of isolation and culture. 
Markers used to identify HPCs in tissue such as cytokeratin 19 (CK19), pancytokeratin 
(panCK), OV-6 and epithelial cell adhesion molecule (EpCAM) are also present on mature 
cholangiocytes. EpCAM -positive cells can be differentiated along both lineages in vitro and 
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form both hepatocytes and cholangiocytes after transplant (55, 75, 76). However as this 
marker also labels mature cholangiocytes, this strategy will not necessarily mark a pure 
population of repopulating HPCs. The repopulation capability of EpCAM positive cells may 
reflect either an ability of all EpCAM expressing mature cholangiocytes to be repopulating 
cells, but this transformation might occur at very low frequency, or alternatively EpCAM 
marks a larger population which includes the specific HPC sub-population. Using a 
combination of surface markers for prospective isolation enables identification of 
populations with the most ‘stem-like’ activity, and helps clarify a hierarchy within the 
subpopulations of cells. For example cells positive for EpCAM, CD133 (a marker usually 
associated with haematopoietic cells) and CD24 identify a population capable of generating 
more frequent colonies when plated at clonal density than EpCAM+ or EpCAM and CD24+ 
dual positive cells (59). In addition these triple positive cells are capable of differentiation 
down the hepatocytic and biliary route in vitro and after transplantation in vivo. Other 
markers of clonogenic HPCs include MIC1-1C3, used in combination with other markers 
including CD133 (74), and Lgr5 which marks cells visible in rodent (77) and human livers 
(78) after injury. These Lgr5+ cells are capable of bi-directional differentiation and 
engrafting in mouse livers after in vitro hepatocytic differentiation. The number of 
proposed markers and repopulating capability of a range of defined populations likely 
reflects that HPCs within the DR represent a heterogeneous population containing cells 
from the most primitive progenitors to more hepatocyte-like cells (79). A single DR appears 
to demonstrate distinct polarity with biliary differentiated cells at one end and hepatocytic 
differentiated cells at the other (80). 
1.5 HPCs and fibrosis 
An association between DRs and the severity of fibrosis has long been established in a 
range of human liver diseases including alcoholic steatohepatitis (81), chronic hepatitis C 
(82), genetic haemochromatosis (83) and most dramatically in recurrence of hepatitis C 
virus after liver transplantation (84) where extremely florid DRs accompany severe fibrosis 
in a condition termed fibrosing cholestatic hepatitis (FCH). It remains unclear however if 
these processes occurs in parallel as two independent parts of the response to injury, if 
HPCs stimulate fibrosis, or if fibrosis supports HPCs (85, 86). Evidence favouring HPCs as the 
driver of fibrosis includes the finding that administration of TNF-like weak inducer of 
apoptosis (TWEAK), which is a mitogen for HPCs via the Fn14 receptor (87), to fibrotic mice 
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undergoing partial hepatectomy resulted in both an increase in HPC numbers and collagen 
deposition (88). When TWEAK stimulation was prevented with a blocking antibody both 
HPC number and collagen accumulation decreased. However direct activation of the 
TWEAK/Fn14 pathway in cultured myofibroblasts from the heart or intestine can promote 
their activation and collagen production, therefore the effect of TWEAK on collagen 
production in the liver could also be direct, rather than a secondary consequence of HPC 
expansion (89, 90). Activated myofibroblasts have been found to be the source of a 
mitogenic ligand, Jagged-1, directly signalling to HPCs and promoting their proliferation 
after liver injury (91). Another study that looked at the timing of fibrosis and matrix 
deposition relative to HPC expansion found that after hepatocellular injury the appearance 
of collagen appeared to precede growth of DRs, suggesting fibrosis may be required for, 
rather than be consequent of HPC expansion (92). There is additional evidence that matrix 
components themselves, and their turnover can influence HPCs (86). Administration of an 
agent that reduces production of matrix components collagen and laminin after 
hepatocellular injury, was associated with an increase in generation of HPC-derived 
hepatocytes, while the number of remaining HPCs fell, suggesting their enhanced 
differentiation (56). Additionally when macrophages were administered to mice receiving 
fibrosis-inducing hepatotoxins, there was upregulation of proteins promoting collagen 
turnover (MMP-9 and MMP-13) with an associated fall in fibrosis, but interestingly numbers 
of HPCs rose and there was an increase in serum albumin levels, suggestive of improved 
regeneration (93). While activated myofibroblasts and matrix components may be 
intricately associated in the development of DRs, this study does suggest that fibrosis may 
not be a necessary accompaniment to HPC expansion. Ultimately novel pro-regenerative 
therapies directed at HPCs should not exacerbate fibrosis.  
1.6 Modelling liver regeneration 
1.6.1 Lineage tracing  
Early studies designed to investigate which cells were responsible for hepatocyte 
repopulation after injury involved administration of a pulse of H3 –thymidine or 5-bromo-2’-
deoxyuridine (BrdU) to label proliferating cells (pulse) and then analysis of the tissue 
following regeneration to identify cells ‘tagged’ as having derived from those proliferating 
cells (chase). While this tagging has been shown to be reliable, the label retention cannot 
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identify distant progeny as detection of label becomes difficult after three cell divisions (94) 
and this technique has largely been superseded by the development of transgenic 
technologies in which involve genomic alterations to permanently tag cells of a particular 
lineage. 
Formal tracing of genetically tagged cells remains the gold standard for defining cell fate, 
however conflicting results from experiments have led to controversies about the capacity 
of liver cells to switch fate (95). Genetic cell tracing involves the generation of mouse lines 
containing two transgenes. The first is cyclization recombinase (Cre), under the control of a 
cell-specific promotor, usually fused to a ligand-binding domain of the oestrogren receptor 
(ER) rendering expression sensitive to administration of tamoxifen, such as SOX9-CreER, 
osteopontin (OPN)-CreERT2, CK19-CreER, LGR5-CreER. There are several variants of the 
tamoxifen-induced Cre system utilised in the liver for example the Mx1-Cre in which Cre is 
induced in Mx-1 expressing cells after exposure to interferon or synthetic double stranded 
RNA such as poly(I:C) and AhCre in which Cre expression is inducible from a cytochrome 
P450 promotor element that is transcriptionally up-regulated in response to lipophilic 
xenobiotics such as beta-naphthoflavone (96-98). The second transgenic element is usually 
under control of the ROSA26 locus and involves a loxP-flanked STOP cassette preceding a 
reporter protein (usually lacZ, YFP or RFP). Thus when a cell expressing the specific 
promotor is exposed to the inducing agent it irreversibly expresses the reporter protein and 
passes this on to its progeny, thus labelling the lineage. High fidelity lineage tracing 
experiments require the tissue-specific promotor to be truly tissue-specific and the Cre-
induction regimen to result in recombination only within the intended cells, and no 
recombination to occur in the absence of either the promotor or inducing agent. Further 
transgenes can be added, where loxP- flanked areas (denoted fl/fl) are inserted into a gene 
of interest. The precise arrangement can result in loss of this gene or alteration in its 
structure or degradability after administration of the inducing agent, to generate loss of 
function or over-expression mutants to assess target gene function. 
After administration tamoxifen persists in the organism with low level induction of Cre-ER 
being been demonstrated up to four weeks after injection (99). This may be shortened by 
altering the solvent used to administer the agent (100). As tamoxifen also can be excreted 
in faeces, this can result in inadvertent exposure and of untreated animals housed in the 
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same cage (101). Tamoxifen is directly toxic to hepatocytes (57) and administration can 
alter gene expression. For example SOX9-CreER is intended to label biliary epithelium, 
however exposure of mice to tamoxifen results in increased expression of SOX9 in 
hepatocytes and therefor there is the potential for inadvertent labelling of hepatocytes (14) 
which after injury could result in aberrant lineage labelling. The possibility that Cre 
specificity is further altered by the injury model must also be considered (see Chapter 3). 
An alternative strategy involves viral-mediated delivery of Cre. Adeno-associated virus 2 
and 8 infect hepatocytes with a specificity that is enhanced by inserting the Cre-encoding 
sequence downstream of a hepatocyte-specific promoter such as transthyretin (Ttr) and 
thyroid binding globulin (TBG) (102, 103). This too is not without potential confounding 
factors as the viral vectors do induce liver toxicity and inflammatory responses which may 
alter the behaviour of the marked cells (104). 
True tissue specificity has also been an issue with lineage tracing experiments. For example 
albumin-CreER is active not just in hepatocytes but in a proportion of cholangiocytes (58, 
104). Likewise, glial fibrillary acidic protein (GFAP)-Cre was intended to label only stellate 
cells, however is also expressed in cholangiocytes (105-107) which may have contributing to 
the controversy as to whether stellate cells can generate epithelial cells. 
Lineage tracing the cell of origin for regenerating hepatocytes can be ‘negative’ or 
‘positive’. Negative lineage tracing involves labelling of all hepatocytes prior to injury and 
observing the appearance of unlabelled hepatocytes (negative patches) suggestive of a 
non-hepatocyte origin. If labelling remains consistent all cells are of hepatocyte lineage. 
Robust negative lineage tracing requires near 100% hepatocyte labelling in order that 
negative patches are not simply expansions of hepatocytes that were not pre-labelled. 
While this method can identify cells not of hepatocyte lineage, it does not demonstrate 
their origin. Positive lineage tracing involves labelling cells of the alternative proposed 
lineage (such as cholangiocytes) and observing the appearance of positively labelled 
hepatocytes after injury. For this method to be robust, labelling of cholangiocytes does not 
need to be extensive, however crucially the level of mislabelling of hepatocytes must be 
negligible if not zero to be sure positive patches of hepatocytes do not represent expansion 
of aberrantly labelled hepatocytes. 
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1.6.2 Traditional models for the study of liver regeneration  
The best characterised model used in the experimental study of liver regeneration is partial 
hepatectomy (2/3 PH) (29). This is achieved surgically due to the multi-lobe structure of 
rodent livers whereby three of the five lobes can be removed without causing any tissue 
damage to the residual lobes. The remaining two lobes grow to restore liver mass within 5-
7 days. Similarly, after resection of liver lobes in humans to remove lesions or after trauma, 
liver volume is restored in 8-15 days. The high degree of reproducibility of 2/3PH in rodents 
has enabled the timing and sequence of ensuing regenerative events to be precisely 
studied. A highly orchestrated series of orderly cellular events have been characterised 
from the first 5 minutes to completion of regeneration from existing hepatocytes and 
cholangiocytes at 5-7 days. When the replicative potential of hepatocytes is not impaired, 
DRs are not seen in this model. Positive lineage tracing experiments using OPN-CreER or 
HNF1-beta Cre have failed to identify a contribution from the biliary or HPC compartment 
(56-58). A negative lineage tracing study by Malato et al found 1.4% of hepatocytes were 
unlabelled after 2/3PH but it remains unclear if this is due to incomplete primary labelling 
or an alternative cell origin (102). 
Loss of liver mass can also be induced by administering hepatotoxic chemicals such as 
carbon tetrachloride (CCl4). CCl4 causes injury to pericentral hepatocytes through the 
formation of toxic intermediates via the cytochrome P450 pathway and alteration of 
calcium homeostasis (108). With chronic delivery it induces hepatic fibrosis however 
neither the acute or chronic injury model classically results in a DR. Results from lineage 
tracing studies have demonstrated with positive lineage tracing no biliary contribution to 
hepatocyte regeneration and with negative tracing only a small contribution after chronic 
administration, again potentially reflecting incomplete labelling (56, 57, 102, 109). 
Paracetamol (acetaminophen, APAP) poisoning is one of the most clinically relevant of the 
injury models as it remains one of the commonest causes of acute liver failure in Europe 
and the USA (110). In humans DRs are seen in cases of massive hepatic necrosis (36). In 
mice a dose and time-dependent bi-phasic expansion of DRs is seen with change in HPC 
number visible within the first 10 hours post-APAP administration (111), however in the 
one published lineage tracing experiment, hepatocytes of biliary (HNF1b-CreER labelled) 
origin were not seen (57). 
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Oral administration of thioacetamide results in formation of toxic metabolites within zone 3 
(pericentral) hepatocytes (112, 113). Prolonged administration results in ductular reaction, 
hepatic fibrosis and in the rat, ultimately dysplasia and biliary carcinoma (114). In the 
mouse, when combined with conditional loss of tumour suppressor gene p53, chronic 
administration of TAA also results in biliary cancer (115, 116). This model has been used to 
lineage trace the cell of origin in cholangiocarcinoma (116), but not the origin of 
hepatocytes after shorter term administration. 
Hepatocyte proliferation in rats can be blocked by administration of the chemical 2-
acetylaminofluorene (AAF), triggering replicative arrest by accumulation of p53 and p21 
(117). When administered prior to 2/3 PH, hepatocytes fail to proliferate and instead 
cholangiocytes, in particular located at the canals of Herring, expand markedly and express 
a mix of biliary and hepatocytic genes (118, 119). These cells take on the ‘oval cell’ 
morphology (ovoid nuclear shape and high nuclear to cytoplasmic ratio). They subsequently 
become basophilic hepatocytes and eventually mature hepatocytes, restoring liver volume 
(54, 94, 120). As described above the precise timing of 2/3PH makes careful analysis of 
dynamic processes of regeneration possible, however current genetic technology does not 
permit the accurate permanent tissue-specific labelling in rats as performed in transgenic 
mouse lines. Unfortunately when the same protocol is applied to mice, they fail to generate 
convincing regenerative DRs, likely because al lack of a sulfotransferase means blockade of 
DNA replication is not achieved (67, 121). 
Several models involving the incorporation of toxins or manipulation of the nutritional 
content of mouse diets have been described. The choline-deficient, ethionine 
supplemented (CDE) diet is frequently used to generate DRs. It involves choline-mediated 
hepatocyte steatosis and injury and ethionine-mediated replicative block and the two 
agents are traditionally given separately in food and water (122). Injury is predominantly 
hepatocytic and HPCs generated in response to this typically form a niche surrounded by 
macrophages (123) after 3 weeks. In lineage tracing studies using OPN-CreER and HNF1b- 
CreER 1.81-2.45% were found to be biliary derived using what is known as the CDE-STOP or 
CDE-recovery protocol where experimental choline deficient diet and ethionine 0.15% in 
drinking water is given for three weeks followed by a 2 week recovery period where 
animals receive chow and the majority of HPC differentiation occurs (56-59). In these 
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studies the age of animals used varied widely from 3-4 weeks to 12-24 weeks at time of 
Cre-induction with diet commenced 1-2 weeks after the final tamoxifen dose. Injury 
resulting from the CDE diet has been found to be highly sensitive to animal age and 
background strain with a very much reduced HPC response in older animals and those of a 
mixed genetic background (124), which may explain the range in results and failure of 
lineage tracing in older animals. Interestingly while two of the groups generated very 
similar results (2.45 vs 2.12% hepatocytes), the authors of one paper concluded this 
demonstrated the potential of HPCs and the other concluded this reflected minimal 
relevance of HPCs (56, 58).  
Espanol-Suner et al report lineage tracing with CDE diet is much reduced in the OPN-CreER 
strain when animals are older and weigh over 20-22g at the start of injury (56).  One study 
using a K19CreER found no biliary contribution to hepatocytes however the injury period 
was shortened to 2 weeks (109). A second study using the K19CreER with a 3 week diet 
protocol and negligible lineage tracing was seen however animals were at least 12 weeks 
old before commencing diet (59). The Stanger group used a combination of positive lineage 
tracing with a K19CreER and negative lineage tracing with an AAV8-TBG-Cre (hepatocyte-
specific promotor) to trace lineages with CDE diet (103). Animals were different ages at the 
time of commencing diet as the AAV8 group received virus at 6-8 weeks followed by a 2 
week ‘washout’ period, commencing two weeks of experimental diet at 10 weeks. The 
K19CreER group commenced diet at age 6-8 weeks and again received only 2 weeks injury, 
however received 3-5 doses of tamoxifen during the second week of diet, rather than being 
labelled prior to commencing injury as in other studies. They found no hepatocytes labelled 
as being of biliary origin. Furthermore the Willenbring group also used a combination of 
positive and negative lineage tracing (K19CreER and AAV8-Ttr-Cre) to perform lineage 
tracing using the CDE diet (125). They found in the negative lineage tracing group 0.76% of 
hepatocytes were unlabelled and therefore potentially of HPC origin, however the positive 
lineage tracing group only labelled a negligible proportion of hepatocytes (<0.1%) leading 
authors to conclude that the unlabelled cells in the negative trace group reflected sub-
100% labelling by the virus, rather than contribution from biliary lineage. Finally, a group 
using a SOX9-CreER traced <1% of hepatocytes however their protocol used a lower 
percentage of ethionine (0.1%) than the standard (0.15%).  
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The importance of a significant CDE-related injury in generating biliary lineage labelled 
hepatocytes is emphasised by the recent publication of a study by Shin et al. In this study 
HPCs appearing after onset of injury using a Foxl1-Cre labelling system were traced. When 
analysis was restricted to animals experiencing >14% weight loss (an indication of 
significant injury), the number of labelled hepatocytes rose to 5% after 15 days diet and 
29% after 4 further days of recovery (126). The authors subsequently demonstrated, by 
introducing a diphtheria toxin-sensitive element to their genetic construct so Foxl1+ cells 
could be ablated, that this population was essential for proper regeneration. As the 
traditional CDE diet involves uncoupling the choline deficiency from the ethionine 
supplementation so each component could be altered independently to better suit the 
tolerability and sensitivity of different strains (122), this does introduce variability as the 
intake of each component varies between individuals. This has led to the optimisation of an 
alternative protocol in which the ethionine is included in the modified diet, reducing 
variability between animals and generating a robust HPC response without animal welfare 
concerns (127).  
The methionine-choline deficient (MCD) diet causes some features similar to human non-
alcoholic steatohepatitis (NASH) (128, 129) with hepatocyte specific injury, however not the 
full spectrum of the condition as insulin resistance is not induced (130). It does however 
generate a robust ductular reaction and fibrosis (131) but formal lineage tracing studies 
have not yet been published. One study has shown a variant of this diet, in which ethionine 
is given in addition (MCDE), gives rise to DRs and biliary derived hepatocytes, although 
concerns have since been raised regarding the specificity of the SOX9-Cre used (70). Huch 
et al have identified Lgr5+ HPCs from animals fed the MCDE diet and demonstrated that 
they differentiate into hepatocytes (77).  
By contrast the 3,5-diethoxycarbonyl-1,4-dihydro-collidine-supplemented (DDC) diet 
induces a predominantly biliary injury with deposition of porphyrins causing occlusion of 
small ductules, although there is associated hepatocyte damage (132). HPCs generated in 
this model are typically intimately associated with activated myofibroblasts (123) and have 
not been shown to be capable of hepatocellular differentiation (56-58). Interestingly when 
the source of cells of the DRs generated in response to DDC diet were analysed, a 
proportion were shown to be of hepatocyte rather than biliary lineage using the AAV8-TBG-
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Cre (103). Suzuki et al also identified cells they determined as cholangiocytes after DDC diet 
to be of hepatocyte origin using an Alb-CreER (104). However due to difficulties 
distinguishing de novo DR cells from mature cholangiocytes, particularly given the 
morphology of DRs in this injury model it is not clear whether these cells represent fully 
differentiated cholangiocytes of hepatocyte origin, particularly as at peak injury 60-70% of 
cells were positive for the hepatocyte lineage marker, yet after recovery this number fell to 
1.1%. In addition the Alb-CreER has been shown to also label a proportion of biliary cells 
(58). Tarlow et al went on to demonstrate the wide scale conversion of hepatocytes to HPC-
like cells of the DRs generated in response to DDC diet (133). In order to do this they 
generated chimeric animals by transplanting hepatocytes positive for the red fluorescent 
protein (RFP) variant Tomato into Fah-/ mice. Fah-/- mice are deficient in 
fumarylacetoacetate hydrolase (Fah), involved in the catabolism of phenylalanine. The 
animals develop fatal tyrosinaemia unless they receive 2-(2(-nitro-4-
trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) and this strain is frequently used as a 
recipient when assessing the repopulation capacity of hepatocytes or HPCs in the liver as 
when sufficient Fah positive hepatocytes engraft, NTBC treatment is not required. In these 
experiments, engrafted and lineage tagged hepatocytes were shown to be the cell of origin 
of many cells of the DR and that these cells reverted to hepatocyte phenotype on removal 
of the injury. A similar result was obtained when human hepatocytes were transplanted 
into immunodeficient mice. This led the authors to conclude that hepatocytes undergo a 
reversible ductal metaplasia in response to injury, and then contribute to restoration of 
hepatocyte mass. 
An alternative model to study biliary injury and regeneration is bile duct ligation (BDL). 
Surgical induction of biliary obstruction results in injury, biliary proliferation, myofibroblast 
activation, the appearance of DRs and an intense fibrotic response comparable to human 
biliary cirrhosis (134-136). Lineage tracing studies using this model have demonstrated the 
cell of origin of DRs lies within the biliary compartment and that there is no contribution to 




1.6.3 Transgenic models of liver injury and regeneration 
Transgenic technology has also been used to induce regenerative responses in the liver. 
Multidrug resistance gene (Mdr2) (also known as Abcb4) deletion in mice results in failure 
of secretion of phospholipid into bile and regurgitation of bile acids from leaky ducts 
resulting in periductal inflammation, a DR, severe ductular fibrosis and ultimately 
obliterative cholangitis due to death of cholangiocytes and duct atrophy (137, 138). 
Negligible contribution to new hepatocytes from biliary lineages has been identified in this 
model (58). 
In the zebrafish, genetic incorporation of the bacterial nitroreductase (NTR) gene under the 
control of a tissue-specific promotor results in conditional ablation of the cell type after 
exposure to the NTR substrate metronidazole (139). Zebrafish engineered to have the NTR 
gene under the control of a hepatocyte specific promotor (lfabp) exhibit extreme ablation 
of hepatocytes after incubation with metronidazole for 24 hours. The liver regenerates to 
50% of normal size at 48 hours and fully regenerates within the next 36-48 hours from cells 
of biliary origin (52). These findings were independently corroborated in a second paper 
using positive and negative lineage tracing under control of a Tp1 biliary and a fabp10a 
hepatocyte promotor (53). Authors of the first study term this hepatocyte repopulating 
capacity of biliary cells ‘transdifferentiation’. This term classically refers to direct conversion 
of one cell type to another, avoiding a pluripotent state, however can include a de-
differentiation step into an intermediate precursor stage (140). He et al demonstrate 
expression of hepatoblast markers Hhex and Foxa3, and Choi et al expression of Prox1, 
consistent with a dedifferentiated bipotential intermediate state. 
A key point in both zebrafish papers in demonstrating substantial regeneration of 
hepatocytes from the biliary compartment was the severity of the hepatocyte injury and 
failure of hepatocyte-mediated regeneration. As discussed above, in rats combination of 
2AAF and 2/3PH results in failure of hepatocyte replication and regenerative DRs (94, 120). 
In advanced human liver disease, hepatocyte-mediated regeneration fails and cells become 
senescent, indicated by expression of markers p21 or p16. DRs are seen in this setting, but 
in the absence of lineage tracing, their functional role in contributing to regeneration is 
unclear (36). One explanation of the apparent discrepancy in findings between murine 
dietary model studies versus zebrafish and rat are differences in the extent to which 
hepatocyte regeneration is impaired. When expression of p21 was analysed in the 
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hepatocytes of mice undergoing dietary models of liver injury such as CDE, hepatocyte 
senescence was found to be minimal (59). To recreate the widespread senescence seen in 
humans and rats, a novel mouse model has been generated in which hepatocyte 
senescence is induced (59). Mouse double minute 2 homolog (MDM2) is an E3 ubiquitin-
protein ligase that degrades p53. In its absence, p53 accumulates resulting in senescence 
and death of the cell. Use of the hepatocyte-specific Cre AhCre in combination with a 
MDM2 locus in which exons 5 and 6 are deleted and rendered inactive following Cre 
induction results in hepatocyte senescence and death, massive expansion of DRs and 
repopulation of the parenchyma by ductular derived HPCs. This study using the AhCre 
MDM2fl/fl strain provides the most compelling evidence to date for the potency of DRs in 
regenerating the liver in mice, although formal lineage tracing using this model has not yet 
been possible. 
1.6.4 The plastic liver hypothesis 
Reliability of labelling, differing definitions of stem and stem-like activity, protocol variation, 
reproducibility of models, clinical relevance of models and differing conclusions drawn from 
similar results have together rendered the field of investigation of the capacity of liver cells 
to switch fate and repopulate highly controversial. 
A most plausible explanation for some of the grossly divergent results from apparently well 
designed and accurate lineage tracing studies using different systems and models that is 
gaining ground within the field is that of the highly plastic liver (33, 141-145), although 
acceptance is not universal (32, 109, 125). This organ has so many vital roles in the 
maintenance of body homeostasis, and in addition is the principal barrier to ingested 
toxins. Therefore it would seem an evolutionary necessity that many if not all cell types, 
particularly cells with common developmental precursors, may retain some potential to 
contribute to regeneration of the whole organ. Thus the results obtained through formal 
lineage tracing experiments reflect the type of cell injured, the degree of injury, and the 
degree to which this cell type’s ability to regenerate is impaired and therefore the degree of 
stimulus applied to other cell types to contribute. Collectively these studies demonstrate 
the diversity and potency of regenerative strategies that the liver can employ, rather than 
conflicting views on the correct representation of a single consistent process. Instead of a 
strictly definable entity, the ‘HPC’ represents an indistinct transitional form; it does not 
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conform to a traditional stem cell model and instead represents a milieu that can 
encompass protective metaplasia through to regenerative potential. 
1.7 Liver homeostasis 
It is perhaps not surprising that there is so much controversy regarding how the liver can 
regenerate when even in homeostasis evidence for which cells are responsible for routine 
tissue turnover is conflicting. 
Early rodent DNA labelling studies using thymidine gave rise to the ‘streaming liver’ 
hypothesis: hepatocytes migrate from the portal area to the central area (69, 146). This has 
been further supported by description of a ‘maturation gradient’ along the same axis (147), 
and clonal expansion of hepatocytes originating in the portal areas (148) in humans. One 
study took the streaming liver hypothesis a step further, demonstrating that biliary cells 
(lineage tagged via expression of Sox9) were the source of hepatocytes under normal 
homeostatic conditions, replacing over 90% of hepatocytes along the portal-central axis in a 
year (70). However subsequent studies have failed to confirm this data: cells positive for 
Sox9 at the time of ductal plate formation were able to subsequently generate periportal 
hepatocytes only (14), and during adult homeostasis no contribution was found from 
labelled biliary Sox9 positive cells (102). While not distinguishing the axis of hepatocyte 
replacement in homeostasis, further tracing studies labelling either hepatocytes or ductal 
cells have demonstrated that existing hepatocytes are responsible for hepatocyte renewal 
(56, 57, 102, 109). Font-Burgada et al have recently demonstrated a population of 
periportal cells that express low levels of Sox9 but not biliary marker CK19 and instead 
express hepatocyte marker HNF4a (149). The role of these cells in homeostasis was not the 
focus of this paper; the authors reporting the number of Sox9-GFP labelled HNF4a positive 
cells remaining stable for at least nine months. However they went on to demonstrate that 
after hepatocyte injury, these cells were responsible for hepatocyte renewal along the 
portal-central axis. In sharp contrast to the concept of new hepatocytes ‘streaming’ from 
the portal tract to the central vein, Wang et al have recently described how streaming may 
actually occur in the opposite direction (150).  It has previously been established that Wnt 
signalling is responsible for formation and maintenance of hepatic zonation with pericentral 
expression of Wnt target genes such as GS (20). In this new study authors observed 
expression of Wnt target gene Axin2 in the same cells and used a tamoxifen-inducible 
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Axin2-CreERT2 to permanently pulse label Axin2 expressing cells with GFP and their 
progeny. These cells were shown to self-renew and generate expanding clones that 
populate the entire lobule over time, although on average 40% of hepatocytes were 
labelled. The central vein endothelium was identified as a local source of Wnt. Most 
hepatocytes are polyploid (151), which may limit replicative potential (152). However, the 
Axin2 positive cells were predominantly diploid, a characteristic of stem cells that may be 
necessary for unlimited duplication (153). This model does however contrast with the 
observation that zone 3 hepatocytes do not show a higher proliferative rate than other 
areas (154), unlike the Axin2 and Lgr5 positive stem cells in the gut. 
1.8 Pathways involved in regeneration 
1.8.1 Notch signalling 
A relatively small set of highly conserved signalling pathways including the sonic hedgehog 
(Shh), Wnt, protein/transforming growth factor beta (BMP/TGFb), phosphatidylinositol 3-
kinase/thymoma viral proto-oncogene (PI3K/AKT) and Notch pathways are used by cells to 
sense cues from their environment and integrate this information into an appropriate 
developmental or physiological response. Most of these pathways involve a ‘core’ signalling 
pathway of components required for signal transduction and a more varied set of ‘auxiliary’ 
proteins that have the capability of modifying the signal (155). The Notch pathway is 
uniquely able to permit cells to communicate with their direct neighbours by ligand-
receptor interactions between adjacent cells to direct a transcriptional response (156). 
1.8.1.1 Notch pathway 
There are four known Notch receptors in mammals (Notch1-4) and five ligands from the 
Jagged (Jagged1 and 2) and Delta-like (Delta-like ligand (Dll) 1, 3 and 4) families. The ligands 
are characterised by the presence of a Delta, Serrate and Lag2 (DSL) domain. 
Notch receptors are generated as a single transmembrane receptor that is cleaved by Furin-
like convertase in the Trans-Golgi (S1 cleavage) to yield heterodimeric Notch receptor 






Figure 1.3: Core components of the Notch signalling pathway: Following manufacture, 
Notch receptors undergo their first proteolytic cleavage by Furin-like convertase and 
transported and exocytosed onto the plasma membrane. Here ligand from the signal 
sending cell, of either the Delta or Jagged families, binds the extracellular domain of the 
receptor. This then triggers cleavage of the extracellular domain by ADAM and TACE 
metalloproteases and this extracellular domain remains bound to the ligand and is 
endocytosed by the signal-sending cell. Further cleavage within the transmembrane 
domain to yield the Notch intracellular domain (NICD) is performed by gamma secretase. 
The NICD enters the nucleus where is associates with a member of the CSL family and co-
activators such as mastermind like (MAML) and target gene expression ensues. 
CBF, C-promotor binding factor; CSL, CBF/Suppressor of hairless/Longevity-assurance gene 




In canonical signalling ligand binds membrane-bound receptor leading to proteolytic 
cleavage of the extracellular domain by ADAM10/TACE metalloprotease (S2 cleavage) and 
this outer portion is then subjected to lysosomal degradation by the ligand-presenting cell. 
The remaining receptor portion is cleaved within its transmembrane domain by the 
gamma-secretase complex (S3 cleavage) as it is endocytosed by the signal-receiving cell, 
resulting in release and nuclear translocation of the Notch intracellular domain (NICD). Here 
is associates with a CSL (CBF1 (C promotor-binding factor)/Suppressor of hairless/Longevity-
assurance gene-1 (LAG-1)) family member. CBF1 is also known as recombination signal-
binding protein kappa (RBP-Jk) in mammals. NICD binding converts it from a transcriptional 
repressor to an activator, resulting in Notch target gene expression. The NICD is rapidly 
consumed and degraded by the proteasome, terminating the signal. There is no signal 
amplification step in this pathway, unlike many others where for example phosphorylation 
of core components occurs. This results in signal transduction in a 1:1 ratio and therefore 
the relationship between signalling input and output and signalling strength is important 
for generating the appropriate cellular response, and explains the sensitivity of the pathway 
to gene dosage deviations (155). 
Notch signalling can also occur independently from canonical ligands and/or from CSL/RBP-
Jk-mediated transcription (non-canonical pathway) (157). Delta-like 1 (Dlk1) is one of the 
first reported non-canonical ligands for Notch (158). This ligand is lacking a DSL domain and 
evidence supports that it interacts in cis, inhibiting Notch signalling (159) although may be 
able to activate Notch signalling via an alternative domain (160). Other non-canonical 
ligands include members of the microfibril-associated glycoprotein family (161) and 
connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed gene 
family member CCN3 (162). Additionally Notch signalling can be transmitted in a CSL/RBP-Jk 
independent manner (163), including through cross-talk with other signalling pathways (see 
1.8.1.2 and 1.10). 
1.8.1.2 Notch actions and regulation 
Despite the small number of core components, Notch signalling is able to affect cell fate 
decisions across a wide range of species and cell types and at different stages in lineage 
progression (164). The outcome of Notch signal is strictly dependent on the cellular context 
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and can influence differentiation, proliferation, migration and apoptosis of cells (165). A 
variety of methods exist to permit both tight control of Notch signalling and generate 
diversity of responses from activating the core conserved pathway. 
Notch receptors share a similar basic structure with an extracellular domain including 
epidermal growth factor (EGF)-like repeats, and a transmembrane region and an 
intracellular region containing at least three conserved domains. These are the RBP-Jk-
associated molecule domain, consecutive Ankyrin repeat domains and a C-terminal proline-
glutamic acid-serine-threonine (PEST) sequence (166). A full transactivation domain (TAD) is 
only found in Notch1 and 2, the structure of the third identified paralog, Notch3, displays 
distinct structural differences most marked in this area which may explain the weak 
transactivation activity of Notch3-ICD (167). In addition these and other structural 
differences could affect interactions with coactivators or repressors (168). 
Tissue distribution of the different paralogs and ligands varies, suggesting difference in 
functionality. This can be seen through the range of phenotypes seen in developmental 
defects and diseases in humans accompanying mutation of pathway components. For 
example mutations in either Jagged1 or Notch2 result in Alagille syndrome, characterised 
by bile duct paucity and to a variable extent cardiac and spine defects and deafness (169-
171). Absence of Dll3 is associated with a disorder of the segmentation of the axial skeleton 
(172), and activating mutations of Notch3 causes cerebral autosomal dominant 
arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), a hereditary 
young-onset stroke disorder (173, 174). 
Post-translational modifications of Notch receptors by proteins such as Fringe family 
members modulate the relative responsiveness of receptors of the Delta versus Jagged 
classes (175-177). Limiting the distribution of Notch ligands and receptors only to certain 
parts of the cell can also contribute to signalling specificity as communication will only 
occur with certain neighbours (155). This enables Notch signalling to generate lateral 
inhibition – a cell adopts a certain fate and prevents its immediate neighbours from doing 
the same. Ligands tend not to be expressed only on the signal-receiving cell. Relatively 
small concentration differences in ligand and receptor establish directionality of signalling. 
This is assisted by the fact that ligands activate receptors on contacting cells (trans-
activation) but inhibit receptors on the same cell (cis-inhibition) (178-181).  
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Ligand-receptor combinations do not seem to influence signal output with the exception of 
Dll3 which is the most structurally divergent ligand (182). It is not capable of activating 
Notch receptors in trans and may exclusively act through cis-inhibition of receptors (183). 
There does however appear to be evidence of ligand-receptor specific interactions, 
particularly in the context of cancer cell survival and growth (184, 185). 
Diversity in signalling response can also be generated at the transcriptional level. Hairy and 
enhancer of split (Hes) and hairy/enhancer-of-split related with YRPW motif (Hey) genes 
encode basic helix-loop-helix transcriptional repressors. These are considered to be the key 
Notch target genes, however it now appears that the immediate Notch transcriptome is 
larger, with many genes activated in parallel, rather than secondary to Hes and Hey genes 
(155). The transcriptome output differs by cell type, stage in cell cycle and lineage 
progression (186, 187) with no ‘obligatory’ Notch target upregulated in all cell types. Other 
genes activated in parallel include c-myc, cyclin D1 and p21 (188-190). There is some 
evidence that the different notch receptors are capable of generating diversity in the 
downstream response, consistent with distinct expression patters of the four paralogs in 
most tissues. For example the configuration of CSL binding sites within Notch target genes 
influences the likelihood of recruiting the NICD of Notch1 or Notch3 (191). 
A number of auxiliary proteins have been shown to affect Notch signalling at various stages 
of the pathway such as proteins that affect ligand intracellular trafficking in the signal-
sending cell such as Mind bomb (Mib) and those that regulate interactions between NICD 
and CSL/RBP-Jk such as Mastermind-like (MAML), contributing to adjustment of signal 
strength (192-194). Numb is an endocytic adaptor protein that suppresses Notch signalling 
(195, 196). It recruits Itch, an E3 ubiquitin ligase, to promote ubiquitination degradation of 
the Notch receptor (197, 198) and regulate post-endocytic trafficking and degradation 
(199). Not all Notch receptors are equal targets for Numb with the absence of key lysine 
residues in Notch3 rendering it relatively resistant to the effects of Numb compared with 
Notch1 and Notch2 (197). Interactions between Notch and Numb are discussed further 
below (see 1.10.1) Notch can be further regulated by phosphorylation, ubiquitylation or 
hydroxylation of the NICD (200-203). 
The Notch signalling pathway can also interact with and be modified by other signalling 
pathways. Interactions with the Wnt pathway are discussed below (see 1.10). Notch can 
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interact with the TGFb signalling pathway – NICD interacts with mothers against 
decapentaplegic (SMAD) transcription factors, and TGFb signalling enhances canonical 
Notch signalling (204, 205). Notch signalling is also linked to the cellular response to 
hypoxia. It can interact directly with hypoxia inducible factor 1 alpha (HIF1a), controls gene 
expression synergistically with HIF1a, and hypoxia itself can lead to stabilisation of the NICD 
(206-208). Hypoxia regulates Notch3 expression in pulmonary artery hypertension, 
important for disease development (209) and hypoxia also maintains colorectal cancer cells 
in a stem-like phenotype in a Notch-dependent manner (210). 
1.8.1.3 Notch and liver development 
Identification of mutations in the Jagged1 gene in most patients with Alagille syndrome, 
and subsequently Notch2 in the remainder, established Notch signalling as key for liver 
development (169-171). Mice compound heterozygote for Jagged1 and a hypomorphic 
Notch2 allele, or mice homozygous for hypomorphic Notch2 exhibit several features of 
Alagille’s syndrome including intrahepatic bile duct paucity (211). 
Notch1-ICD and Notch2-ICD overexpression models demonstrate conversion of bipotential 
hepatoblasts to biliary lineage and the formation of the three-dimensional architecture of 
intrahepatic ducts (12, 212). Notch1 versus Notch2 effects are largely redundant in 
hepatoblasts, however Notch2 appears to be more prominent and mediates many of the 
Notch effects during intrahepatic biliary duct development (212, 213). The Jagged1 signal-
sending cells are likely to be the portal mesenchyme (214). Interestingly even in the 
absence of canonical Notch signal from early development (such as in inducible Rbpjfl/fl 
mice), specification of ductal plate cells still occurs, although at a lower rate (215). The key 
biliary fate-determining properties of Notch are further demonstrated by the over-
expression of Notch1-ICD in adult hepatocytes which results in upregulation of Sox9 and 
ultimately their reprograming into biliary cells (103, 215). 
Further distinct roles have been attributed to the different Notch paralogs during 
development with Notch2 and Notch4 associated with proliferation of hepatoblast cell lines 
and Notch3 associated with a more hepatocyte-like morphology (216). While Notch1, 2 and 




While several key Notch regulated genes including Sox9, HNF1b and Hes1 are critical for 
biliary development, there is no single factor exclusively downstream of Notch mediating all 
effects on biliary development (156) and instead a complex network exists involving 
communication with other signalling pathways including TGFb and Wnt to define the 
transcriptome that directs biliary specification and maturation (217). 
1.8.1.4 Notch and liver injury 
In the rat after 2/3 PH NICD migrates to hepatocyte nuclei within 15 minutes. Notch 
effectors Hes-1 and Hes-5 are upregulated by 30 minutes (218). RNA interference to 
Jagged1 or Notch1 partially suppressed regeneration and delivery of recombinant Jagged1 
to cultured hepatocytes induced DNA synthesis, demonstrating a pro-proliferative role for 
Notch signalling in liver regeneration (218), however some of this effect may be indirect in 
vivo due to effects of Notch signalling on liver sinusoidal epithelial cells (219, 220).  
Following liver injury when DRs are generated, vital roles for Notch, along with the other 
important developmental morphogens such as Wnt and Shh have been proposed. In human 
disease, the type of injury appeared important as to the activation status of these pathways 
(123, 221). Expansion of DRs in various rodent injury models is sensitive to Notch pathway 
inhibition with gamma-secretase inhibitors (GSIs) (123, 222). Genetic interference with 
Notch signalling in the biliary/HPC compartment through conditional deletion of RBP-Jk 
impedes their expansion after injury (58) and Notch2 specifically is required for proper 
tubular morphogenesis (223). Similarly, genetic over-expression of the Notch2-ICD within 
this compartment in the absence of injury results in spontaneous generation of DRs (224). 
Specific interaction has also been identified between Jagged1 expression on myofibroblasts 
and Notch1 on biliary cells, directly causing their proliferation and generation of DRs (91). 
When this axis is disrupted in mice, they were unable to survive biliary injury from bile duct 
ligation, the impaired DRs associated with massive hepatic necrosis and mortality, providing 
evidence of a further role for DRs in supporting the parenchyma, even if not contributing 
directly to repopulation. In the ablative zebrafish model of liver regeneration, after extreme 
loss of hepatocytes, remaining biliary cells underwent de-differentiation losing their tubular 
morphology, proliferated and expressed hepatocyte markers, repopulating the parenchyma 
(52). This process was Notch dependent.  
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Notch signalling has also been proposed to direct fate of HPCs along the cholangiocyte 
route akin to the developmental specification of the hepatoblast during development with 
Jagged1 ligand provided by activated myofibroblasts in the surrounding inflammatory niche 
in response to biliary injury (123). Administration of DDC diet to mice has been shown to 
result in upregulation of the Notch pathway within hepatocytes, akin to forced over-
expression of Notch1-ICD, both resulting in their conversion to biliary cells (103). Likewise 
forced activation of Notch2-ICD in hepatocytes results in biliary lineage conversion (224). 
On the other hand, inducible conditional deletion of canonical Notch signalling in HNF1b-
positive (i.e. biliary) cells did not result in conversion to hepatocytes, however it is not clear 
if this is due to absence of effect on fate or failure of DR activation and expansion (58). 
Provision of Jagged1 ligand to ductular cells by activated stellate cells results in ductal 
proliferation, however may also influence the biology of the stellate cell itself, inducing 
production of alpha-smooth muscle actin and collagen (225). Myofibroblasts have also been 
shown to upregulate Notch3 in rat CCl4-induced liver fibrosis and when transduced with a 
viral vector interfering with Notch3 production, fibrosis was attenuated (226). 
1.8.1.5 Notch and liver cancer 
Roles for Notch signalling have been proposed in both major types of liver cancer, 
hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). There is 
evidence to date that ICC can derive from both biliary and hepatocyte lineages (103, 116, 
227, 228). Genetic over-activation of Notch1 (by transgenic insertion of constitutively active 
N1-ICD) in hepatocytes not only re-directs them to the biliary lineage, but also activates the 
cancer program: it appears that in this context too, Notch not only determines fate but 
promotes proliferation (104, 227, 229). With regard to HCC, lineage tracing suggests it 
arises principally, if not exclusively from hepatocytes (58, 230). Activation of Notch1 or N2-
ICD in hepatoblasts also results in HCC (231, 232). 
1.8.2 Wnt signalling 
In development Wnt signalling is crucial for the generation of patterned tissues during 
embryogenesis by acting as a symmetry-breaking signal. In vertebrates this signalling 
system also functions in pattern maintenance: by fuelling stem cell activity in many organs 
they sustain tissue renewal. In addition when some stem cells are ablated, they are 
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replaced by more differentiated cells that under the influence of Wnt signalling regain 
characteristics of their stem cell origin to effect tissue repair (233). 
1.8.2.1 Canonical Wnt pathway 
After production in the signal sending cell, the palmitoyltransferase Porcupine induces 
addition of a palmitate group to Wnts. This lipidated state both tethers it to membranes or 
receptors and permits binding to transmembrane protein Wntless (Wls) which conveys it to 
the cell membrane for secretion or externalisation (234). The classical description of Wnt is 
as a long-range signal in Drosophila development, however recent evidence suggests a non-
diffusible membrane-tethered form of the protein may instead be the principal mode of 
action (235). Within the context of the stem cell niche, action is primarily short-range 
between adjacent cells (233). 
Wnt ligand binds Frizzled receptors on the target cell via the palmitate group and the 
Lrp5/6 co-receptor (low density lipoprotein receptor-related protein 5 and 6), inducing it to 
form a complex with Frizzled, enabling phosphorylation by associated protein kinases. The 
phosphorylated cytoplasmic domain of Lrp inhibits glycogen synthase kinase 3 beta (GSK3b) 
and binds Axin (see Figure 1.4). In the absence of Wnt signal, a complex of proteins 
including Axin, adenomatous polyposis coli (APC) and GSK3b, known as the ‘destruction 
complex’ phosphorylates b-catenin, continuously targeting it for degradation by the 
proteasome. Wnt-induced inhibition of the destruction complex leaves beta-catenin 
available for translocation to the nucleus where it associates with T-cell factor/lymphoid 
enhancer factor (TCF/LEF) transcription factors, inducing target gene expression. Target 
genes include pro-proliferative myc and cyclin. R-spondin proteins enhance Wnt signalling 
strength; their binding to Lgr family receptors, most notably Lgr5, itself a Wnt-responsive 
gene, results in inhibition of E3 ubiquitin ligases usually responsible for degradation of 





Figure 1.4: The canonical Wnt pathway: (A) in the absence of Wnt signal the destruction 
complex which includes Axin, APC and GSK3b phosphorylates beta-catenin. This identifies it 
for ubiquitination and degradation in the proteasome. (B) When Wnt ligand is present it 
binds Frizzled receptor and the Lrp5/6 co-receptor resulting in phosphorylation of the 
cytoplasmic domain of Lrp5/6 by associated kinases. The phosphorylated version of Lrp 
binds and sequesters Axin and with dishevelled (Dvl) inhibits GSK3b. This permits 
cytoplasmic accumulation of active (un-phosphorylated) beta-catenin which translocates to 
the nucleus and associates with TCF/LEF transcription factors to induce target gene 
expression. 
Lrp5/6, low density lipoprotein receptor-related protein 5 and 6; APC, adenomatous 
polyposis coli; GSK3b, glycogen synthase kinase 3 beta; Dvl, dishevelled; TCF/LEF, T-cell 




This thesis focuses on canonical Wnt signalling; however Wnt signalling can also occur via 
non-canonical pathways. Beta-catenin is a multifunctional protein and can interact with 
additional proteins such as cadherins, and is therefore involved in cell adhesion (237). Wnt 
signalling can also occur independent of beta-catenin and is mediated by jun N-terminal 
kinase (JNK) or intracellular calcium with cell polarity and motility the main outcomes of 
signalling. 
1.8.2.2 Wnt functions 
Wnt signalling has key and myriad roles in development, homeostasis and regeneration. 
Mutations in pathway components have been shown to generate diverse phenotypes from 
problems with bone mass, virilisation, and tooth agenesis to type II diabetes (238). One of 
the most studied areas is the role of Wnt signalling in intestinal homeostasis and 
malignancy after the genetic loss of a negative regulator of Wnt signalling (subsequently 
designated APC) was identified as the cause of hereditary cancer syndrome familial 
adenomatous polyposis (FAP) as well as sporadic cancers (239, 240). The gut epithelium 
undergoes rapid turnover, largely replaced every 4-5 days (241). Cells from the absorptive 
surface, the protruding villi, are continuously shed into the gut lumen and are replaced by 
cells generated from Lgr5+ stem cells located in the crypts at the villus base (41). Disruption 
of Wnt signal results in abrupt cessation of proliferation within the crypts, loss of villi, and 
gut failure (242, 243). Addition of Wnt agonist R-spondin, or loss of negative pathway 
regulators, stimulates proliferation (233, 244). Labelling Axin2 or Lgr5 positive cells in a 
range of other tissues including mammary gland (245, 246), skin (42, 247), brain (248) and 
liver (150) has demonstrated crucial roles for ‘Wnt responding’ cells in tissue renewal. 
In addition to effects driven through direct induction of genes related to cell growth and 
proliferation, Wnt/beta-catenin signalling interacts with a number of other pathways and 
cell-regulatory molecules, for example Wnt stimulates the activation of the tyrosine kinase 
Src (via Dishevelled-2) (249) which in turn enhances Wnt signalling and it may promote 
serine/threonine kinase mTOR activity through direct effects on ligand production, 




1.8.2.3 Wnt and liver development  
During the patterning of the endoderm, Wnt signalling must be supressed to allow 
expression of early liver transcription factors (252), however subsequently during the early 
stages of hepatic morphogenesis, Wnt signalling is required for liver specification and 
growth (252, 253), highlighting changing temporal requirements for this pathway during 
development. The requirement for Wnt signal persists with beta-catenin being required for 
proliferation and differentiation of hepatoblasts into the hepatocyte fate (254), but even at 
this later stage there is likely to be careful regulation of signal as when beta-catenin is 
depleted from E9.5 onwards hepatoblast proliferation and differentiation is impaired, 
whereas when negative regulator of Wnt-signal APC is deleted starting from E11.5 
proliferation and differentiation were also reduced. As discussed above, Wnt/beta-catenin 
signalling is responsible for establishing appropriate zonation of hepatocytes late in 
development, and maintaining that zonation through adult life with negative regulator APC 
most strongly expressed in zone 1 and 2 hepatocytes and Wnt target genes including GS 
expressed exclusively in zone 3 (20). Recently the Lemaigre group have demonstrated that 
beta-catenin is not required for differentiation of hepatoblasts into cholangiocytes and bile 
duct morphogenesis. They also found that excessive beta-catenin activity in developing 
ducts actively stimulated biliary development, however ducts showed aberrant morphology 
and perturbed differentiation, reinforcing the importance of tight control of levels of Wnt 
signalling (255). 
1.8.2.4 Wnt, liver regeneration and cancer 
The pro-proliferative and fate determining functions of Wnt signalling suggest potential 
further roles in liver regeneration. However, unchecked proliferation might result in 
malignant transformation. 
Wang and colleagues’ model of liver homeostasis driven by Wnt-responsive Axin2-positive 
zone 3 hepatocytes has yet to be interrogated in the injury setting, however a role for Wnt 
signalling has been established in other regenerative models. After 2/3 PH beta-catenin is 
visible in the nucleus of hepatocytes after 5-10 minutes and for up to 6 hours (256). 
Hepatocyte growth factor (HGF) is a principal early driver of liver regeneration (257-260). In 
cultured hepatocytes HGF induces dose-dependent nuclear translocation of beta-catenin, 
independent of Wnt ligand and thus beta-catenin is thought to be responsible for some of 
the multifunctionality of HGF in liver regeneration (261).  
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HPC-mediated regeneration in rats undergoing the 2AAF 2/3PH protocol is accompanied by 
expression of active beta-catenin in the DRs (262). After induction of biliary injury with DDC 
diet DRs report Wnt activity and when the HPCs are isolated, they proliferate in response to 
administration of Wnt3a (263). Deletion of beta-catenin abrogates the ductular response to 
DDC injury (262). Periductal cells positive for Wnt-dependent marker Lgr5 have been 
identified after liver injury. These cells have been lineage traced into hepatocytes and when 
isolated expand and differentiate in the presence of Wnt agonist and Lgr5 ligand R-spondin. 
Once transplanted into a non-competitive model (Fah-/- mice) they behave as functional 
hepatocytes (77). Furthermore the mass repopulation of hepatocytes from biliary cells 
demonstrated in the ablative zebrafish models has been shown to require Wnt (in this case 
Wnt2bb) (53). 
Aberrant activation of beta-catenin pathway is observed in 30-40% cases of human HCC, 
principally due to mutations in beta-catenin itself or Axin (264, 265). Viral mediated Cre-
inactivation of APC results in nuclear accumulation of beta-catenin in hepatocytes, and 
induction of target genes including GS. This accompanies hepatomegaly, hepatocyte 
hyperplasia and rapid mortality (266). When the dose of adenoviral-delivered Cre is 
reduced, compatible with both survival and persistence of beta-catenin activated cells, 2/3 
of mice develop HCC. Promotion of beta-catenin signalling by its core protein is one 
mechanism by which hepatitis C virus is thought to drive HCC (267). In addition to HCC, 
activation of Wnt signalling has been identified in cholangiocarcinoma. In this condition 
when associated with liver fluke infestation, mutations in a negative regulator of Wnt 
signalling (RNF43) have been detected (268). In cases of sporadic disease, a ‘high-Wnt’ state 
has also been identified, in this case driven by inflammatory macrophages in the 
surrounding cancer stroma, reflecting an aberrant injury repair mechanism (115).  
In addition to pro-proliferative effects of Wnt signalling, roles in hepatocytic differentiation 
of HPCs have been established in the mouse, rat and human (77, 78, 123, 269). In vitro 
differentiation protocols in all three species involve Wnt agonism and interference with 
Wnt signalling in vivo prevents hepatocytic differentiation. 
1.9 Systems where Notch and Wnt signalling co-exist  
In the gut Wnt signalling is essential for maintenance of the stem cell compartment with 
pathway inhibition or genetic ablation resulting in loss of the Lgr5 stem cell population (41, 
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242). In addition Notch signalling, in particular via Dll1 and Dll4 ligands, are required to 
maintain this same population (270). There is also a requirement for an intact Wnt 
signalling cascade within cells to respond to Notch-dependent mitogenic stimulus (271), 
thus further demonstrating a requirement for both pathways in stem cell maintenance. 
As discussed above Wnt signalling can be involved in fate decisions and in the gut is 
involved in Paneth cell differentiation (272, 273) while overexpression of Wnt inhibitor 
Dkk1 leads to loss of all secretory cells (274). In contrast Notch signalling negatively 
regulates secretory cell differentiation in favour of generation of absorptive cells 
(enterocytes) with goblet cell hypertrophy occurring in response to Notch inhibition (275, 
276). Again careful regulation of these two pathways is required for maintenance of 
effective organ function and cell differentiation (277).  
Effective regeneration in any tissue requires a switch from progenitor cell proliferation to 
differentiation. In muscle Notch has been identified as a key driver of activation and 
expansion of myogenic progenitors (278). Subsequently it has been determined that a 
temporal switch from Notch to Wnt signalling is required for these cells to differentiate. 
These signals in the correct sequence permit the regulated proliferation then 
differentiation required for effective muscle regeneration (279). Crosstalk between these 
two pathways appears to be mediated by GSK3b.  
1.10 Interactions between Notch and Wnt pathways  
1.10.1 Numb 
Numb can act as a juncture between Notch and Wnt signalling. Numb is a direct 
transcriptional target of the Wnt signal (280), and binds to the NICD, recruiting the E3 
ubiquitin ligase Itch leading to polyubiquitination and degradation by the proteasome (198, 
281). Numb can also disrupt trafficking of Notch receptor, re-directing it to an endocytic 
compartment for degradation (199). Finally, Numb supresses Shh signal (282); Shh 
regulates Notch activity and when inhibited, accumulation of ductular cells after biliary 
injury is impaired (107, 283).  
Previous work has proposed a model for hepatocellular regeneration in which HPCs enter a 
window where Wnt signal results in Numb expression which inhibits Notch and results in 
hepatocyte fate (123). In this setting Wnt ligand is supplied by inflammatory macrophages 
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within the niche in response to the engulfment of dead hepatocytes. In the absence of 
hepatocyte death (for example in the case of predominantly biliary injury), there is no Wnt 
signal from macrophages and Notch signal is unopposed and HPCs proceed down the biliary 
fate.  
The Notch receptor paralogs are not equivalent targets for Numb-mediated ubiquitination 
and degradation: the loss of a number of conserved lysine residues in Notch3ICD makes it a 
poor target for the Numb/Itch complex (197) and correlates with the finding that Notch3 is 
not degraded by the proteasome (284). The concept of Notch3 a more ‘permissive’ Notch in 
the context of Wnt signalling is supported from the finding in liver development where 
Notch3 is more associated with progenitor cells undergoing hepatocellular differentiation 
versus the other paralogs (285).  
1.10.2 Ascl2  
Transcription factor Achaete Scute-Like 2 (Ascl2/MASH2) also occupies a potentially 
interesting position between the two signalling pathways. In the gut Ascl2, a direct target of 
canonical Wnt signalling, is required for maintenance of the Lgr5 stem cell pool in adult 
intestinal epithelium (286, 287). Recently it has been revealed that the continuous Wnt 
gradient seen along the intestinal crypt is translated to a discrete Ascl2 ‘on’ switch at the 
crypt base through a Wnt/R-spondin activated auto regulatory loop (288). Interestingly 
Notch signalling can both induce Ascl2 expression and repress it via Hes-1 in epidermal 
development (289), further highlighting the tight controls on this Notch/Wnt sensitive 
system.  
1.10.3 IGF1 axis 
Several studies have demonstrated interactions between the IGF1 axis and Notch or Wnt 
signalling. Insulin-like growth factor 1 (IGF1) is principally produced in the liver in response 
to growth hormone (GH) (290-292). It enters the circulation bound to IGF binding proteins 
(IGFBPs) which transport it into tissues and regulate bioavailability (293). IGF1 also acts in a 
paracrine fashion (294). The type 1 IGF receptor (IGF1R) is a transmembrane tyrosine kinase 
and exerts most of the biological actions of IGF1. This receptor has been identified on 
ductular cells (295). Following ligand binding the kinase is active, autophosphorylates and 
can then bind several substrates including the insulin receptor substrates (IRS), initiating 
phosphorylation cascades resulting in activation of phosphatidylinositol 3-kinase (PI3K) and 
p70 S6K kinase which results in increasing the active ribosomal pool necessary for cell cycle 
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entry, and Akt. Akt further enhances proliferative protein synthesis through mechanistic 
target of rapamycin (mTOR) activation (294). Additional pro-proliferative IGF1R actions 
include recruitment of Ras and activations of Raf-1/MEK/ERK (296, 297). In muscle where 
Notch and Wnt are also both important for regeneration, IGF1 is of key importance in 
proliferation and differentiation of muscle progenitor cells (298). 
 
 
Figure 1.5: The IGF1 axis and mTOR pathway: Growth hormone releasing hormone from 
the hypothalamus stimulates release of growth hormone from the pituitary gland. This 
induces expression of IGF1 in the liver which can enter the circulation bound to IGF binding 
proteins or act in a paracrine fashion. IGF1 binds one of the insulin family receptors, 
principally the type 1 IGF receptor (IGF1R). Activation of this tyrosine kinase triggers an 
intracellular phosphorylation cascade mediated via the intracellular adaptor protein IRS1 
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and PI3K. This results in phosphorylation of Akt, activation of mTOR and the subsequent 
activation of ribosomes via p70 S6 kinase. In addition negative regulator of translation 
4EBP1 is phosphorylated and deactivated. The net effect is increased protein synthesis and 
cellular proliferation. 
GH growth hormone; IGF1 insulin-line growth factor 1; IGF1R type I IGF1 receptor; IRS1 
insulin receptor substrate 1; PI3K phosphoinositide 3-kinase;  Akt thymoma viral proto-
oncogene; mTOR mechanistic target of rapamycin; SK6 ribosomal protein S6 kinase; S6 
ribosomal protein S6; 4EBP1 eukaryotic translation initiation factor 4E-binding protein. 
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The IGF1R is directly induced by Notch1 in hypoxic conditions within lung adenocarcinoma, 
leading to activation of pro-survival Akt (299). It is also a target of Notch1 in human T acute 
lymphoblastic leukaemia (T-ALL) initiating cells (300). In addition to directly proliferative 
actions, Notch can regulate hepatic glucose production and lipid metabolism via forkhead 
box protein O1 (FoxO1) and Akt/mTOR with Notch inhibition blocking mTOR activity, 
increasing insulin sensitivity and preventing hepatosteatosis (23, 24). The relationship 
between Wnt signalling and the IGF1 axis is complex but suggests a positive feedback loop 
between the two pathways (301). IGF1 can regulate the stability and transcriptional activity 
of beta-catenin and, via activation of PI3K, stimulate TCF/LEF dependent transcription (302, 
303). 
In patients with liver cirrhosis plasma levels of total IGF1 and free IGF1 are low while GH is 
increased, indicating GH resistance and reduced hepatic functional reserve; indeed the 
degree of IGF1 deficiency correlates with the progression of liver disease (304-306). Some 
of the clinical manifestations of advanced cirrhosis such as malnutrition and muscle wasting 
may reflect loss of this anabolic activity (307). 
1.10.4 Others 
In addition to Numb- and IGF1-mediated cross-talk between Wnt and Notch signalling 
pathways, other direct and indirect interactions have been reported. For example GSK3b is 
able to bind and phosphorylate Notch2 resulting in inhibition of Notch target gene 
expression (200), similarly other components of the beta-catenin destruction complex can 
influence Notch trafficking (308). Jagged1 has been identified as a beta-catenin target gene 
(309). Beta-catenin can also act in synergy with the NICD-CSL/RBP-Jk complex on Notch 
target genes (310, 311). During somite differentiation, beta-1 integrin activity controls both 
Wnt and Notch signalling, and both signals must be active for downstream gene activation 
of cMeso1/MesP2, involved in the formation of a morphological intersomitic boundary 
(312). MAML, in addition to its role in stabilising NICD-CSL/RBP-Jk interactions, can also 
bind GSK3b decreasing MAML transcriptional activity (313) and beta-catenin itself (314), 
where it behaves as a transcriptional co-activator.  
The Notch-regulated ankyrin repeat protein (Nrarp) is induced by Notch signalling and 
functions as a negative feedback regulator of Notch both by binding the NICD and reducing 
Notch target gene expression (315, 316).  Genetic loss of Notch3 in muscle results in 
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apparently normal myogenesis (317). However, in Notch3 null animals gross muscle 
hypertrophy occurs after muscle injury due to unchecked proliferation of progenitors which 
is largely driven by Notch1 (318). As Notch3-ICD overexpression results in increased Nrarp 
expression it has been proposed as a mechanism by which Notch3 can negatively regulate 
Notch1.  
Further integration between Wnt and Notch pathways is also conferred by Nrarp: in 
addition to modulating Notch protein turnover it acts independently as a positive regulator 
of the Wnt signalling pathway (319, 320). This is achieved by stabilising and preventing 
proteasome-mediated degradation of pivotal Wnt pathway element and transcription 
factor Lef1.  
1.11 Summary 
Chronic liver disease remains a significant cause of morbidity and mortality and establishing 
how the liver regenerates, from which cell types and the potency of those cells, has been 
hotly debated in recent years. In this most regenerative of organs we are arriving at the 
concept of a state of regenerative plasticity, where traditional definitions of stem cells may 
not be appropriate and instead the nature, degree and persistence of liver injury determine 
which of many potential regenerative avenues are deployed. It has now been established 
that the bile ducts, and ductular reactions (DRs) generated in response to injury, do contain 
cells with hepatocyte repopulation capacity. Therefore understanding how they do this is 
vital for the development of novel therapies that can enhance this endogenous function. 
In the gut Wnt signalling is essential for maintenance of the stem cell compartment with 
pathway inhibition or genetic ablation resulting in loss of the Lgr5 stem cell population (41, 
242). In addition Notch signalling, in particular via Dll1 and Dll4 ligands, are required to 
maintain this same population (270), thus demonstrating a requirement for both pathways. 
After muscle injury, effective regeneration requires Notch followed by Wnt signal in 
sequence (279). It has previously been demonstrated that, in end-stage models of liver 
regeneration, HPCs require differentiation signals through the Notch and Wnt pathways 
(123) however whether there is a more complex temporal interaction between Notch and 







Both Notch and Wnt signalling are required for an effective HPC regenerative response to 
hepatocellular injury 
The roles of these signalling pathways differ with regards to expansion, migration and 
differentiation 
Notch3 has a previously unrecognised role in liver regeneration 




Develop models to further study the HPC response 
Characterise the Notch/Wnt axis in hepatocellular regeneration 
Characterise the role of Notch3 in the ductular response to hepatocellular injury 





2 Materials and methods 
2.1 Animal studies 
2.1.1 Generation of animal strains 
2.1.1.1 AhCre MDM2 strains: 
AhCre MDM2fl/fl (59) was crossed with Notch3d1 (Notch3-/-) (321), CBF:H2B-Venus (322) or 
TCF/Lef:H2B/GFP mice (323) (obtained from Jackson Laboratories stock numbers 010547, 
020942 and 013752) to give AhCre MDM2fl/fl;Notch3+/+, AhCre MDM2 fl/fl;Notch3-/-, AhCre 
MDM2 fl/fl;CBF:H2B-venus and AhCre MDM2 fl/fl;TCF/Lef:H2B-GFP strains. 
2.1.1.2 Krt19-Cre strains: 
Krt19-CreERT (324), was crossed with the Ai14 TdTomato strain (325) (Jackson Laboratories 
stock number 007914) to give Krt19-CreERT;RCL-tdT strain. 
2.1.1.3 OPN-iCre strains: 
OPN-iCreERT2;R26RYFP mice (56) (a gift from Frederic Lemaigre, de Duve Institute) were 
crossed with Notch3-/- as above to give OPN-iCreERT2;R26RYFP;Notch3+/+ and OPN-
iCreERT2;R26RYFP;Notch3-/-, and Igf1rfl/fl (326) (Jackson Laboratories stock number 012252) to 
give OPN-iCreERT2;R26RYFP;Igf1rfl/fl and OPN-iCreERT2;R26RYFP;Igf1rwt/wt. 
2.1.1.4 Notch3 null strains: 
Notch3d1 (Notch3-/-) (as above) (321) mice were crossed with C57BL/6 (wild type) mice 
(Charles River) to give Notch3-/-, Notch+/-, and Notch3+/+ strains. 
2.1.1.5 Genotyping: 
Genotyping was performed commercially by Transnetyx© (Memphis, TN, USA). Ear notches 
were taken at the time of weaning at 4 weeks of age. During my maternity leave animal 
colonies were maintained and bred to usable genotype by Janet Man. She also assisted 
with the running of animal experiments to my experimental protocols and subsequent 
tissue harvest. 
2.1.2 Induction of Cre and liver injury models 
Animals were housed with 12 hour light/dark cycle and given chow and water ad libitum. 
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2.1.2.1 AhCre MDM2 strains: 
All AhCre MDM2fl/fl strains received 20mg/kg beta-naphthoflavone (BNF) (Sigma-Aldrich) in 
corn oil intra-peritoneal (i.p.) for Cre induction.  
Time course experiment: Animals were harvested at day 0, 3, 5, 7, 10 and 14 post-Cre-
induction. This experiment was carried out by Michael Williams. Due to morbidity levels by 
day 14 all subsequent experiments were terminated at day 10.  
Notch inhibition experiments: mice received 50mg/kg/dose DAPT (N-[N-(3,5-
Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester) (Sigma-Aldrich) or equivalent 
volume of vehicle daily for 3 days by i.p. injection as outlined in the experimental schematic 
in Figure 4.5. Animals received DAPT days 2-4 (‘early’), days 4-6 (‘mid’) or days 7-9 (‘late’) 
and were harvested 24 hours after the final dose. Notch1 or 2 blocking antibody (clones 
aN1_E7, aN1_E10, aN2_B6 and aN2_B9) or control antibody (aDesmin) (327) (a gift from 
John McCafferty, University of Cambridge) was administered by single dose of 10mg/kg by 
i.p. injection 24 hours after Cre-induction. Animals were culled on day 5 post-Cre induction. 
AhCre MDM2fl/fl;Notch3+/+ and AhCre MDM2fl/fl;Notch3-/- mice received only BNF induction 
and were culled 7 days later.  
Wnt inhibition experiments: mice received 5mg/kg/dose ICG001 (Tocris) or vehicle for 4 
days by i.p. injection for the periods demonstrated in the experiment schematic in Figure 
5.4. Animals received ICG001 days 1-4 (‘early’) or days 6-9 (‘late’). C59 (Cellagen) was 
administered at a dose of 20mg/kg/dose or vehicle was administered by i.p. injection day 6 
and day 8 post-Cre-induction as per the experimental schematic in Figure 5.4 and 5.7A.  
IGF axis experiments: mice received daily i.p. injection of: AG1024 (Santa Cruz 
Biotechnology) 30ug/dose or vehicle, rapamycin (Tocris) 10mg/kg/dose or vehicle or 
recombinant murine IGF1 (rIGF1) (Sigma-Aldrich) 0.5mg/dose or vehicle days 6-9 post-Cre 
induction, as per the schematics in Figures 6.9-12. 
2.1.2.2 Krt19-Cre strains: 
Six week old Krt19-CreERT;RCL-tdT mice were given 3 injections of 4 mg tamoxifen in olive 
oil (Sigma-Aldrich) by i.p. injection 48 hours apart.  
When mice reached 22g for females and 25g for males (a minimum of 17 days after the last 
tamoxifen injection) they received methionine-choline-deficient (MCD) diet (Dyets) for 14 
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days. During the dietary injury period they received 3 doses per week of DAPT (25mg/kg), 
ICG001 (5mg/kg) or equivalent volume of vehicle by i.p. injection. 
2.1.2.3 OPN-iCre strains: 
OPN-iCreERT2;R26RYFP mice received the CDE-stop protocol (choline-deficient ethionine-
supplemented diet, MP Biomedicals) as previously described (56). This involved 
commencing Cre-induction with tamoxifen at 21 days old and injury diet at least 14 days 
after final tamoxifen dose when the mice reached 20g. During the 2 week ‘STOP’ period 
DAPT (25mg/kg), ICG001 (5mg/kg) or equivalent volume of vehicle was administered three 
times per week by i.p. injection. This experiment was conducted by Noemi van Hul at 
Universite catholique de Louvaine and the tissue and serum shipped to me for analysis. 
OPN-iCreERT2;R26RYFP strains OPN-iCreERT2;R26RYFP;Notch3+/+, OPN-iCreERT2;R26RYFP;Notch3-
/-, OPN-iCreERT2;R26RYFP;Igf1rfl/fl and OPN-iCreERT2;R26RYFP;Igf1rwt/wt having been generated 
through crosses with mice on a C57Bl/6 background were smaller than the original CD1 
parent strain and less tolerant of CDE diet. Therefore induction of Cre with tamoxifen took 
place at 5-6 weeks old and CDE diet was commenced 14 days after the last injection once 
animals reached an acceptable starting weight and were harvested after 3 weeks of diet. 
OPN-iCreERT2;R26RYFP;Igf1rfl/fl and OPN-iCreERT2;R26RYFP;Igf1rwt/wt mice also underwent 14 
days of the MCD diet with induction of Cre at six weeks of age and commencing diet on 
reaching 22g for females and 25g for males (a minimum of 17 days after the last tamoxifen 
injection). 
2.1.2.4 DDC diet: 
Mice of genotypes Notch3-/-, Notch+/-, and Notch3+/+ aged 12-16 weeks received 7 days of 
0.1% w/w 3,5-diethoxycarbonyl-1,4-dihydrocollidine (DDC) in chow (Special Diet Service 
824943). This induces biliary injury via accumulation of porphyrins. Due to the 
predominantly C57Bl/6 background of these mice which results in increased sensitivity to 
DDC diet, this experiment used older mice for a shorter time period than traditionally used. 
2.1.3 Tissue and serum harvest 
Mice were euthanized according to UK Home Office regulations by a Schedule 1 procedure 
(either C02 asphyxiation or cervical dislocation). 
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Blood was collected at time of sacrifice by cardiac puncture and the resulting serum 
analysed by a biochemist using a commercial kit for alanine aminotransferase (ALT; Alpha 
Laboratories Ltd). 
2.2 Cell culture 
The HPC cell line BMOL was provided by George Yeoh, University of Western Australia. Cells 
were maintained in WilliamsE + GlutaMAX-1 medium (Gibco) containing 2% foetal calf 
serum (FCS) supplemented with 100units/ml penicillin and 100ug/ml streptomycin (PAA). 
Cells were cultured in a humidified atmosphere wth 5% CO2 at 37oC.  
The SWA cell line was generated by Wei-Yu Lu and Atsunori Tsuchiya from cells from the 
non-parenchymal cell (NPC) fraction of the livers of mice fed CDE diet for 21 days. NPCs 
were isolated by centrifugation over a discontinuous Percoll (Sigma-Aldrich) gradient and 
expanded on rat tail collagen I coated plates (Sigma-Aldrich). When HPC colonies were 
observed expansion media was changed to a serum free purification media (328) until HPC 
colonies were exclusively observed. HPCs were then maintained in 1% FCS supplemented 
purification media and passaged with the diluted trypsin assisted replating method as 
described previously (59) then weaned onto Williams E medium as above supplemented 
with 5% FCS generating a similar growth rate to the BMOL line. These cells can be 
differentiated down the biliary or hepatocyte route as previously described (59).  
Cells were tested for the presence of mycoplasma in-house at the beginning of the study 
and after resuscitation from cryopreservation and were found to be negative. 
2.3 Immunohistochemistry 
At the time of sacrifice, livers were perfused with 5mls sterile PBS via the IVC before being 
fixed overnight in 10% buffered formaldehyde. After paraffin embedding tissue sections 
were cut at 4 μm. Sections were de-waxed in xylene and rehydrated through graduated 
alcohol. Sections were subject to heat-mediated antigen retrieval performed by 
microwaving in either 0.01M sodium citrate pH6, Tris-EDTA pH9 or treating with 125ug/ml 
proteinase K in a waterbath at 37oC.  
For colorimetric staining with diaminobenzidine (DAB), endogenous peroxide activity was 
quenched with Bloxall (Vector) prior to blocking with avidin/biotin (Life technologies). Non-
specific binding was blocked by incubation with protein block (Vector). Primary antibody in 
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Antibody Diluent Reagent Solution (Life technologies) was applied for one hour at room 
temperature or overnight at 4oC. After washing, slides were incubated with species 
appropriate biotinylated secondary antibody (Vector) for 30 minutes, followed by ABC 
reagent (Vector) for 30 minutes. Sections were then treated with DAB (Liquid Dab Substrate 
Chromogen System, DAKO) for 5 minutes before counterstaining with Harris Haematoxylin 
and Scott’s tap water. Finally sections were dehydrated through graduated alcohols and 
xylene and mounted in Pertex hard set mounting medium. 
For immunofluorescence sections were blocked with protein block prior to incubation with 
primary antibody. Sections were incubated overnight with primary antibodies at 4°C. After 
washing, sections were stained with species-appropriate secondary antibodies conjugated 
to Alexa 488 or Alexa 555 (Life technologies). Where further amplification of signal was 
required or for dual immunofluorescence where both primary antibodies were in the same 
species, a Tyramide Signal Amplification kit was used (Perkin Elmer) prior to further heat 
treatment. Slides were mounted using DAPI Fluoromount-G (Southern Biotech). 
For frozen sections a liver lobe was frozen in optimal cutting temperature (OCT) medium 
(Fischer Scientific) at time of sacrifice and stored at -20oC prior to cutting to 6um. These 
sections were air dried and fixed in a 1:1 ratio of ice cold methanol and acetone for 10 
minutes. 
In all cases specificity of staining was confirmed by the use of appropriate isotype controls. 
For a complete list of primary antibodies, see Table 2.1. 
 
Primary antibodies 
Alpha SMA Sigma A5228 
Beta-catenin BD Biosciences 610154 







Dll-1 R&D systems AF3970 
IGF1 Abcam ab40657 
IGF1 receptor pY1161 Abcam ab39398 
Jagged-1 Santa-Cruz Sc-8303 
Jagged-2 Santa-Cruz 25-255 
Ki67 Abcam ab16667 
Notch1-ICD Abcam Ab8925 
Notch3 Abcam Ab23426 
panCK DAKO Z0622 
PCNA Abcam ab29 
pmTOR (Ser2448) Cell signalling 2976 
RFP SICGEN AB0081-500 
Sox9 Millipore AB5535 
YFP Abcam ab6673 
Table 2.1 Primary antibodies used in this study 
2.4 Immunocytochemistry 
For immunocytochemistry cells were fixed in frozen methanol for 10 minutes and 
permeablised with 0.5% PBS-Tween (Sigma-Aldrich) prior to application of protein block. 
Fluorescent immunostaining was then performed as above. 
2.5 In situ hybridisation 
Formalin fixed paraffin embedded samples were analysed using RNAscope 2.0 Reagent Kit-
Brown (AdvancedCellDiagnostics#310035) according to manufacturer’s instructions. Probes 
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used were; Mm Axin-2 (#400331); Mm Lgr5 (#312171); positive control Mm Ppib 
(#313911); negative control Mm DapB (310043). This was performed by central histology 
services at the Beatson Institute, Glasgow. 
2.6 Microscopy and cell counting 
2.6.1 Photography and manual cell counting 
Images were obtained on a Nikon Eclipse E600 microscope in conjunction with Axiovision 
Elements software v3.0.  
Cell counts were performed manually using Fiji ImageJ (EMBL) on blinded slides and more 
than 20 consecutive non-overlapping fields at x200 (colorimetric) or x400 
(immunofluorescent) magnification. Interlobular bile ducts were excluded from 
quantification. 
2.6.2 Picrosirius red quantification 
Picrosirius red quantification was performed on 30 consecutive non-overlapping x200 fields 
by pixel analysis using Adobe Photoshop CS6. 
2.6.3 Automated quantification of cell proliferation 
For analysis of PCNA positivity in RFP or YFP-expressing cells after performing 
immunofluorescent staining for the fluorescent reporter, PCNA and DAPI, slides were 
scanned using the Operetta high-content analysis system (PerkinElmer). A minimum of 30 
10X long working distance objective fields (0.4cm2) liver tissue was analyzed using the 
Columbus image data storage and analysis system. Briefly, a sliding parabola was applied to 
the DAPI channel to remove variation in background level across and between samples. All 
nuclei were identified using method M standard settings and from this population, cells 
positive for the reporter were identified based on a common threshold. From this second 
population those with nuclear PCNA staining were again identified using a common 
threshold. Results are reported as % RFP/YFP positive cells also PCNA positive. Fields 
containing artefacts that affected image analysis were excluded manually. ‘Pipeline’ 
illustrated in Appendix 1. 
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2.7 Quantitative PCR analysis 
At time of harvest a whole liver lobe was snap frozen on dry ice and stored at -80oC. 2-
3mm3 of liver tissue was defrosted and lysed into Tri-Reagent (Ambion) and homogenized 
using a tissue tearer. Lysates were mixed with 1:5 chloroform/TriReagent and centrifuged 
at 12000 rpm for 15 minutes at 4oC. The aqueous RNA containing phase was collected and 
mixed with an equal volume of 70% molecular grade ethanol.  For RNA extraction from cells 
lysis directly into RLT lysis buffer (Qiagen) was performed before the addition of ethanol. 
An RNEasy Mini kit (Qiagen) was used for RNA purification according to the manufacturer’s 
protocol. RNA concentration and purity was determined using a Nanodrop 
spectrophotometer (ThermoFisher). RNA concentration over 100ng/ul, RNA purity 260/280 
ratio >2 and 260/230 ratio 1.8 were taken as an acceptable standard. 
1ug RNA was reverse transcribed after concentrations were standardised with RNase free 
water. Reverse transcription was performed using the Qiagen kit according to 
manufacturer’s instructions, including a genomic DNA wipe-out step.  
Real time qPCR was performed using SYBR Green (Qiagen). Reactions were performed in 
384 well plates and consisted of 5ul cDNA diluted 1:10 in RNase free water, 6.25ul SYBR and 
1.25ul primers. Pre-designed validated primer sets were purchased from Qiagen and are 
listed in Table 2.3. All samples were run in triplicate. A Roche LightCycler480 was used to 
run reactions to the following specifications: 
 
Cycles Temperature (oC) Duration (s) 
Activation 95 20 
40 cycles: denaturation 










Cooling 40 30 




Specificity of PCR products was confirmed by melting curve analysis. Standard curves for 
each primer’s amplification efficiency was generated using cDNA template from each 
sample combined and serially diluted in RNase free water. The relative standard curve 
method was used to estimate changes in gene expression. RNA concentration in 
experimental sample triplicates was calculated from the generated standard curves and 
normalised to expression levels of housekeeping gene Gapdh as internal control and the 
mean taken. The values were then normalised to the experimental control group (day 0 
expression levels or control blocking antibody or genotype as stated in the individual figure 
legends).  
Primers  
Ascl2 Qiagen QT01066513 
Axin2 Qiagen QT00126539 
CyclinE1 (Ccne1) Qiagen Qt00103495 
Dll1 Qiagen QT00113239 
Dll3 Qiagen QT00113477 
Dll4 Qiagen QT01053598 
Epcam Qiagen QT00248276 
Gapdh Qiagen QT01658692 
Hes1 Qiagen  QT00313537 
Hey1 Qiagen QT00115094 
Hey2 Qiagen QT00129885 
HeyL Qiagen  QT00128954 
Igf1 Qiagen QT00154469 
Igf1r Qiagen  QT00155351 
Jagged1 Qiagen  QT00115703 
Jagged2 Qiagen  QT01043819 
Krt19 Qiagen QT00156667 
Lef1 Qiagen QT00148834 
Lgr5 (Gpr49) Qiagen QT00123193 
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Notch1 Qiagen  QT00156982 
Notch2 Qiagen  QT00153496 
Notch3 Qiagen  QT01051729 
Notch4 Qiagen  QT00135653 
Numb Qiagen QT00097328 
Sox9 Qiagen QT00163765 
Wnt7b Qiagen QT00168812 
Wnt9a Qiagen  QT01062250 
Table 2.3 Tables of primers used in this study 
2.8 MTT assay 
For in vitro cell viability assays, cells were plated at 2x105/cm2 density and treated for 48 
hours with DAPT, ICG001, AG1024 or recombinant IGF1 or the relevant vehicle at the 
concentrations shown in the figures. Anti-Notch antibodies or control were used at 
10ug/ml. 6 wells were used per concentration per experiment. MTT assay was conducted 
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (5 mg/ml) (Sigma-
Aldrich) diluted in PBS (Sigma-Aldrich). Cells were treated for 12 hours, and MTT crystals 
were dissolved in DMSO and read at 570/690 nm using a FluoStar Omega (BMG Labtech). 
2.9 EdU assay 
EdU incorporation assay (C10337, ThermoFisher Scientific) was conducted as described in 
the manufacturer’s instructions. Cells were plated at 2000 cells per well. After adhering 
overnight, media was changed to include DAPT (10uM), ICG001 (5uM) or volume-matched 
DMSO for 24 hours. EdU was added to give a working concentration of 10uM and incubated 
for 3 hours. Media was removed and cells fixed with 4% formaldehyde for 15 minutes. They 
were then washed with 3% BSA in PBS and permeabilised by treating with 0.1% triton X for 
20 minutes. Clickit reaction buffer and buffer additive were made up as per manufacturer’s 
instructions, added to the wells and incubated in the dark on a rocker for 30 minutes. 
Nuclear counterstaining was performed with DAPI Fluoromount-G. 
2.10 siRNA transfection 
Small interfering RNA (siRNA) against Notch3 was obtained from Qiagen (FlexiTube 
GeneSolution Cat no. 1027416, GS18131). Four independent sequences were obtained (see 
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Table 2.4) as well as a scrambled sequence control (Qiagen negative Allstars siRNA control). 
Oligonucleotides were suspended in 100ul RNAse-free water. BMOL cells were plated at 105 
cells per well. Cells were transfected using HiPerFect (Qiagen) as per manufacturer’s 
instructions. A mastermix of siRNA was prepared to the ratio 75ng siRNA: 6ul HiPerFect: 
200ul serum free water, mixed and left for 10 minutes at room temperature to form 
complexes. This was added a drop at a time onto cells while continuously swirling the plate 
to ensure even distribution. After 48 hours cells were lysed for RNA extraction to check 
gene knockdown efficiency. Sequences Notch3_6 and Notch3_3 did not cause significant 
knock-down compared to untransfected or scrambled controls and therefore were not 
used for further experiments. The experiment was repeated with sequences Notch3_7 and 
Notch3_5 and cells lysed for RNA at 24, 48, 72 and 96 hours to confirm effective duration of 
knockdown. Finally the procedure was repeated with multiple wells (n=4 per sequence) and 
after 48 hours cells were fixed with ice cold methanol and stained for Ki67 (see above). 
 






Table 2.4 Notch3 siRNA sequences 
2.11 Migration assay 
BMOL or SWA cells were trypsinised and incubated with 5ug/ml mitomycin C for 90 
minutes to inhibit proliferation. Wells of an Oris migration plate (Platypus Technologies) 
were coated with 60ul of 20ug/ml human placental laminin (Sigma L6274) for 2 hours at 
37oC. Excess solution was removed and central stoppers inserted. 5000 cells were added 
per well and incubated overnight to allow confluent cell attachment.  Stoppers were 
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removed to create a standardised central defect. Control (time=0) wells were fixed 
immediately with 5% glutaraldehyde. Media for the remaining wells was changed to 
contain DAPT (10uM), ICG001 I5uM) or volume matched DMSO and returned to the 
incubator for 24 hours. The remaining wells were fixed and cells stained with crystal violet 
and photographed. Quantification of cell migration was performed using Photoshop CS6 to 
generate standard defect size and ImageJ for pixel analysis. 
2.12 ELISA detection of IGF1 
Conditioned medium from cells cultured with ICG001 (5uM) or vehicle for 48 hours was 
tested for IGF1 concentration using an IGF1 Mouse ELISA kit (ab100695 Abcam) following 
the manufacturer’s protocol. This involves using a plate with wells pre-treated with capture 
antibody. Protein standards and samples were added and incubated for 2.5 hours at room 
temperature. After washing, biotinylated IGF1 detection antibody was added and incubated 
for one hour at room temperature. After further washing a HRP-streptavidin solution was 
added and incubated for 45 minutes. Finally TMB One-Step Substrate Reagent was added 
for 30 minutes prior to Stop Solution. The plate was read immediately at 450nm using a 
spectophotometer (SPECTROstar Omega). Test samples were run against the standard 
curve generated. This concentration was normalised to protein content of secreting cells 
(determined using a BSA standard and Pierce reagent) as a surrogate for cell number. 
2.13 Immunoblotting 
Cell extracts were prepared from BMOL or SWA cells treated with DAPT (10uM) or vehicle 
for 48 hours.  Protein content was quantified using a BSA standard and BCA reaction with 
Pierce reagent. Protein quantity was standardized using lysis buffer before sampled were 
resolved using precast 4-12% Bis-Tris NuPAGE gels and 1X MOPS running buffer (all 
ThermoFisher Scientific). Precision Plus Dual Colour ladder (BioRad) was used to assess 
molecular weight.  
Gels were transferred onto nitrocellulose membrane using Toubin’s transfer buffer. Protein 
transfer was confirmed using Ponceau red solution. Blots were washed with TBS-Tween 
before blocking with 5% powdered fat-free milk (Marvel) in TBS-Tween. Immunoblots were 
split at the 70kDa mark and incubated at 4°C overnight with primary antibody anti-Igf1R 
Y116 (Abcam) or anti-beta-actin clone AC-74 (Sigma-Aldrich) as a loading control. 
Appropriate horseradish peroxidase labelled secondary antibodies were used (Cell 
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signaling) and signal detected with ECL reagent (Thermo Scientific) on photographic film. 
Images were scanned and densitometric analysis performed in photoshop and ImageJ.  
2.14 Statistical analysis 
Prism software (GraphPad Software) was used for all statistical analysis. Data are presented 
as mean ± s.e.m. n refers to biological replicates. Normal distribution of data was 
determined using the D’Agostino and Pearson omnibus normality test. For parametric data, 
data significance was analysed using a two-tailed unpaired Student’s t-test. In cases where 
more than two groups were being compared, then a one-way ANOVA was used. In 
instances where the n was too small to determine normal distribution or the data were 
non-parametric then a two-tailed Mann–Whitney U-test was used. Kruskall-Wallis test was 
used when comparing multiple non-parametric data. Levels of significance are denoted as 
follows:  *p ≤ 0.05; **p ≤ 0.01; ***p ≤ 0.001. 
2.15 Study approval 
All studies involving human tissue were approved by the University of Edinburgh and NHS 
Lothian Academic and Clinical Central Office for Research Development (ACCORD) tissue 
governance unit (approval number: 10/S1402/33). Animal studies had local ethical approval 
and were conducted under license issued by the UK Home Office (Project licence number 








Notch and Wnt are key signals in liver development with Notch directing fate of the 
hepatoblast down the biliary route and Wnt signal directing fate down the hepatocyte 
route. They are also known to be important in regeneration after liver injury in the adult, 
but here their roles are less well understood. During HPC-mediated regeneration HPCs 
within the DR must become activated, proliferate, migrate and differentiate, and in doing 
so transition from the Notch determined biliary phenotype to the Wnt determined 
hepatocyte fate. This process likely requires careful regulation of these two signalling 
pathways. While fate may represent an example of antagonistic functions of Notch and 
Wnt, other actions such as proliferation and migration are similar. This leads to the 
questions – ‘are these pathways dynamically regulated?’ and ‘are they capable of 
cooperation?’ 
Traditional models used for the generation of hepatocyte injury and ductular reactions 
involve several weeks of ingestion of toxic diet (122, 329). Continuous exposure to the toxin 
results in ongoing hepatocellular damage and activation of DRs, limiting our ability to study 
what signals may drive a DR over time. Lu et al have recently demonstrated that beta-
naphthoflavone (BNF) induction of AhCre causing hepatocytic loss of MDM2 in the AhCre 
MDM2fl/fl mouse strain results in a florid DR from which HPCs can be isolated and are 
capable of repopulating the parenchyma in meaningful numbers (59). In this chapter I 
utilise this strain with a Cre induction regimen that generates a robust DR with low levels of 
short term morbidity and mortality. I sought to determine if this model could be used to 
study the ductular response over time. I then go on to determine if Notch and Wnt 
pathways were present and active, and if this activity appeared to be dynamic, consistent 
with temporal regulation of these pathways in the regenerative response. I characterise the 
Notch and Wnt expression profile of two HPC lines (BMOL and SWA) (330) to identify if they 
are typical of the DRs seen in the in vivo models. Finally I examine human tissue to see how 
representative my models may be and look for evidence of Notch and Wnt activity. 
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3.2 AhCre MDM2fl/fl is a model for the temporal study of hepatic 
progenitor cell response over time 
The AhCre MDM2fl/fl mouse model produces a DR in response to widespread hepatocellular 
injury and senescence as a consequent of loss of MDM2. This protein acts as a negative 
regulator of p53 and thus its loss results in accumulation of p53 causing senescence and 
apoptosis (Figure 3.1A). It has been established in previous work that a dose of 20mg/kg 
beta napthoflavone is sufficient to induce a ductular reaction within 10 days with a 
hepatocyte recombination rate of 85.1%. At 10 days 17% of the animals appear unwell and 
require euthanizing. This dose of BNF was administered and groups of mice harvested over 
a 14 day period for further analysis of the DR generated and the activity of Notch and Wnt 
pathways (Figure 3.1B). The animal experiment to generate the AhCre MDM2fl/fl time-
course tissues was conducted by Michael Williams. All subsequent tissue analysis presented 
in this chapter was performed by myself.  
 
Figure 3.1 Using the AhCre MDM2fl/fl model of hepatic progenitor cell (HPC) activation to 
study the ductular reaction over time: (A) The activation of HPCs requires both 
hepatocellular injury and inhibition of hepatocyte replication. The AhCre line contains the 
rat Cyp1A1 promotor upstream of Cre recombinase and when combined with a strain 
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bearing an Mdm2 locus in which exons 5 and 6 are flanked by loxP sites, the AhCre 
MDM2fl/fl strain is generated. Following administration of xenobiotic beta-naphthoflavone 
(BNF), Cre recombinase is expressed in hepatocytes where it results in inactivation of 
Mdm2. MDM2 is an E3 ubiquitin-protein ligase that degrades p53. Loss of MDM2 results in 
upregulation of p53 and induces p53-mediated hepatocyte death and senescence. This 
results in rapid activation of HPCs with the potential to restore liver architecture and 
function. (B) Cre-recombinase was induced with BNF and groups of mice harvested 3, 5, 7, 
10 and 14 days later for comparison with day 0 controls.                                                                                             
Following Cre induction, using the ductular markers panCK, cytokeratin 19 (CK19) and SOX9, 
a highly predictable expansion, morphological change and parenchymal invasion of ductular 
cells occurs (Figure 3.2A). Quantification of panCK positive cells confirms a predictable and 
sequential rise in ductular cell number (Figure 3.2C). I observed expression of SOX9 in 
hepatocytes (Figure 3.2A, middle panel) after injury. SOX9 is traditionally seen as a biliary or 
HPC marker however can be seen in hepatocytes after tamoxifen administration (14) and 
also has been reported to be expressed in low levels in uninjured periportal hepatocytes, in 
one study defining them as the cell responsible for cell turnover in liver homeostasis (149). 
Analysis of gene expression data shows changes in expression of ductular markers over 
time with cytokeratin19 (Krt19) being the first to rise, accompanying expression of putative 
HPC marker Ascl2 (Figure 3.2D). Following induction of hepatocyte senescence there is a 
rapid rise in proliferation rate of ductular cells which peaks at day 5 (approximately 20%) 
(Figure 3.3). These data confirm the utility of this model in studying the DR over time. Due 
to the morbidity beyond day 10, and that 10 days was sufficient to generate a robust DR 
with cell number by day 14 plateauing, any new animals experiments using the AhCre 






Figure 3.2 Single time-point MDM2 deletion from hepatocytes induces a temporal 
ductular response: (A) Immunohistochemistry for a range of ductular/HPC markers over 14 
days following Cre induction; panCK (upper panels), cytokeratin 19 (CK19) (middle panels) 
and SOX9 (lower panels). (B) Isotype controls. (C) Quantification of panCK positive cells 
following Cre induction (p<0.0001) (n=5-8 per time-point). (D) Gene expression of 
ductular/progenitor markers cytokeratin 19 (Krt19), Sox9, Epcam and Ascl2 following Cre-
induction relative to Gapdh normalised to day 0 levels (n=5-8 per time-point). Data are 
presented as mean ± SEM. Kruskal-Wallis test was used for comparison of multiple groups 
(p value shown in legend above) with Dunn’s multiple comparison post-test analysis 







Figure 3.3 Single time-point MDM2 deletion from hepatocytes induces predictable 
ductular proliferation: (A) Immunohistochemistry for panCK (green) and Ki67 (red) 
following Cre induction (day post-induction inset). Dual positive cells shown (white arrows). 
(B) Quantification of panCK/Ki67 dual positive cells as a proportion of single positive panCK 
cells (p<0.0001) (n=5-8 per time-point). (C) Single stain/isotype controls. Data are presented 
as mean ± SEM. Kruskal-Wallis test was used for comparison of multiple groups (p value 
shown in legend above) with Dunn’s multiple comparison post-test analysis included in the 




3.3 Notch pathway is active in HPC mediated regeneration in vivo 
To assess the involvement of Notch signalling after hepatocyte injury, I began by 
quantifying the expression of the Notch receptors over the AhCre MDM2fl/fl time-course 
tissue, to identify which receptors were expressed and whether this changed over time. 
There was an early marked increase in expression of Notch1 (by day 3), which then steadily 
fell (Figure 3.4A). Notch2 was detectable throughout the time-course but expression levels 
did not vary. Notch3 showed marked up-regulation, peaking at day 5 and showing more 
protracted expression than Notch1. Notch4 was undetectable at all time-points. 
Immunohistochemistry confirmed that expression of Notch1, specifically the active Notch1 
intracellular domain (NICD) was detectable within cells positive for ductular marker panCK, 
confirming expression within the DR (Figure 3.4B). Notch3 also co-localised with ductular 
marker panCK. Notch1 and Notch3 were both clearly evident within blood vessels, 
consistent with previous reports  (331). Notch2 was just detectable within the major ducts 






Figure 3.4 Expression of Notch receptors after MDM2-mediated hepatocellular injury is 
dynamic and is identified within ducts: (A) Gene expression of Notch receptors following 
Cre-induction relative to Gapdh normalised to day 0 levels. Notch4 was undetectable. (B) 
Immunohistochemistry for Notch1 intracellular domain (ICD) on day 3 (upper panel) and 
Notch3 on day 7 (lower panel) (red) and panCK (green) in AhCre MDM2fl/fl model. (C) Single 
stain/isotype staining controls (D) Immunohistochemistry for Notch2. For gene expression 








As so little is known about Notch3 in the liver, I was keen to ensure the ductular expression 
seen in the AhCre MDM2fl/fl model was representative of other traditional models of 
hepatocellular injury. Animals treated with 3 weeks of choline-deficient, ethionine-
supplemented (CDE) or 2 weeks methionine-choline deficient (MCD) diet showed also 
expression of Notch3 within CK19 positive ductular cells (Figure 3.5). In addition there 




Figure 3.5 Notch3 is expressed in other models of hepatocellular injury: 
Immunohistochemistry for Notch3 (red) and CK19 (green) in CDE- (top) and MCD- (bottom) 
diet treated animals. Consistent with AhCre MDM2fl/fl model, Notch3 co-localises with 
ductular cells, blood vessels and some myofibroblasts accompanying the ductular reaction. 
Photomicrograph scale bars: 100uM. 
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In order to confirm this, I co-stained tissue from the AhCre MDM2fl/fl model and CDE model 
with myofibroblast marker alpha-smooth muscle actin (aSMA) (Figure 3.6). In both models 
most animals showed only co-localisation of Notch3 and aSMA in blood vessels, however in 
a subset of animals, myofibroblasts were Notch3 positive (2 out of 5 animals examined), 





Figure 3.6 Expression of Notch3 in myofibroblasts after hepatocellular injury: 
Immunohistochemistry for Notch3 (green) and aSMA (red) in AhCre MDM2fl/fl model (top) 
and CDE diet (bottom). Most animals after MDM2 or CDE diet-mediated injury show 
Notch3 isolated to ductular cells and blood vessels (upper panels) however in a subset of 
animals, Notch3 positive aSMA positive (myofibroblast) cells are seen (lower panels). 
Photomicrograph scale bars: 100uM. 
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To identify which ligands might be signalling to Notch1 and Notch3 I quantified the 
expression of Notch ligands over the AhCre MDM2fl/fl time-course (Figure 3.7A). Jagged1 
rose rapidly, peaking at day 3. Jagged2 expression also appeared dynamic and peaked at 
day 5. Dll1 expression did not change markedly over the time-course. Dll3 and Dll4 were 
not detectable. I went on to confirm expression at the protein level by performing 
immunohistochemistry for Jagged1, Jagged2 and Dll1. Jagged1 was strongly expressed in 
blood vessels and around ducts, as was Jagged2. Interestingly Dll1 in addition to staining 
blood vessels appeared to localise to ducts. This was confirmed by dual staining with 
ductular marker panCK. This suggests a capacity may exist for local Notch signalling within 





Figure 3.7 MDM2-mediated hepatocellular injury induces dynamic expression of Notch 
ligands: (A) Gene expression of Notch ligands following Cre induction relative to Gapdh 
normalised to day 0 levels. Dll-3 and Dll-4 were undetectable. (B) Immunohistochemistry 
for Notch ligands Jagged-1 (left), Jagged-2 (middle) and Dll-1 (left), (red) and Dll-1 (red) with 
panCK (green) (lower panel) (all day 5 post-induction).  For gene expression data n=5-8 per 





Figure 3.8 Expression of Notch effector genes after MDM2-mediated hepatocyte injury 
follows a characteristic profile or ‘signature’: Gene expression of classic canonical Notch 
target genes after Cre induction Hes1, Hey1 and Hey2 relative to Gapdh normalised to day 0 
levels. n=5-8 per time point. Data are presented as mean ± SEM.  
 
Notch signalling results in the expression of a great many genes. In order to determine if 
Notch signalling might be active after hepatocellular injury, I began by analysing the 
expression of genes from the classic canonical Notch effector Hes and Hey families (Figure 
3.8). Genes followed a characteristic expression profile, rising from day 3 and peaking at 
day 10, suggestive of a Notch expression ‘signature’. 
The presence of dynamic changes in expression of Notch ligands, receptors and effectors 
would suggest an intact and active signalling pathway after hepatocellular injury. In order 
to provide further evidence of this and confirm if activity was located within the ductular 
reaction I crossed the AhCreMDM2fl/fl mice with a strain that reports active canonical Notch 
signalling at single cell resolution CBF:H2B-venus (322). A nuclear localised H2B:venus 
protein, a variant of YFP is expressed when a cell is in receipt of canonical Notch signal. 
Nuclear translocation of the NICD following ligand binding results in binding of NICD to C 
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promotor binding factor (CBF) at CBF response elements. This results in transcription from 
the simian virus (SV) 40 minimal promotor of the transgene H2B-venus (Figure 3.9A). In the 
uninjured AhCreMDM2fl/fl; CBF:H2B-venus mice, Notch activity was reported in ductular 
cells as demonstrated by co-localisation of YFP with ductular marker CK19. Cohorts of 
animals underwent Cre-induction with BNF and were harvested 0, 3, 5, 7 and 10 days later. 
Immunohistochemistry in these animals confirms Notch signalling within all ductular cells 
persisting until day 7. At day 7 some ductular cells are negative for the reporter and by day 
10 reporter expression is infrequent.  
Together these data suggest that there is dynamic regulation of the Notch pathway 
following hepatocyte injury with differential expression of Notch1 and Notch3, and that 





Figure 3.9 AhCre MDM2fl/fl CBF:H2B-venus strain permits visualisation of Notch signal 
within ductular cells: (A) Schematic of AhCre MDM2fl/fl CBF:H2B-venus strain. A nuclear 
localised H2B-YFP venus fusion protein is expressed under control of multiple CBF1 binding 
sites and SV40 minimal promoter. Canonical Notch signalling results in nuclear 
translocation of the notch intracellular domain (NICD), association with CBF1 and its binding 
to the response elements resulting in reporter expression. (B) Low power image of AhCre 
MDM2fl/fl CBF:H2B-venus strain for CK19 (green), YFP (red). PT = portal tract, CV = central 







Figure 3.10 Expression of Notch reporter in AhCre MDM2fl/fl CBF:H2B-venus strain 
confirms dynamic Notch activity after hepatocellular injury: Immunohistochemistry for 
YFP venus (red) and CK19 (green) after Cre induction in Notch reporter strain AhCre 
MDM2fl/fl CBF:H2B-venus. Arrows denote reporter-negative ductular cells. Photomicrograph 




3.4 HPC lines express Notch pathway 
Having established in vivo that DRs demonstrate Notch activity, I went on to characterise 
the expression of the Notch pathway in HPC lines to further confirm if HPCs are likely to be 
sensitive to Notch signalling. In order to determine the direct effects of Notch signalling on 
HPCs in the absence of direct or indirect influence from other cell types, I used two HPC 
lines, BMOL (330) and SWA. Both are derived from the livers of mice who have been fed 
CDE diet to induce a HPC response and can be differentiated along the hepatocyte lineage.  
The BMOL cell line was derived from HPCs that have undergone spontaneous 
immortalisation (330). Digested liver tissue was passed through a Percoll density 
centrifugation gradient to generate primary cultures which were then serially diluted to 
obtain single cell cultures, some of which overcame growth inhibition to form clonally-
derived lines. Phenotypic markers of both biliary and hepatocytic lineages are expressed 
and they can be differentiated towards hepatocytes using dexamethasone with insulin-
transferrin-selenium and nicotinamide or Wnt3a (123, 330). 
SWA cells were generated by Wei-Yu Lu and Atsunori Tsuchiya and differ in that the 
primary cultures were grown in a highly restrictive media (328) to prevent fibroblast 
overgrowth and then passaged using a diluted trypsin technique to lift small colonies of 
cells (59). After 16 passages the cells were weaned onto the standard growth medium used 
for culturing BMOLs and became tolerant to usual methods of trypsinisation. With similar 
changes to the growth media differentiation into hepatocytes is possible (59). 
Both cell lines expressed Notch1 and Notch3. Notch1-ICD staining was most marked in the 
smaller cells at the centre of colonies. Notch3 stained all cells within the culture (Figure 
3.10). Notch2 was just visible in the BMOL line and weakly stained a small proportion of 
cells of the SWA line. 
Next I stained both HPC lines for the three Notch ligands identified in the AhCre MDM2fl/fl 
time-course (Figure 3.11). Both lines were negative for Jagged1 and Jagged2, however both 
stained positive for Dll1, consistent with the immunostaining from injured livers and further 




Figure 3.11 Expression of Notch receptors in HPC lines: Immunocytochemistry for Notch1 
intracellular domain (Notch1-ICD), Notch2 and Notch3 in BMOL (upper panel) and SWA 
(lower panel) cell lines.  DAPI co-stain omitted to help demonstrate nuclear location of 
Notch3, all cells were positive for Notch3. Photomicrograph scale bars: 100uM. 
 
  
Notch1 ICD Notch3 Notch2 
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Figure 3.12 Expression of Notch ligands in HPC lines: Immunocytochemistry for Jagged-1 
(green), Jagged-2 (green) and Dll-1 (red) in BMOL (upper panel) and SWA (lower panel) cell 
lines. Photomicrograph scale bars: 100uM. 
 
3.5 Wnt pathway is involved in HPC mediated regeneration in vivo 
To assess the involvement of Wnt signalling after hepatocyte injury, I began by quantifying 
the expression of Wnt ligands over the AhCre MDM2fl/fl time-course tissue. Wnt ligands 9a 
and 7b rise rapidly after induction of Cre in AhCre MDM2fl/fl mice (Figure 3.13A). Wnt 
signalling has a vast number of target genes. Axin2 and Lef1 are considered classical targets 
of canonical Wnt signal. Wnt signalling is known to be important in maintenance of 
hepatocyte function (150, 332) so it was not unexpected that expression of Wnt target 
effectors including Lef1 and Axin2 fall sharply after Cre-mediated induction of hepatocyte 
senescence and injury.  After day 5 expression rapidly returned to pre-injury levels. Wnt 
target gene and Notch antagonist Numb also follows this trajectory. As these genes follow a 
typical expression profile, akin to the characteristic expression pattern seen amongst the 
Notch effector genes, this suggests there is also a Wnt expression ‘signature’. Interestingly 
Wnt-sensitive stem cell marker Lgr5 also follows this expression profile and would be 
consistent with previous studies identifying a putative Lgr5+ HPC population only after liver 





Figure 3.13 Hepatocyte injury induces dynamic changes in expression of the Wnt 
pathway: (A) Gene expression of Wnt ligands Wnt9a and Wnt7b following Cre-induction 
relative to Gapdh normalised to day 0 levels. (B)  Gene expression of Wnt target genes Lef1, 
Axin2, Numb and Lgr5 following Cre-induction. n=5-8 per timepoint. Data are presented as 
mean ± SEM.  
I went on to demonstrate by in situ hybridisation that Axin2 and Lgr5 were expressed 
within DRs (Figure 3.14). In the uninjured liver, Axin2 was detectable in zone 3 hepatocytes 
(Figure 3.14B) consistent with previous reports (150). However I also observed expression 
within ductular cells (Figure 3.14A). After injury Axin2 expression is seen in expanding DRs. 
Lgr5 was not visible in uninjured ducts but was present in DRs after injury and in pericentral 









Figure 3.14 Wnt target effectors are expressed by ductular cells after MDM2-mediated 
hepatocellular injury: (A) Expression of Axin2 RNA in the ducts of uninjured animals and 
days 7 and 10 after hepatocellular injury (filled arrows). (B) Expression of Axin2 in zone 3 
hepatocytes (unfilled arrows) (upper panel) and gut (lower panel). (C) Lgr5 RNA is not 
detectable in the ducts of uninjured animals but can be detected in expanding DRs after 
injury (filled arrows) and by day 10 in hepatocytes adjacent to DRs (unfilled arrow). (D) 
Expression of Lgr5 RNA in zone 3 hepatocytes of uninjured liver (unfilled arrows) (upper 
panel) and gut (lower panel). (E) Staining controls: negative control probe DapB and 




The presence of dynamic changes in expression of Wnt ligands and effectors would suggest 
an intact and active signalling pathway after hepatocellular injury. In order to provide 
further evidence of this and further confirm activity was located within the ductular 
reaction I crossed the AhCreMDM2fl/fl mice with a second reporter strain, this time one that 
reports active canonical Wnt signalling at single cell resolution TCF/LEF:H2B-GFP (323). This 
strain expresses a nuclear localised H2B-GFP fusion protein in response to binding of 
TCF/LEF to its response element. Canonical Wnt signalling results in nuclear translocation of 
active (de-phosphorylated) beta-catenin which acts as a co-activator of TCF/LEF and thus 
reporter expression (Figure 3.15A). 
In the uninjured AhCreMDM2fl/fl TCF/LEF:H2B-GFP mice pericentral or zone 3 hepatocytes 
demonstrated Wnt activity, consistent with previous reports (150, 333) (Figure 3.15B). In 
uninjured animals, reporter expression was also detected at a reduced intensity in CK19-
positive ductular cells, suggesting a tonic level of Wnt signal in biliary homeostasis, similar 
to the gut. Cohorts of animals underwent Cre-induction with BNF and were harvested 0, 3, 
5, 7 and 10 days later. Immunohistochemistry in these animals identified that after injury 
there is expansion of GFP-negative ductular cells, suggesting Wnt is not required for this 
early expansion. By day 7 most ductular cells are positive, consistent with progressive 
upregulation of Wnt activity.  
Together these data suggest that Wnt activity, although potentially required to maintain 
the biliary compartment in a state of readiness to respond to hepatocyte injury, is not 
involved in the early expansion of the ductular reaction. However as the DR progresses, the 





Figure 3.15 AhCre MDM2fl/fl TCF/LEF:H2B-GFP strain permits visualisation of Wnt signal 
within ductular cells: (A) Schematic demonstrating AhCre MDM2fl/fl TCF/LEF:H2B-GFP 
strain. A H2B-GFP fusion protein is expressed under control of a TCF/Lef1 response element 
and a heatshock protein 1B minimal promotor. Canonical Wnt signalling results in nuclear 
translocation of beta-catenin, a co-activator of TCF/LEF, response element binding and 
expression of the construct. (B) Low power image of AhCre MDM2fl/fl TCF/LEF:H2B-GFP 
strain for CK19 (green), GFP (red). PT = portal tract, CV = central vein. Photomicrograph 






Figure 3.16 Expression of Wnt reporter in AhCre MDM2fl/fl TCF/LEF:H2B-GFP strain 
confirms dynamic Wnt activity after hepatocellular injury: Immunohistochemistry for GFP 
(red) and CK19 (green) after Cre induction in Wnt reporter strain AhCre MDM2 
fl/fl;TCF/LEF:H2B-GFP. Arrows denote reporter-negative ductular cells. Photomicrograph 




3.6 HPC lines express Wnt pathway 
To determine if my HPC lines were representative of the cells of the DRs seen in vivo, I 
performed immunocytochemical staining for beta-catenin. All cells of both BMOL and SWA 
lines were positive (Figure 3.17). In addition, cells were positive for an antibody that 
identifies the dephosphorylated (i.e. active) form of beta-catenin. This form was seen 




Figure 3.17 The Wnt pathway is identified in HPC lines: Immunocytochemistry for total 
beta-catenin (red) and dephosphorylated (active) beta-catenin (ABC) (red) in BMOL (upper 
panel) and SWA (lower panel cell lines). Photomicrograph scale bars: 100uM. 
 
3.7 Notch and Wnt pathways co-exist in HPC-mediated 
regeneration 
As experiments above suggested that DRs express elements of both Notch and Wnt 
pathways, I was interested to see if both pathways could be expressed in the same cell as 
was suggested by the frequency of reporter expression at day 7 in AhCreMDM2fl/fl; 
CBF:H2B-venus and AhCre MDM2 fl/fl; TCF/LEF:H2B-GFP mice. I stained tissue from the 
80 
 
AhCre MDM2fl/fl time-course for Notch3 and beta-catenin and dephosphorylated beta-
catenin and found dual expression within the DR. While this does not confirm both 
pathways are active in the same cell in itself, taken with the Notch and Wnt reporter 
evidence it strongly suggests a Notch-Wnt permissive state. This is further supported by 
dual staining of HPC lines for beta-catenin and Notch3 (Figure 3.19). 
 
 
Figure 3.18 The ductular reaction after hepatocellular injury expresses both Notch and 
Wnt: (A) Immunohistochemistry for Notch3 (red) and beta-catenin (green) in AhCre 
MDM2fl/fl model. (B) Immunohistochemistry for Notch3 (red) and dephosphorylated beta-





Figure 3.19 Notch and Wnt pathways co-exist in HPC lines: Immunocytochemistry of beta-
catenin (red) and Notch3 (green) in BMOL (upper panels) and SWA (lower panels) HPC lines. 
 
3.8 Notch and Wnt pathways are present in human disease 
DRs are known to be present in a range of human liver diseases. I received Local ethical 
approval (number 10/S1402/33) for access to tissue samples held as part of the South East 
Scotland SAHSC Bioresource. I used tissue from liver explants from patients with 
hepatocellular disease (both acute and chronic) to identify samples containing DRs. Staining 
of tissue from these cases of advanced liver disease and identified those with robust DRs 
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(Figure 3.20). Robust DRs were seen in 2/5 cases fulminant liver failure, 2/3 cases hepatitis 
C virus and 1/1 case autoimmune hepatitis. I went on to identify if there was evidence of 
Notch and Wnt pathway presence in these samples. Staining of this tissue identified 
occasional cells positive for Notch1-ICD but Notch3 was more widely expressed and co-
localises with ductular cells, confirming the relevance of Notch3 even in advanced human 
disease. In the short-term mouse models Notch3 stained all ductular cells, whereas in end-
stage human disease while all parent ducts were positive, not all ductular cells within the 
expanded DR were positive in all samples. This may reflect differences between short-lived 
and long term disease. 
DRs in chronic human disease also stained positive for beta-catenin in all conditions 







Figure 3.20 Ductular reactions occur in chronic hepatocellular injury in humans: (A) 
Representative images of immunohistochemistry for panCK in fulminant hepatic failure, 




Figure 3.21 Notch is expressed in human chronic hepatocellular injury: Representative 
images of immunohistochemistry (from left to right) for panCK,  Notch1-ICD, Notch3 and 
co-stain for Notch3 (red) and panCK (green) in human hepatocellular liver diseases: 
hepatitis C virus infection (upper panel), fulminant liver failure (middle panel) and 




Figure 3.22 Beta-catenin is expressed by the ductular reaction after hepatocellular injury 
in human disease: Representative images of immunohistochemistry for panCK (red) and 
beta-catenin (green) in human hepatocellular liver diseases: hepatitis C virus infection 
(upper panel), fulminant liver failure (middle panel) and autoimmune hepatitis (lower 




Classic models used to study the response to hepatocellular injury or hepatocyte loss are 
acetaminophen (APAP) poisoning and 2/3 partial hepatectomy (29, 111). In both these 
models the insult is administered at a single point in time and thus the dynamics of injury 
and repair can be studied. DRs are not typically generated in these models and therefore 
temporal study of the HPC response is not possible. Classic rodent dietary injury models do 
generate DRs and replicate some of the features of human chronic liver disease, however 
not the wide scale replicative arrest that appears necessary in rodents for generation of a 
DR with extensive hepatocytic differentiation of HPCs (59, 118, 119). In addition, studying 
signalling pathways that may be expressed dynamically as a DR generates is limited when 
injury is continuous, with temporal changes that may be masked by ongoing injury and HPC 
activation. In order to study Notch and Wnt signalling after hepatocellular injury further, in 
this chapter I used a recently established potent model of HPC activation AhCreMDM2fl/fl 
that replicates the hepatocyte senescence seen in advanced human disease. I took 
advantage of the synchronised injury delivered in the AhCreMDM2fl/fl model to study the 
temporal dynamics of DRs and the signalling pathways involved in generating the HPC 
response. 
Using tissue from AhCreMDM2fl/fl animals taken at various time-points after induction of 
Cre-mediated MDM2 hepatocyte injury, I was able to monitor the DR as it developed. There 
was a predictable increase in ductular cell numbers which began to plateau between days 
10 and 14. Accompanying this increase in cell number was a change in cell morphology 
from expanding numbers surrounding a ductal lumen to an elongated appearance and then 
physical migration into the parenchyma away from the parent duct. I also studied the 
proliferation dynamics confirming a highly proliferative cell type with the peak proliferation 
rate reached at day 5. Detectable changes in expression of reported HPC markers were also 
seen over the time-course, further confirming the utility of this model in studying the 
development of DRs. 
I went on to use this model to interrogate expression of the Notch pathway. I identified 
changes in expression of Notch receptors Notch1 and Notch3 after induction of injury. The 
expression profile of Notch1 was relatively short lived with localisation of the active 
intracellular domain within cells of the DR. Expression of Notch3 was more persistent 
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following injury. Notch3 has not been well studied in the liver. It has a potential role in 
regulating the activation of hepatic stellate cells and thus may be pro-fibrotic (226, 334), 
and in the foetal liver, Notch3-expressing cells are more hepatocyte-like with Notch3 
activity appearing conducive to hepatocyte differentiation (285). A role in biliary epithelium 
or HPCs has not been established. I identified expression of Notch3 in the DRs of 
AhCreMDM2fl/fl animals and confirmed this was not model specific by replicating the finding 
in two traditional dietary models of hepatocellular injury. A subset of animals showed 
expression of Notch3 within fibroblasts, however this was not universal and therefore the 
role of Notch3 is unlikely to be restricted to fibrosis. The expression profiles of Notch 
receptors in my two HPC lines were similar to the in vivo models. 
I identified dynamic expression of Notch ligands Jagged1 and Jagged2 which localised to the 
area around ductular cells, most likely expressed by myofibroblasts, consistent with 
previous reports (91, 123). I was also able to detect expression of Dll1 by ductular cells. This 
was further supported by identifying Dll1 expression in both HPC lines. This is an interesting 
observation as it suggests there may be potential for paracrine Notch signalling within the 
ductular compartment. It also explains how Notch signalling may occur in a HPC line 
monoculture, given Jagged ligands are not expressed by the HPCs themselves. 
I found expression of classical Notch effectors, the Hes and Hey family of genes, followed a 
distinctive expression pattern in the AhCreMDM2fl/fl animals. This leads me to describe a 
‘signature’ expression profile of Notch target genes. 
Identifying dynamic changes in ligand, receptor and effectors suggested an intact signalling 
pathway. To confirm this I added a reporter of Notch activity to my transgenic model. This 
demonstrated active Notch signalling particularly marked in the early part of the injury 
response. As the half-life of GFP and its variants is reported to be 24 hours it could be 
argued that Notch activity was over-estimated. This could be overcome by using GFP 
variants with a shorter half-life (335, 336). 
Using a similar strategy I demonstrated dynamic expression of Wnt pathway components in 
the AhCreMDM2fl/fl model. The canonical Wnt target genes examined followed a 
characteristic profile or Wnt ‘signature’ of loss during the first 5 days, followed by rapid 
return to pre-injury levels. The early fall likely reflects loss of Wnt pathway expression by 
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injured hepatocytes. Of particular interest was the observance of a similar expression 
profile of stem cell marker Lgr5 and localisation of expression to ducts post-injury. The late 
finding of rising Lgr5 expression suggests this does not mark a resting resident population, 
rather is induced in another population after injury. This is consistent with the previous 
observations that Lgr5+ cells are only identified in the liver after injury (77). The marked 
rise I identified in Ascl2 expression, known to be upstream of Lgr5, further supports this.  
The identification of GFP reporter expression in uninjured AhCreMDM2fl/fl; TCF/LEF:H2B-
GFP mice was a particularly interesting finding. The intensity of signal was lower than in 
pericentral hepatocytes likely reflecting lower expression levels, but clearly positive. This 
does however suggest a tonic level of Wnt signal in biliary homeostasis, suggesting parallels 
to the gut stem cell compartment where both Notch and Wnt are required for maintenance 
of stem cell populations (41, 242, 270). Expression of reporter in ducts occurred regardless 
of the animals’ age and thus not reflective of residual reporter activity from immature 
animals. Analysis of HPC lines further supports active Wnt signalling within the DR. 
Benhamouche et al performed in situ hybridisation for Wnt target gene Axin2 as part of 
work determining that liver zonation was maintained by a balance of Wnt signalling (20). By 
in situ hybridisation they identified Axin2 expression in pericentral hepatocytes but 
interestingly the ducts also appear to show some expression. Using an RNAScope method 
for in situ hybridisation I was able to identify Axin2 in both ductular cells and pericentral 
hepatocytes. A TOPGAL TCF/LEF reporter strain has previously been used to analyse Wnt 
activity in uninjured and DDC-treated animals in which beta-catenin binding to TCF/LEF 
response elements results in beta-galactosidase (beta-gal) expression encoded for by the 
lac z gene (263). This study demonstrated minimal beta-gal reporter activity in the portal 
region of non-injured animals with reporter expression limited to the pericentral 
hepatocytes. After biliary injury, there was increased beta-gal activity in DRs. In my TCF/LEF 
reporter system, the use of a bright fluorescent reporter enabling single cell resolution and 
the construct containing six TCF/LEF binding sites means the sensitivity of this system is 
higher (323) and may explain the discrepancy in our findings.  
Notch and Wnt have antagonistic functions in fate determination of hepatoblasts and HPCs, 
yet often appear to drive similar cellular processes. I wanted to establish if Notch and Wnt 
signals represented an either/or state or might be able to coexist. The frequency of 
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reporter expression in the AhCreMDM2fl/fl; CBF:H2B-venus and AhCreMDM2fl/fl; 
TCF/LEF:H2B-GFP mice suggested a capacity to overlap. Analysis of the HPC lines identified 
Notch3 and beta-catenin within the same cell. Staining the AhCreMDM2fl/fl confirmed this in 
vivo. Through the actions of the Wnt target gene Numb, Wnt antagonises Notch. The 
structural differences between the paralog Notch receptors results in differences in their 
sensitivity to antagonism via Numb. Notch3 is relatively resistant to Numb-mediated 
degradation and thus is congruent with a Notch/Wnt permissive state possible within adult 
HPCs. This is highly consistent with the finding that in foetal liver progenitor cells, where 
Wnt is essential for hepatocyte differentiation of hepatoblasts, Notch3 expression is 
conducive to hepatocytic differentiation (285). 
Finally, I have confirmed that in the DRs of advanced human hepatocellular disease, Notch, 
in particular Notch3, remains present, as does beta-catenin. In the short-term mouse 
models Notch3 stained all ductular cells. However, in end-stage human disease, while all 
parent ducts were positive, not all cells within the DRs were positive in all samples. This 
may reflect differences between short-lived and long term disease. Spee et al have 
previously identified expression of Jagged1 and LEF1 accompanying DRs in human acute 
and chronic hepatocellular injury, suggesting both Notch and Wnt pathways may be 
involved, although propose Notch pathway is less relevant to hepatocellular injury based on 
Notch1-ICD staining (221). Further supporting a role for Wnt signalling within the biliary 
compartment in the regeneration of hepatocytes from HPCs in human disease is the recent 
publication of a study identifying expression of Wnt target gene glutamine synthetase (GS) 
in ducts that appear to contribute to hepatocyte replacement (51).  
The descriptive work outlines in this chapter identifies dynamic expression and activity of 
Notch and Wnt pathways after hepatocellular injury and led me to perform further 
experiments to investigate if these pathways are functional, what these functions might be, 




4 The functional role of Notch signalling in progenitor 
mediated hepatocellular regeneration 
 
4.1 Introduction 
Canonical Notch signalling involves Jagged or Delta family ligands binding to the 
extracellular domain of transmembrane Notch receptors on neighbouring cells. This leads 
to cleavage by ADAM10/TACE metalloprotease releasing the extracellular component, then 
a further cleavage by the gamma-secretase complex allowing release and nuclear 
translocation of the Notch intracellular domain (NICD) where it binds RBP-Jk and drives 
transcription of Notch target genes (see Figure 1.3). 
During development Notch signalling is critical for the formation of cholangiocytes and the 
maturation and patterning of the biliary tree (214, 337). Mesenchymal Jagged-1 signalling 
via Notch2 results in NICD/RBPJK mediated activation of biliary specification gene HNF6 
(338). In the adult liver, Notch continues to direct biliary fate of DRs and HPCs with Notch2 
remaining a key paralog for this process (123, 222, 224). These studies also show a role for 
Notch in expansion of DRs after biliary injury and most recently it has been demonstrated 
that genetic loss of Notch signalling intermediate RBPJK or specific interference between 
Jagged1-Notch1 signalling impedes proliferation of cholangiocytes and DRs generated in 
response to biliary injury (58, 91). 
Having established dynamic changes in expression of Notch pathway after hepatocellular 
injury, I wanted to investigate if these changes reflect temporally regulated functionality 
within DRs. In order to do this I used a number of techniques to disrupt Notch signalling – 
small molecule inhibitors, blocking antibodies, small interfering RNA (siRNA) and genetic 
loss of function. 
As key roles identified for Notch in the liver relate to biliary differentiation and proliferation 
of cholangiocytes and DRs after biliary injury, I have focused on answering whether Notch 
signalling governs proliferation of the DR after hepatocellular injury. 
In this chapter I begin by determining if the proliferation of HPC lines is sensitive to Notch 
inhibition and determine which Notch paralogs are responsible for this effect. I also 
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examine a potential role for Notch in the migration of HPC lines. I then go on to  determine 
if the dynamic Notch pathway component and Notch reporter expression demonstrated in 
chapter 3 reflects changes in functional activity driving the ductular response. 
4.2 Notch signalling promotes proliferation of HPC lines 
Using my two HPC lines, I began by ascertaining whether their proliferation appeared 
sensitive to Notch inhibition. I first used a MTT assay which reports the ability of live cells 
to convert yellow 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
to purple formazan; the rate of conversion reflecting the number of viable cells. 
However, it should be noted that cell number will be affected by both cell proliferation 
and cell death. To inhibit Notch I used small molecule gamma secretase inhibitor DAPT 
(N-[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester). The gamma 
secretase complex is responsible for cleavage of the NICD from the membrane, therefore 
gamma secretase inhibitors prevent cleavage and nuclear translocation and transmission of 
signal. This small molecule has been confirmed to effectively block Notch signalling in the 
liver both in vitro and in vivo in multiple studies (91, 123). Incubating cells with increasing 
concentrations of DAPT resulted in a dose-dependent decrease in viable cell number 
(Figure 4.1A). To determine if this reduction in cell number was caused by a drop in 
proliferation rate, I selected the concentration of DAPT which reduced absorbance in both 
lines by approximately 50% (10uM) for use in a 5-ethynyl-2’-deoxyuridine (EdU) 
incorporation assay, a more specific measure of cell proliferation. EdU is an analogue of 
nucleoside thymidine incorporated into DNA during S-phase. After incubation with DAPT for 
48 hours EdU incorporation in BMOLs was reduced from a mean of 48.3% to 25.4% and 
SWAs from 47.5% to 27.2% (Figure 4.1B). To confirm this reduction in proliferation rate 
related to Notch inhibition, I measured expression of classical Notch effector genes Hes1 
and Hey1 in cells exposed to the same concentration of DAPT for 48 hours and found 









Figure 4.1: Notch inhibition with gamma secretase inhibitor reduces proliferation of HPC 
lines: (A) MTT assay using BMOL (left) and SWA (right) lines treated with increasing 
concentrations of DAPT or vehicle. Data presented as mean ± SEM of 6 experimental 
replicates, experiment was repeated twice. (B) Representative images (left) and 
quantification of EdU incorporation in BMOL (upper panel) and SWA (lower panel) lines 
treated with DAPT or vehicle (n=6 per group). (C) Gene expression of Notch target genes 
Hes1 (left) and Hey1 (right) relative to Gapdh in cell lines BMOL (upper panels) and SWA 
(lower panels) treated with DAPT compared to vehicle (n=6 per group). Data are presented 
as mean ± SEM. DAPT dose-response experiments were analysed by 2-way ANOVA. Mann 
Whitney test was used for experiments with two groups. **p<0.01; ***p<0.001. 





As expression profiles of the different Notch receptors differed both in the cell lines and in 
vivo after hepatocellular injury. I wanted to determine if this Notch-mediated effect on 
proliferation was receptor-specific. Using blocking antibodies raised against Notch2, 
Notch2, Jagged1 and a control antibody – raised against an intracellular epitope (desmin) I 
performed further cell viability assays. Two clones of Notch1 (aN1_E7 and aN1_E10) and 
Notch2 (aN2_B6 and aN2_B9) blocking antibodies were used to confirm the effect (Figure 
4.2). Notch1 reduced cell number of both cell lines. Reductions in viable cell number after 
Notch2 blockade did not reach significance. Interestingly blocking Jagged1 did not 
significantly reduce cell number either. This would further support that some part of the 
Notch signalling effect, at least within these HPC lines, can be mediated via Dll1.  
As no blocking antibody was available to Notch3, I used small interfering RNA (siRNA) to 
knock-down endogenous Notch3 expression in the BMOL line. I tested four sequences of 
siRNA to Notch3, a scrambled sequence and untransfected cells. As transfection can result 
in a degree of non-specific knockdown, knockdown efficiencies were expressed as a 
proportion of expression relative to the scrambled sequence. Two of the Notch3 siRNAs 
(Notch3_5 and Notch3_7) resulted in 80-90% knockdown. This effect persisted for 48 hours 
and expression was returning to normal levels by 96 hours (Figure 4.3). At 48 hours post 
transfection, I stained cells for proliferation marker Ki67 and found Notch3 siRNAs reduced 
proliferation (p=0.0022). When compared to scrambled sequence the Notch3_7 sequence 
reached statistical significance on post-test analysis. These data suggest Notch1 and Notch3 






Figure 4.2: Notch1 blockade reduces viability of HPC lines: MTT assay using BMOL (left, 
p=0.0031) and SWA (right p=0.0049) cell lines treated with one of 2 clones of anti-Notch1 
(aN1_E7 and aN1_E10), anti-Notch2 (aN2_B9 or aN2_B6), anti-Jagged1 or control antibody 
(to intracellular epitope desmin). Data presented as mean ± SEM of 6 experimental 
replicates, experiment was repeated twice. Significant p value for Kruskal-Wallis test for 
experiments with multiple groups presented above with Dunn’s multiple comparison post-







Figure 4.3: Loss of Notch3 results in attenuated proliferation in HPC lines: (A) Expression 
of Notch3 relative to Gapdh in BMOL cells transfected with two sequences of siRNA to 
Notch3 (Notch3_5 and Notch3_7) or scrambled sequence 24, 48 and 72 hours post-
transfection. Data presented as mean of 3 technical replicates. (B) Percentage of BMOL 
cells positive for Ki67 48 hours after transfection with Notch3 or scrambled sequence 
siRNAs as above or addition of transfection vehicle (p=0.0022). Data presented as mean ± 
SEM of 6 experimental replicates. Significant p value for Kruskal-Wallis test for experiments 
shown above with Dunn’s multiple comparison post-test shown in figure. *p<0.05.  
4.3 Notch inhibition does not affect HPC migration in vitro 
Functions of Notch can include migration (339-341). When cells proliferate, the area they 
occupy will expand with cells appearing further from their starting point, unless the 
daughter cells become progressively smaller. This is clearly distinct from true cell migration. 
In order to determine if Notch might have an effect on migration of HPCs, I performed an 
assay in which cell proliferation is blocked, and thus with no change in cell number, 
migration can be better assessed. This assay involved plating BMOL and SWA cells at 
confluent density on extracellular matrix (laminin) coated plates around a central plug. The 
cells had been pre-treated with mitomycin C to inhibit proliferation. Once cells had 
adhered, the central plug was removed creating a standard circular area into which the cells 
could migrate. The media was changed to one containing DAPT or vehicle and after 24 
hours cells were fixed and stained (Figure 4.4). Images were taken and migrating cells 





Figure 4.4: Notch inhibition does not prevent migration of HPC lines: (A) Representative 
images of migration assay of BMOLs (upper panel) and SWA (lower panel) towards the 
centre of the well after exposure to DAPT 10uM (right) or control media (left).  (B) 
Quantification of cell migration by pixel analysis normalised to control conditions. n=8 per 
group. Data are presented as mean ± SEM. Statistical analysis by Student’s 2-tailed t test.  
 
4.4 Notch pathway is functionally active during the HPC response in 
vivo 
Having established a functional role for Notch signalling in the proliferation of HPC lines in 
vitro, I sought to confirm this effect in vivo. As I have identified temporal changes in 
expression of Notch pathway components and pathway activity reporting in the AhCre 
MDM2fl/fl strains, I designed experiments to assess the functional relevance of these 
changes to the expansion of the DR.  
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4.4.1 Inhibition of Notch reduces HPC number and proliferation in a time-
sensitive manner 
Experiments were designed to reflect the apparent time-sensitive nature of Notch signalling 
after hepatocellular injury. AhCre MDM2fl/fl mice received DAPT or vehicle by daily i.p. 
injection to coincide with the peak expression of Notch1 (days 2-4, ‘early’) or peak 
expression of Notch3 (days 4-6, ‘mid-point’), both times when Notch reporter (H2B:venus) 
expression was high. In a third experiment DAPT or vehicle was administered when Notch 
receptor and Notch reporter expression were falling (days 7-9, ‘late’) (Figure 4.5). Animals 
were harvested 24 hours after the final dose.  
 
 
Figure 4.5: Schematic depicting experimental design for Notch inhibition experiments in 
AhCre MDM2fl/fl strain: Notch inhibitor DAPT or vehicle was administered days 2-4 (‘early’) 
post Cre-induction to coincide with peak expression of Notch1, days 4-6 (‘mid’) to coincide 
with peak expression of Notch3, both time periods when CBF:H2B-venus expression was 
high. DAPT was then given days 7-9 (‘late’) when Notch receptor and CBF:H2B-venus 
expression was falling. Animals were harvested 24 hours after the final dose. (n=5 per 
group). 
 
‘Early’ inhibition of Notch (Figure 4.6) resulted in a reduction in number of ductular cells 
(Figure 4.6C), a time when Notch1 and H2B:venus expression were high. Proliferation as 
determined by the proportion of ductular cells that stained positive for proliferation marker 
Ki67 was also affected (8.4% vs 19.5%) (Figure 4.6D). The level of injury as determined by 
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serum ALT level (Figure 4.6E) was consistent between groups and therefore initiation of 
injury was equivalent and not responsible for the changes in DR seen. 
‘Mid-point’ inhibition of Notch (Figure 4.7) also resulted in a reduction in number of 
ductular cells, a time when Notch3 and H2B:venus expression were high. Ductular 
proliferation was also reduced (5.7% vs 11.3%). In this experiment ALT levels were again 
consistent and therefore level of initiating injury not responsible for the change in size of 
the DR. 
‘Late’ inhibition of Notch (Figure 4.8) did not affect the size or proliferation rate of ductular 
reactions. This was consistent with the finding of low expression levels of Notch reporter 
over this period in the AhCre MDM2fl/fl; CBF:H2B-venus. ALT levels remained consistent. 
Taken together these data suggest: 
1.  The AhCre MDM2fl/fl; CBF:H2B-venus strain accurately reports active Notch 
signalling and  






Figure 4.6: Notch signalling drives expansion of the early ductular reaction after 
hepatocellular injury: (A) Schematic demonstrate the strategy for time-dependent 
treatment with Notch inhibitor DAPT or vehicle following MDM2-mediated hepatocyte 
injury. (B) Representative images of panCK staining in DAPT and vehicle-treated animals. (C) 
Quantification of effect on ductular response in terms of panCK-positive cell number and 
(D) Ki67 positive proportion. (E) Serum ALT levels. (n=5 per group). Data are presented as 





Figure 4.7: Notch signalling drives expansion of the mid-point ductular reaction after 
hepatocellular injury: (A) Schematic demonstrate the strategy for time-dependent 
treatment with Notch inhibitor DAPT or vehicle following MDM2-mediated hepatocyte 
injury. (B) Representative images of panCK staining in DAPT and vehicle-treated animals. (C) 
Quantification of effect on ductular response in terms of panCK-positive cell number and 
(D) Ki67 positive proportion. (E) Serum ALT levels. (n=5 per group). Data are presented as 
mean ± SEM. Mann Whitney test was used. *p<0.05; **p<0.01. Photomicrograph scale 






Figure 4.8: Notch signalling does not drive expansion of the late ductular reaction after 
hepatocellular injury: (A) Schematic demonstrate the strategy for time-dependent 
treatment with Notch inhibitor DAPT or vehicle following MDM2-mediated hepatocyte 
injury. (B) Representative images of panCK staining in DAPT and vehicle-treated animals. (C) 
Quantification of effect on ductular response in terms of panCK-positive cell number and 
(D) Ki67 positive proportion. (E) Serum ALT levels. (n=5 per group). Data are presented as 
mean ± SEM. Mann Whitney test was used. *p<0.05; **p<0.01. Photomicrograph scale 




4.4.2 Loss of DR is due to loss of proliferation capacity rather than premature 
differentiation 
While the experiments in the AhCre MDM2fl/fl strain support the loss of ductular cells after 
Notch inhibition being due to impaired proliferation, given Notch inhibition in HPC lines and 
primary HPCs promotes differentiation down the hepatocyte lineage (123), it could be 
argued that differentiation could contribute to the reduction in cell number. As the DRs in 
the AhCre MDM2fl/fl model are not lineage labelled, it is not possible to test this with this 
strain. OPN-iCreERT2;R26RYFP is a strain in which Cre is induced in osteopontin (OPN) 
expressing cells (near exclusively ductular cells in the uninjured liver (203)) after 
administration of tamoxifen. This results in excision of a loxP-flanked STOP codon upstream 
of YFP within the Rosa26 locus and subsequent YFP labelling of the cell and its progeny (56). 
This strain has been shown to label ductular cells in liver injury and when induced mice 
receive three weeks of CDE diet followed by a two week ‘STOP’ or recovery period on 
regular chow, approximately 2.45% of hepatocytes are labelled as having been of ductular 
origin. Krt19CreERT;RCLtdT is a strain in which Cre is induced in cytokeratin 19 (Krt19) 
expressing cells after administration of tamoxifen resulting in excision of a loxP-flanked 
STOP codon resulting in expression of downstream red fluorescent protein (RFP) variant 
tdTomato in the cell and its progeny. This strain was generated by crossing the parent strain 
Krt19CreERT (324) with the Ai14(RCL-tdT) strain (325). We have confirmed it can lineage 
label ductular cells in dietary models of liver disease and when mice are given the CDE-stop 
protocol, small numbers of Krt19 lineage labelled hepatocytes are seen (59). Using these 
two strains I designed experiments to determine the effect of Notch inhibition on the ability 
of DRs to generate hepatocytes and to confirm in another model the effects of Notch on 





Figure 4.9: Lineage tracing confirms loss of ductular cells after Notch inhibition in 
hepatocellular injury: (A) Schematic demonstrating experimental strategy for assessment 
of the effect on the ductular reaction of Notch inhibition using Krt19-CreERT;RCL-tdT strain 
with MCD diet to induce hepatocellular injury. (B) Quantification of RFP-positive cell 
number. (C) Representative immunohistochemistry for RFP label. (D) Serum ALT levels. (n=5 
per group). Data are presented as mean ± SEM. Mann Whitney test was used. **p<0.01. 
Photomicrograph scale bars: 100uM.   
 
Groups of Krt19CreERT;RCLtdT mice received three doses of tamoxifen i.p. at 5-6 weeks old 
to induce Cre recombination. After a two-week washout period to reduce the chance of 
residual tamoxifen mislabelling cells whose expression profile may change in response to 
injury, the mice received two weeks of MCD diet to induce hepatocellular injury. As the 
dietary injury models involve continuous exposure to the toxin, DAPT was administered at a 
frequency of three doses per week for the duration of the injury diet to assess the effect of 
Notch inhibition on the expanding DR (Figure 4.9A). This experiment was designed to 
answer the question whether change in numbers of DR cells was due to premature 
differentiation (and thus loss of ductular marker and not detectable in the AhCre MDM2fl/fl 
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model) or reduced proliferation of cells. I then stained the tissue for the RFP lineage label 
and quantified the cells. There was a marked reduction in lineage labelled cells (Figure 4.9B) 
and this could not be explained by differences in the level of liver injury as determined by 
serum ALT levels (Figure 4.9D). The RFP cells all appeared to be of ductular morphology and 
subsequent co-staining of tissue for RFP with hepatocyte marker HNF4a failed to identify 
lineage labelled hepatocytes above a negligible frequency (0-1 per section examined). 
Having established that the RFP positive cells remained ductular and were not hepatocytes, 
I wanted to confirm if the loss in cell number was due to loss of proliferation consistent 
with the AhCre MDM2fl/fl model. The quantification of Ki67 positive ductular cells had 
required staining for a ductular marker (panCK), then co-staining for the proliferation 
marker, then photographing multiple microscopic fields at a high magnification to enable 
manual counting. The research centre had subsequently acquired a high-content analysis 
system (Operetta) with a facility for scanning, imaging and analysing whole slides. As the 
lineage tracing strains both resulted in label expression that involved the nucleus, the site 
of expression of many proliferation markers, generating an analysis ‘pipeline’ that could 
automate the quantification of proliferating reporting cells appeared possible. As the 
manual identifying, photographing and counting of fields is extremely time consuming, this 
limits the number of fields analysed. An automated process offers the opportunity to 
increase the amount of tissue analysed and thus the reliability of the results. Effective 
staining protocols were in place for both RFP and YFP reporters. Ki67 staining could on 
occasion vary in intensity across a slide, which could cause difficulties in setting standard 
thresholds for quantification, and therefore tissue was instead stained for proliferating cell 
nuclear antigen (PCNA) which resulted in more consistent staining. Examples of the staining 
achieved are shown in Figure 4.11A. In collaboration with other members of the group 
(Eoghan O’Duibhir, Phil Starkey-Lewis and Alex Raven), we trialled the Operetta screening 
system and accompanying Columbus analysis software to develop pipelines for detection of 
nuclear stains in liver tissue. The analysis ‘pipeline’ I used for all analysis of RFP or YFP and 
PCNA stained tissue is included in Appendix 1. Quantification of the proportion of RFP 
positive cells that were PCNA positive fell in the Krt19CreERT;RCLtdT mice receiving DAPT 






Figure 4.10: Loss of ductular cells in DAPT-treated animals is not due to hepatocytic 
differentiation: (A) Immunohistochemistry for RFP (red) and HNF4a (green) in Krt19-
CreERT;RCL-tdT animals treated with DAPT or vehicle while receiving MCD diet to induce 
hepatocellular injury. Ductular lineage-traced hepatocyte remained at negligible frequency 
in both groups (0-1 cells per section). (B) Single stain/isotype controls. Photomicrograph 





Figure 4.11: Notch signalling drives proliferation of the ductular reaction after 
hepatocellular injury: (A) Representative Immunohistochemistry for PCNA (red) and RFP 
(green) in Krt19-CreERT;RCL-tdT strain administered MCD diet to induce hepatocellular 
injury. (B) Quantification of RFP-positive cell number (left) and PCNA positive proportion 
(right) in Krt19-CreERT;RCL-tdT strain administered DAPT or vehicle during MCD diet (n=5 
per group). Data are presented as mean ± SEM. Mann Whitney test was used. *p<0.05; 
**p<0.01. Photomicrograph scale bars: 100uM.   
 
I designed an experiment using the OPN-iCreERT2;R26RYFP strain and the previously 
established CDE-recovery protocol (56) with the initial intention of identifying whether in 
this system DAPT administration has an effect on HPC differentiation. However, having now 
clearly established a role for Notch in the proliferation of DRs, I was not sure if any effect on 
differentiation could be assessed without considering the impact of proliferation, clearly a 
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necessary part of the response.  This animal experiment was performed by Noemi van Hul 
from the Leclercq lab at Universite Catholique de Louvaine in Belgium, to my experimental 
protocol, pending the rederivation of the strain into our animal unit. I performed all 
subsequent analysis. OPN-iCreERT2;R26RYFP mice received three doses of DAPT or vehicle 
per week during the ‘recovery’ period (Figure 4.12A). In the vehicle treated group patches 
of YFP positive hepatocytes of ductular origin could be detected, however these were 
absent in the DAPT treated group (Figure 4.12B). Few labelled hepatocytes were seen but 
this was barely above the frequency of aberrant recombination events seen in uninjured 
animals 7 weeks after tamoxifen administration (Figure 4.12F). After the recovery period, 
serum ALT levels in both groups had returned to normal Figure 4.12D). Further animals 
underwent the CDE-recovery protocol with groups taken off at the end of injury (day 0), 
and after 3 and 7 days of recovery. The proportion of YFP positive cells that were 
proliferating (PCNA positive) were quantified in all groups and proliferation rate remained 
high (27%, 19% and 17% respectively) (Figure 4.12E). Given the persisting high rate of DR 
proliferation during the first part of the recovery period, the sensitivity of DR proliferation 
to Notch and the requirement for cell division during differentiation, ascertaining a direct 





Figure 4.12: Notch inhibition results in a reduction in lineage-labelled hepatocytes using 
the CDE-STOP regimen: (A) Schematic of experimental strategy for assessing the effect on 
generation of biliary lineage-derived hepatocytes of Notch inhibition with DAPT using OPN-
iCreERT2;R26RYFP strain and the CDE-STOP protocol to induce differentiation. (B) 
Representative images of YFP staining from the experiment. (C) Quantification of resultant 
YFP-positive hepatocytes and serum ALT levels (D) (n=6 per group). (E) Quantification of 
proportion of YFP+ cells PCNA-positive at the end of 3 weeks CDE diet (Day 0 n=4), and after 
3 and 7 days of recovery (Day 3 n=3, Day 7 n=7). (F) Proportion of YFP-labelled hepatocytes 
7 weeks after tamoxifen induction in uninjured mice. Data are presented as mean ± SEM. 
Mann Whitney test was used for experiments with two groups. *p<0.05; **p<0.01; 
***p<0.001. Photomicrograph scale bars: 100uM. 
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4.4.3 Effects of Notch on ductular response are receptor specific 
I had identified in HPC lines that the Notch-related proliferation effect was mediated by 
Notch1 and Notch3. Given the dynamic expression patterns of these receptors in vivo I 
wanted to see if these were the important receptors for the proliferation phenotype in 
vivo. 
I administered the Notch1, Notch2 and control antibodies used in Figure 4.2 to AhCre 
MDM2fl/fl mice one day after Cre induction with BNF (Figure 4.13A). This was to cover the 
time when Notch1 expression was high. As Notch2 expression did not change over the 
time-course, it seemed most appropriate to administer it over this same time period as this 
coincides with high levels of Notch driven H2B:venus expression. Ductular cell number fell 
in animals receiving either clone of Notch1 blocking antibody (Figure 4.13C), as did their 
proliferation rate from 28.6% to 9.8 and 10.1%. Blocking Notch2 had no effect on ductular 





Figure 4.13: Notch1 but not Notch2 drives expansion of the ductular reaction after 
hepatocellular injury: (A) Schematic representing strategy for blocking antibody-mediated 
Notch inhibition with one of two clones of Notch1 (aN1_7 or aN1_E10) or Notch2 (aN2_B6 
or aN2_B9) blocking antibody or control antibody (to intracellular epitope of desmin 
aDesmin) in the AhCre MDM2fl/fl model. (B) Representative immunohistochemistry of 
panCK staining from the experiment. (C) Quantification of effect on ductular response in 
terms of panCK-positive cell number (p=0.0015) and (D) Ki67 positive proportion 
(p=0.0024). (E) Serum ALT values.  (n=5 per group). Data are presented as mean ± SEM. 
Kruskal-Wallis test was used for comparison of multiple groups (p value shown in legend 
above) with Dunn’s multiple comparison post-test analysis included in the figure. *p<0.05; 




In order to investigate the role of Notch3 in the ductular response, in the absence of 
available Notch3 blocking antibodies, or specific small molecule inhibitors, I used a genetic 
knock-out approach. As there is no floxed allele for Notch3 available, I used a Notch3 null 
strain Notch3-/- (321), recognising the limitation that as with the Notch1 and Notch2 
blocking antibodies, it would not limit the effect to the ductular compartment. No liver 
developmental phenotype has been identified in this strain (317, 321) and there are no 
published reports of its response to liver injury.  Studies using mice with the Notch3 null 
mutation to examine muscle regeneration had observed an unusual phenotype. While 
muscle appeared to have developed normally, when injured the Notch3 null strain 
demonstrated a hypertrophic response (318). This was due to increased proliferation of 
muscle progenitors which is largely dependent on Notch1 and thus Notch3 was thought to 
provide negative regulation of Notch1-driven proliferation by inducing Notch inhibitor 
Nrarp. I was therefore particularly intrigued to see the effect on liver regeneration of the 
loss of Notch3 and could anticipate no phenotype if it was truly redundant, impaired 
regeneration if it was required or enhanced progenitor activity if the role of Notch3 was to 
regulate Notch1.  
For further experiments I crossed the Notch3-/- strain with the AhCre MDM2fl/fl and OPN-
iCreERT2;R26RYFP strains. While these new strains were being bred, I used the Notch3-/- 
colony to identify if I would likely require homozygous knockout rather than 
haploinsufficiency to observe any phenotype. Given the marked variation in background 
strain sensitivities to dietary injury, in particular CDE diet, I put groups of Notch3+/+, 
Notch3+/- and Notch3-/- animals on the DDC biliary injury diet to assess the response (Figure 
4.14A). Although the focus of this thesis is hepatocellular injury, this diet model was chosen 
for this experiment because 1. It is a rapid and reliable inducer of DRs, 2. Given the 
published literature on the role of Notch after liver disease, an effect of loss of any of the 
receptors would be predicted to be most marked in a biliary injury model. If no effect was 
seen with the different genotypes with CDE diet it would not be clear whether this related 
to alterations in the background strain and thus sensitivity to injury or if Notch3 had no 
functional role. There was no change in ductular cell number between Notch3+/+ and 
Notch3+/- mice, however there was a significant reduction in cell number in the homozygous 
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knockout (Figure 4.14C). Using this information to direct my breeding strategy for the other 
Notch3 knockout strains, I bred AhCre MDM2fl/fl Notch3+/+ and AhCre MDM2fl/fl Notch3-/- 








Figure 4.14: Homozygous loss of Notch3 attenuates ductular response to biliary injury: (A) 
Schematic demonstrating experimental strategy for assessment of the effect on the 
ductular reaction of genetic Notch3 loss using Notch3+/+, Notch3+/- and Notch3-/- animals 
with DDC diet to induce biliary injury. (B)  Representative immunohistochemistry for panCK. 
(C) Quantification of ductular cells in each group. P=0.0110. (n=5 per group). Data are 
presented as mean ± SEM. Kruskal-Wallis test was used for comparison of multiple groups 
(p value shown in legend above) with Dunn’s multiple comparison post-test analysis 




I administered BNF to induce Cre expression in AhCre MDM2fl/fl Notch3+/+ and AhCre 
MDM2fl/fl Notch3-/- mice and harvested tissue 7 days later (Figure 4.15A). I chose this time 
period to cover when Notch3 expression should be at its peak. Cell number and 
proliferation rate was reduced in the AhCre MDM2fl/fl Notch3-/- mice (Figure 4.15C and D). 
Serum ALT values were much higher in this experiment than in other AhCre MDM2fl/fl 
experiments (Figure 4.15E). This may reflect a variation in concentration in the BNF 
administered, a difference in response due to the alteration in background strain following 
the cross, an effect of loss of Notch3 from other cell types or potentially a protective effect 
of a ductular reaction. 
Having established that loss of Notch3 attenuates the DR and that this appears to be due to 
a loss in proliferation, I wanted to be sure that cell loss due to precocious hepatocyte 
differentiation was not contributing. Using OPN-iCreERT2;R26RYFP;Notch3+/+ and OPN-
iCreERT2;R26RYFP;Notch3-/- strains, groups of animals received 3 weeks of CDE diet to induce 
a ductular response two weeks after Cre induction with tamoxifen (Figure 4.16A). Again 
there was a marked loss in ductular lineage labelled cells. The number of lineage labelled 
hepatocytes was small and in fact lower in the iCreERT2;R26RYFP;Notch3-/- strain and 





Figure 4.15: Notch3 drives expansion of the ductular reaction after hepatocellular injury: 
(A) Schematic represents experimental design for assessing the effect on ductular response 
of loss of Notch3 in MDM2-mediated hepatocyte injury. AhCre MDM2fl/fl Notch3+/+ n=5, 
AhCre MDM2fl/fl Notch3-/- n=4. (B) Representative immunohistochemistry of panCK staining 
from the experiment. (C) Quantification of effect on ductular response in terms of panCK-
positive cell number and (D) Ki67 positive proportion. (E) Serum ALT values. Data are 
presented as mean ± SEM. Mann Whitney test was used for experiments with two groups. 





Figure 4.16: Loss of ductular cells in Notch3-/- animals is not due to increased hepatocyte 
differentiation: (A) Schematic of experimental design to assess effect of loss of Notch3 on 
the ductular response hepatocellular injury induced with choline deficient ethionine 
supplemented (CDE) diet using OPN-iCreERT2;R26RYFP;Notch3+/+ and OPN-
iCreERT2;R26RYFP;Notch3-/- strains (n=6 per group). (B) Representative images for YFP 
staining. (C) Quantification of YFP-positive ductular cell number confirming loss of ductular 
cells in Notch3-/- animals and (D) Proportion of hepatocytes YFP-positive (p=0.1062). (E) 
Serum ALT values. Data are presented as mean ± SEM.  Mann Whitney test was used for 





Macrophage-derived Wnt promotes proliferation of DRs after hepatocyte injury (123), 
however when the liver is depleted of macrophages HPCs remain able to expand but fail to 
migrate into the parenchyma instead forming ‘duct like’ structures (342). The persisting 
ability to expand suggests alternative signals are involved in their initial proliferation. 
Important signals identified to date in HPC activation and proliferation include HGF/c-met, 
EGFR, Shh, TWEAK and TGF-β (343-345). In this chapter I have established a role for Notch 
signalling in ductular proliferation in response to hepatocyte injury. 
Using HPC lines I have demonstrated that their proliferation is Notch sensitive. Pan-Notch 
inhibition with DAPT (222) or using a mouse strain where RBPJK is conditionally deleted in 
the ductular compartment (58) has confirmed a role for Notch in proliferation of DRs after 
biliary injury in vivo. By designing experiments to coincide administering Notch inhibition 
with the dynamic changes in Notch pathway expression in the AhCre MDM2fl/fl model 
shown in chapter 3, I have confirmed that these changes reflect functionality of the Notch 
pathway and control of DR proliferation after hepatocellular injury. When Notch was 
inhibited while Notch1 expression was high and when Notch pathway reporter was 
expressed, there was a reduction in proliferation of DRs. This phenotype was also 
demonstrated by inhibiting Notch when Notch3 expression was at its peak. When Notch 
receptor and Notch pathway reporter expression was low, Notch inhibition did not affect 
DR proliferation. 
This is the first description of a role of Notch in regeneration from biliary compartment 
after hepatocellular injury in mouse. He et al (52) performed complex experiments in 
zebrafish where the hepatocyte compartment was genetically ablated. They determined 
nearly all the biliary cells lost their tubular morphology, proliferated and expressed 
hepatocyte-specific markers. Lineage tracing demonstrated that most new hepatocytes 
arose from the biliary compartment and this required Notch signalling. Regenerating cells 
expressed a Notch reporter and delivery of DAPT concurrent with hepatocyte injury 
resulted in a marked reduction in formation of new hepatocytes. The authors also proposed 
that activation of early endoderm and hepatoblast markers indicated biliary 
transdifferentiation included a step of de-differentiation into a bi-potential intermediate 
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involving activation of Sox9 which was Notch-dependent, however the relative contribution 
of different paralogs was not examined. 
I performed experiments using blocking antibodies and demonstrated that when growing in 
isolation, proliferation of HPCs is governed by Notch1 but not Notch2 or the Notch ligand 
Jagged1. As I have shown that BMOL and SWA cells do not express Jagged1, then Jagged1 
blocking antibody would not be anticipated to have an effect on HPC proliferation. I have 
demonstrated that HPCs express instead Dll1 and this may be the source of Notch ligand in 
BMOL and SWA monocultures. By reducing expression of Notch3 in the BMOL cell line using 
siRNA, I was also able to demonstrate a role for Notch3 in proliferation of HPCs. The use of 
cell lines for these experiments has both advantages and disadvantages. A cell line that has 
undergone spontaneous immortalisation may not behave in the same was as primary cells 
with regard to proliferation, conducting similar experiments with primary cells may 
overcome this, however when cultured in the absence of niche-derived ligands, the biology 
of these cells too may be altered, particularly with regard to sensitivity to those same 
niche-derived ligands. The number of cells required for this work would require many more 
experimental mice to be used. In addition determining which primary HPCs to isolate and 
from which time points after injury would markedly increase the complexity of experiments 
and potentially impede interpretation of results. 
Boulter et al (123) co-cultured HPCs with Jagged1 expressing myofibroblasts. When Notch 
inhibitor DAPT was added to block Notch signalling, expression of Notch responsive Hes and 
Hey genes fell, as did biliary genes HNF6 and gamma-glutamyltranspeptidase (GGT), 
supporting a role for Notch signalling via Jagged1 in promoting biliary differentiation of 
HPCs. Kim et al (91) have shown that after biliary injury, the interaction between Jagged1 
expressed on myofibroblasts and Notch1 expressed within the DR results in proliferation. 
CCN1, a matricellular protein that binds distinct cell surface integrin receptors, binds 
integrin αvβ5/αvβ5 on myofibroblasts activating NK-ƙB leading to Jagged1 expression. A 
further interesting finding in this paper is that when knock-in mice expressing a CCN1 
mutant that is unable to bind αvβ5/αvβ5 undergo biliary injury by bile duct ligation (BDL), 
there is an impaired DR which leads to massive hepatocyte collapse and mortality; this can 
be rescued by administration of soluble Jagged1. This further emphasises the importance of 
DRs and ductular Notch signalling in supporting liver regeneration, even when not directly 
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providing new hepatocytes. In order to determine if this Jagged1-Notch1 interaction is 
specific to biliary disease or if proliferation of my HPC lines derived from hepatocellular 
injury models could be promoted by Jagged1, they could be co-cultured with Jagged1 
expressing myofibroblasts in the presence or absence of anti-Jagged1 or as a monoculture 
in the presence of soluble Jagged1. I have demonstrated that in vivo Jagged1 and Jagged2 
ligand are available and intimately associated with the DR. Administration of the anti-
Jagged1 antibody in vivo could permit observation of an effect on proliferation of the DR, 
and would suggest but would not confirm a direct effect of interrupting signalling between 
Jagged1 expressing myofibroblasts and cells of the DR. It may be that the involvement of 
multiple ligands builds redundancy into this system and/or potential for paired ligand and 
Notch paralog signals like the specific Jagged1-Notch1 interaction demonstrated by Kim et 
al (91). 
By using the anti-Notch1 and anti-Notch2 blocking antibodies in vivo I confirmed a role for 
Notch1 but not Notch2 in the proliferation of DRs. I had found no dynamic changes in 
expression of Notch2 therefore this combined with the lack of effect on proliferation of DRs 
of Notch2 blockade suggests this paralog has no role in DR proliferation after hepatocellular 
injury. This may reflect functional redundancy however would also be consistent with 
divergent roles for Notch1 and Notch2. Interfering with pan-Notch signalling or the specific 
interaction between Jagged1 and Notch1 limits proliferation of DRs after biliary injury (91, 
222). Overexpression of Notch1 in the hepatocytes of newborn and adult mice results in 
their transdifferentiation to cholangiocytes (103, 215). Loss of Notch2 but not Notch1 in 
development compromises intrahepatic duct development (213). Loss of Notch2 in biliary 
injury does not limit accumulation of DRs but instead they fail to progress to mature ducts 
(222). Together this suggests the role of Notch2 is primarily related to determination of 
biliary fate, with potentially a wider range of actions for Notch1. 
As a Notch3 blocking antibody was not available, I used genetic deletion to investigate if 
this paralog has a role in proliferation of DRs in vivo as suggested by the siRNA experiment 
in vitro. Mice that were null for Notch3 failed to generate appropriate DRs in response to 
both CDE diet and MDM2-mediated hepatocyte injury and DDC diet induced biliary injury. 
Further analysis of the AhCre MDM2fl/fl Notch3+/+ and AhCre MDM2fl/fl Notch3-/- strains 
confirmed a loss of proliferation within the DR. Silencing of Notch3 in the liver by virus 
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mediated transfer of shRNA reduced fibrosis in response to CCl4 in rats associated with 
reduction in activated stellate cells and transforming growth factor beta-1 (TGFb1) (226). As 
the CCl4 model does not induce a DR, whether the observed effect was a primary effect 
related to loss of activated myofibroblasts or loss of biliary activation is unclear. Likewise it 
would be pure speculation to suggest the phenotype observed in my Notch3-/- mice 
resulted from loss of activated myofibroblasts to support a DR rather than a direct effect on 
the DR itself. In human foetal liver, interactions between Jagged1, expressed on the 
embryonic ductal plate, and Notch3, expressed on the adjacent portal tract mesenchyme 
and hepatic arterial endothelium, are thought to play a role in the process of ductal plate 
remodelling and the subsequent development of the intrahepatic biliary tree (346). 
Although there is no reported developmental phenotype in the Notch3-/- mice, it remains 
possible that there may be a defect in biliary development or development of cells with 
HPC capability that would only be revealed after the administration of liver injury (318, 
321). As Notch3 is also expressed by blood vessels in the liver, an indirect effect on DRs 
from loss of vascular Notch3 cannot be excluded. To demonstrate a direct effect on HPCs in 
vivo and corroborate the proliferation effect seen in vitro would require experiments with a 
mouse strain where the Notch3 alleles were flanked by loxP site so could be specifically 
targeted to the biliary compartment in adult mice. The direct effect on proliferation in the 
cell line monoculture, would suggest at least part of the proliferative effects on HPCs of 
signalling via Notch3 were direct. 
A potential role for Notch signalling from the vascular compartment in general and 
endothelium in particular on DRs is intriguing. Conditional deletion of Notch1 from all liver 
cell compartments causes the generation of lesions similar to nodular regenerative 
hyperplasia (NRH) (347). This phenotype is related not to a direct effect on hepatocytes but 
rather loss of pan-Notch (via RBP-JK) or Notch1 inactivation within liver sinusoidal 
endothelial cells (LSECs) resulted in their dedifferentiation and proliferation with formation 
of abnormal vessels and veno-occlusive disease. There was subsequent hepatocyte 
apoptosis and reduced proliferation after partial hepatectomy (219, 220).  This highlights 
further the importance of both context and cell-type specificity of Notch signalling in the 
liver and how altering Notch activity levels in the vascular compartment may have multiple 
indirect effects on other cell compartments (156).  
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Notch signalling can play a role in cell migration and invasion (207, 341), triggering 
epithelial-mesenchymal transition by mechanisms including upregulation of Snail1. When I 
exposed HPC lines to Notch inhibition with DAPT there was no effect on cell migration, 
therefore it is likely that this pathway is not involved directly in migration of HPCs 
generated in response to hepatocellular injury. Attempting to confirm this in vivo presents 
difficulty: when cells proliferate, unless sequentially smaller cells are generated, the space 
they occupy will increase. This will give the appearance of cells further from the starting 
point in the absence of any true migration. As Notch drives proliferation of the DR, 
distinguishing a change in migration from proliferation is further hampered. Inhibiting 
proliferation of the DR, while preserving Notch signal and not altering hepatocyte or other 
cell type behaviour is beyond the limits of current models. Further inference of a lack of 
effect on HPC migration could be sought from examining if at a time when Notch is not 
directing proliferation, Notch inhibition results in less migratory DRs. Examining distance of 
DRs from the portal tract in animals given DAPT or vehicle in the AhCre MDM2fl/fl  ‘late’ 
experiment showed no difference (data not shown) however as the AhCre MDM2fl/fl ; 
CBF:H2B-venus data suggests Notch pathway is not active at this time, any effect or lack of 
it cannot be attributed to Notch signalling. Generation of a computer simulation that could 
determine predicted distance from portal tract based on number of cell divisions and thus 
assess whether Notch inhibition results in less than expected movement could be a way 
around this predicament. 
Due to the key role of Notch in fate determination, I wanted to ensure that loss of DRs was 
principally due to loss of proliferation, not hepatocytic differentiation. Using two 
independent strains I performed lineage tracing experiments in two models of 
hepatocellular injury. First to more closely replicate the conditions of the AhCre MDM2fl/fl 
model, I gave MCD diet to induce hepatocellular injury in Krt19CreERT;RCLtdT animals and 
administered DAPT throughout the injury period. The continuous nature of the injury 
meant classification of injury into early and late was not practical. In this model there was 
again a reduction in DRs and their proliferation, however this time I could confirm that loss 
of cells was not due to differentiation into heptaocytes as Krt19 lineage labelled 
hepatocytes appeared only at negligible frequencies in treatment and control groups. 
Similarly using OPN-iCreERT2;R26RYFP;Notch3+/+ and OPN-iCreERT2;R26RYFP;Notch3-/- strains, 
loss of Notch3 was associated with a diminished ductular response to CDE diet, without the 
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appearance of frequent OPN lineage labelled hepatocytes. As previous work has suggested 
significant hepatocytic differentiation of HPCs only occurs after a period of recovery from 
injury, I also administered DAPT to animals in the recovery phase of the CDE-recovery 
model. Contrary to seeing an increase in lineage labelled hepatocytes due to Notch 
inhibition, the number of labelled cells fell markedly. This can best be explained by viewing 
the proliferation rate of DRs during the recovery period. This remained high and thus if 
Notch-driven proliferation was prevented, the number of lineage labelled hepatocytes 
resulting would also decrease. The intimate association of cell division with differentiation 
where the same signal can govern both processes presents a significant obstacle. Using a 
system where downstream mediators of Notch driven proliferation could be targeted such 
as Notch-dependent cyclin genes or AKT signalling may permit direct differentiation related 
effects of Notch to be further studied, however loss of cell division may prevent 
differentiation from occurring. 
In summary this chapter describes a functional role for Notch signalling that is tied 
temporally to the stage of regenerative response. Notch1 and Notch3 specifically are 








Canonical Wnt signalling is initiated by binding of soluble Wnt ligand to cell surface Frizzled 
and low-density lipoprotein receptor-related protein (LRP) 5 or 6 (see Figure 1.4). A key 
event in the transduction of the Wnt signal inside the cell is the stabilization of cytoplasmic 
β-catenin. In the absence of ligand binding, beta-catenin is recruited by the destruction 
complex that includes axin, adenomatous polyposis coli (APC), and glycogen synthase 
kinase-3b (GSK3b) where it is phosphorylated by casein kinase I and GSK3b which targets it 
for ubiquitination and proteasomal degradation (238). Binding of Wnts to their receptors 
results in inhibition of the destruction complex. This permits accumulation of non-
phosphorylated beta-catenin in the cytoplasm and its resultant translocation to the 
nucleus. In the nucleus beta-catenin forms a complex with members of the T-cell 
factor/lymphoid enhancer-binding factor (TCF/LEF) family of transcriptional factors. This 
complex recruits transcriptional co-activators including cAMP response element-binding 
(CREB)-binding protein (CBP) or its homolog p300 as well as other components of the 
transcription machinery. Together, these events turn TCF/LEF from transcriptional 
repressor into transcriptional activator, thereby initiating transcription of Wnt target genes 
(238, 348).  
The actions of beta-catenin in liver development are complex, with roles in expansion of 
hepatoblasts and biliary cells and hepatocyte maturation (253, 333, 349-352). Depending 
on the time of transgene activation, loss of negative regulator of beta-catenin APC results in 
failure of expansion of foetal hepatoblasts and constitutively activated beta-catenin causes 
failure of liver development (350); yet when beta-catenin is deleted, hepatoblasts fail to 
proliferate, apoptose and fail to differentiate into hepatocytes (254). Inappropriate over 
activation of beta-catenin can also result in hepatocyte hyperplasia, hyper-proliferation and 
ultimately animal death (353). Thus during ontogeny there is a requirement for careful 
temporal regulation with of Wnt signal for effective liver development.  
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The requirement for Wnt does not end at birth. Recently Wang et al have demonstrated 
that Wnt-responsive pericentral (zone 3) hepatocytes are responsible for producing new 
hepatocytes during homeostatic renewal (150). Central vein endothelial cells provide Wnt 
ligand that maintains pericentral hepatocytes in a state where they express early liver 
progenitor marker Tbx3, Wnt-responsive gene Axin2 and are diploid (unlike mature 
hepatocytes which are mostly polyploid). These cells also express glutamine synthetase 
(GS), another Wnt-responsive gene that also is used to distinguish zone 3 hepatocytes 
(354). In terms of roles of Wnt in HPC-mediated regeneration, in rats when a potent HPC 
response induced by 2-acetylaminofluorine (2AAF) and two-thirds partial hepatectomy 
(2/3PH), there is a marked increase in active beta-catenin, localising to ductular reactions 
and occurs when HPCs are proliferating rapidly (262). Murine HPCs have been shown to 
report Wnt activity after biliary injury (DDC) diet and respond to administration of Wnt3a 
by proliferating (263) and deletion of beta-catenin diminishes the ductular response to the 
same dietary injury model (262). An adult HPC line derived from DDC diet fed animals also 
demonstrated increased proliferation in response to GSK3b inhibitor BIO which mimics 
activation of canonical Wnt signalling by suppressing GSK3b-mediated phosphorylation and 
subsequent degradation of beta-catenin (355). Lineage tracing using the Wnt-dependent 
stem cell marker Lgr5 has also identified expansion of Lgr5 positive periductal cells after 
liver injury and these cells can be lineage traced into hepatocytes after hepatocellular 
damage or isolated, expanded then differentiated in media containing Wnt agonist and 
Lgr5 ligand R-spondin prior to transplantation where they behave as functional hepatocytes 
in a non-competitive transplantation model (Fah-/- mice) (77). Taken together these studies 
all support Wnt signalling as being of key importance in HPC-mediated regeneration. 
Having demonstrated Wnt pathway activity in ductular cells after MDM2-mediated 
hepatocyte injury, and that this activity appeared to be dynamic, I wanted to confirm if this 
reflected dynamic functionality of the Wnt pathway. As studies have identified proliferation 
as a key function of Wnt signalling in liver development and after biliary injury, and the rat 
2AAF 2/3PH model has suggested a role in HPC proliferation in response to hepatocellular 
injury, I focused in this chapter on examining a potential role for Wnt signalling in 
proliferation of ductular cells after hepatocyte injury. 
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5.2 Wnt signalling promotes proliferation of HPC lines 
Using a similar approach as I had in determining the role of Notch signalling, I again used a 
MTT assay to determine if there was a dose-response effect to Wnt inhibition in my HPC 
cell lines. I used increasing doses of the small molecule inhibitor ICG001 (356) which 
selectively inhibits the CBP/beta-catenin/TCF/LEF interaction and found a dose-dependent 
loss in viable cell number (Figure 5.1A). To determine if this reduction in cell number was 
caused by a drop in proliferation rate, rather than cell death, I selected a concentration of 
ICG001 that from the dose-response curve reduced absorbance in both lines by 
approximately 50% (5uM) and performed an EdU incorporation assay. After incubation for 
48 hours, EdU incorporation in BMOLs was reduced from 48.2% to 11.7% and in SWAs from 
47.5% to 9.8% (Figure 5.1B). To confirm this reduction in rate related to Wnt inhibition, I 
measured expression of classical Wnt effector genes Lef1 and cyclin E1 (CCne1) in cells 






Figure 5.1: Wnt inhibition with small molecule inhibitor ICG001 reduces proliferation of 
HPC lines: (A) MTT assay using BMOL (left) and SWA (right) lines treated with increasing 
concentrations of ICG001 or vehicle. Data presented as mean ± SEM of 6 experimental 
replicates, experiment was repeated twice. (B) Representative images and quantification of 
EdU incorporation in BMOL (upper panel) and SWA (lower panel) lines treated with ICG001 
or vehicle (n=6 per group). Data are presented as mean ± SEM. ICG001 dose-response 
experiments were analysed by 2-way ANOVA. Mann Whitney test was used for experiments 




Figure 5.2: Small molecule inhibitor ICG001 reduces expression of Wnt target genes in 
HPC lines: Gene expression of Wnt target genes Lef1 (left) and CyclinE1 (Ccne1) (right) 
relative to Gapdh in cell lines BMOL (upper panels) and SWA (lower panels) treated with 
ICG001 compared to vehicle (n=6 per group). Data are presented as mean ± SEM. Mann 
Whitney test was used for experiments with two groups. *p<0.05; **p<0.01. 
5.3 Wnt signal controls HPC migration in vitro 
Functions of Wnt can include migration (357-360). In order to determine if Wnt signalling 
causes migration of HPCs I performed the same migration assay as described in Chapter 4.3 
(and Figure 4.4), blocking proliferation of cells with mitomycin C to exclude the influence of 
cell expansion upon apparent migration. While Notch inhibition did not influence migration 
of the HPCs into the centre of the well, exposure to ICG001 impaired migration in both cell 
lines. This supports the theory that while Notch and Wnt can have similar functions, these 
functions are highly context-dependent, and temporal regulation of these signals can assist 
in generating a program of HPC activation, proliferation, migration and hepatocytic 













Figure 5.3: Wnt inhibition prevents migration of HPC lines: (A) Representative images of 
migration assay of BMOLs (upper panel) and SWA (lower panel). Migration of cells towards 
centre of well was assessed after proliferation had been inhibited with mitomycin C and 
cells exposed to ICG001 5uM (right) or control media containing an equivalent volume of 
DMSO (left).  (B) Quantification of cell migration by pixel analysis normalised to control 
conditions. n=8 per group. Data are presented as mean ± SEM. Statistical analysis by 
Student’s 2-tailed t test. **p<0.01; ***p<0.001. 
 
5.4 Wnt pathway is functionally active during the HPC response in 
vivo and directs HPC proliferation 
Having established a functional role for Wnt signalling in the proliferation of HPC lines in 
vitro, I sought to confirm this effect in vivo. As I have identified temporal changes in 
expression of Wnt pathway components and Wnt reporter activity in the AhCre MDM2fl/fl 
strains, I designed experiments to assess the functional relevance of these changes to the 
expansion of the DR. 
Experiments were designed to reflect the apparent time-sensitive nature of Wnt signalling 
after hepatocellular injury. AhCre MDM2fl/fl mice received ICG001 or vehicle by daily i.p. 
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injection to coincide with falling levels of expression of Wnt effectors and H2B-GFP (days 1-
4, ‘early’). Further groups received ICG001 or vehicle days 6-9 (‘late’) when Wnt effector 
and H2B-GFP expression was rising. I then designed a further experiment using an 
alternative Wnt inhibitor C59, which prevents palmitoylation and secretion of Wnt ligand by 
inhibiting porcupine (361), to ensure any observed effect was not inhibitor specific (Figure 
5.4). Animals were harvested 24 hours after the final dose. 
 
 
Figure 5.4: Schematic depicting experimental design for Wnt inhibition experiments in 
AhCre MDM2fl/fl strain: Wnt inhibitor ICG001 or vehicle was administered days 1-4 (‘early’) 
post Cre-induction to coincide with falling levels of expression of Wnt effectors and 
TCF/LEF:H2B-GFP, and days 6-9 (‘late’) when Wnt effector expression was rising and 
TCF/LEF:H2B-GFP expression was high. A second small molecule Wnt inhibitor which 
prevents secretion of Wnt, the porcupine inhibitor C59 or vehicle was then given to a 
second group of animals at the ‘late’ time-point. Animals were harvested 24 hours after the 
final dose. (n=5 per group). 
 
‘Early’ inhibition of Wnt (Figure 5.5) did not result in any change in ductular cell number. 
Cell proliferation was also unchanged. Serum ALT levels were similar indicating comparable 
initiating injury levels. 
In contrast ‘late’ inhibition of Wnt (Figure 5.6) resulted in loss of ductular cells (Figure 5.6B 
and C). Staining for proliferation marker Ki67 confirmed this loss reflected a reduced 





Figure 5.5: Wnt signalling does not drive ductular proliferation early after hepatocellular 
injury: (A) Schematic demonstrates the strategy for time-dependent treatment with Wnt 
inhibitor ICG001 or vehicle following MDM2-mediated hepatocyte injury. (B) 
Representative images of panCK staining in ICG001 and vehicle-treated animals. (C) 
Quantification of effect on ductular response of Wnt inhibition in terms of panCK-positive 
cell number (centre) and (D) Ki67 positive proportion (right) (n=5 per group) (E) Serum ALT 
values were equivalent. Data are presented as mean ± SEM. Mann Whitney test was used.  





Figure 5.6: Wnt signalling drives ductular proliferation late after hepatocellular injury: (A) 
Schematic demonstrates the strategy for time-dependent treatment with Wnt inhibitor 
ICG001 or vehicle following MDM2-mediated hepatocyte injury. (B) Representative images 
of panCK staining in ICG001 and vehicle-treated animals. (C) Quantification of effect on 
ductular response of Wnt inhibition in terms of panCK-positive cell number (centre) and (D) 
Ki67 positive proportion (right) (n=5 per group). (E) Serum ALT values were equivalent. Data 
are presented as mean ± SEM. Mann Whitney test was used. *p<0.05. Photomicrograph 





Figure 5.7: Use of a second Wnt inhibitor C59 confirms Wnt signalling drives ductular 
proliferation late after hepatocellular injury: (A) Schematic demonstrates the strategy for 
time-dependent treatment with Wnt secretion inhibitor C59 or vehicle following MDM2-
mediated hepatocyte injury. (B) Representative images of panCK staining in C59 and 
vehicle-treated animals. (C) Quantification of effect on ductular response of Wnt inhibition 
with C59 in terms of panCK-positive cell number (centre) and (D) Ki67 positive proportion 
(right) (n=5 per group) (E) Serum ALT values were equivalent. Data are presented as mean ± 




When I administered the alternative Wnt inhibitor, C59, there was also a reduction in 
ductular cells (Figure 5.7A and B). Staining for proliferation marker ki67 confirmed again 
this was due to a reduced proliferation rate (Figure 5.7D). Serum ALT levels were constant 
(Figure 5.7E). 
Taken together these data suggest that: 
1.  The AhCre MDM2fl/fl; TCF/LEF:H2B-GFP strain accurately reports active Wnt 
signalling and  






5.5 Loss of DR is due to loss of proliferation capacity, not change in 
differentiation capacity when Wnt is inhibited 
 
The experiments inhibiting Wnt in the AhCre MDM2fl/fl strain support the loss of ductular 
cells being due to impaired proliferation. However the ductular cells are not lineage traced 
and so should there be a difference in their differentiation capacity, this would contribute 
to observed loss of cell number. As Wnt appears important in promoting the hepatocellular 
differentiation of HPCs (75-78, 123), it would be surprising if differentiation increased after 
Wnt inhibition. To ensure Wnt inhibition was not causing unexpected effects on 
differentiation I again employed the Krt19-CreERT;RCL-tdT and OPN-iCreERT2;R26RYFP strains 
to lineage trace ductular cells after hepatocyte injury. Using the two strains I designed 
experiments to determine the effect of Wnt inhibition on the ability of DRs to generate 
hepatocytes, and to confirm in another model system the effects of Wnt on ductular 
proliferation after hepatocellular injury. 
Groups of Krt19-CreERT;RCL-tdT mice received three doses of tamoxifen i.p. at 5-6 weeks 
old to induce Cre recombination. After a two week washout period to reduce the chance of 
any residual tamoxifen inappropriately labelling non-ductular cells in response to injury, 
mice received 2 weeks of MCD diet to induce steatohepatitis and a DR. As the dietary injury 
models involve continuous exposure to the toxin, ICG001 was administered three doses per 
week for the duration of the injury diet (Figure 5.8A). I then stained the tissue for the RFP 
lineage label and quantified the cells. There was a marked reduction in lineage labelled cells 
(Figure 5.8B and C) and this could not be explained by differences in the level of liver injury 
as determined by serum ALT levels (Figure 5.8D). The RFP cells all appeared to be of 
ductular morphology and subsequent co-staining of tissue for RFP with hepatocyte marker 
HNF4a failed to identify lineage labelled hepatocytes above a negligible frequency (0-1 per 
section examined) (Figure 5.9B). Having established that the RFP positive cells remained 
ductular and were not hepatocytes, I wanted to confirm if the loss in cell number was due 
to loss of proliferation consistent with the AhCre MDM2fl/fl model. I again used the Operetta 
high-content analysis system (described in Appendix 1) to quantify the proliferation rate of 
the RFP-reporter positive cells and confirmed a reduction in proliferation from 32% to 







Figure 5.8: Lineage tracing confirms loss of ductular cells after Wnt inhibition in 
hepatocellular injury: (A) Schematic demonstrating experimental strategy for assessment 
of the effect on the ductular reaction of Wnt inhibition using Krt19-CreERT;RCL-tdT strain 
with MCD diet to induce hepatocellular injury. (B) Quantification of effect of Wnt inhibition 
on RFP-positive (lineage labelled) cell number. (C) Representative immunohistochemistry 
for RFP label. (D) Serum ALT levels were equivalent. (n=5 per group). Data are presented as 








Figure 5.9: Lineage tracing confirms loss of ductular cells after Wnt inhibition is due to 
loss of proliferation: (A) Quantification of effect of Wnt inhibition on PCNA-positive 
(proliferating) proportion of lineage labelled RFP-positive cells in Krt19-CreERT;RCL-tdT 
strain administered ICG001 or vehicle during MCD diet to induce hepatocellular injury (with 
experimental schematic left). (n=5 per group). (B) Representative immunohistochemistry 
for RFP (red) and HNF4a (green) in these animals. Ductular lineage-traced hepatocyte 
remained at negligible frequency in both groups (0-1 cells per section). (C) Single 
stain/isotype controls. Data are presented as mean ± SEM. Mann Whitney test was used. 
*p<0.05. Photomicrograph scale bars: 100uM.    
 
Using the OPN-iCreERT2;R26RYFP strain and the previously established CDE-recovery protocol 
(56) I designed an experiment where Wnt inhibitor ICG001 was administered during the 
two week recovery period, to ascertain the effect on hepatocellular differentiation of DRs 
(Figure 5.10A). As with the Notch inhibitor experiment, this was performed at Universite 
Catholique de Louvaine in Belgium, to my experimental protocol, pending the rederivation 
of the strain into our animal unit. I performed all subsequent analysis. From the Notch 
experiment, I had established that proliferation remained ongoing during the recovery 
period, therefore the effect of Wnt inhibition during this same period on differentiation 
capability was difficult to predict. Loss of Wnt may impair differentiation and thus number 
of labelled hepatocytes, however if DR proliferation was inhibited, the resultant number of 
differentiated hepatocytes may fall further. As ICG001 specifically blocks CBP/beta-catenin 
function there may be a net increase in beta-catenin-mediated p300 activation, with 
potential effects on proliferation and differentiation (see discussion). If Wnt inhibition 
resulted in reduction in Wnt-dependent production of Notch inhibitor Numb, then Notch-
mediated effects on proliferation may be higher and potentially result in increased lineage 
labelled hepatocytes, as would potentially any imbalance between any other Notch and 
Wnt-sensitive nodes. Ultimately the mean proportion of labelled hepatocytes did not 
change significantly, although trending to rise. The variation in number of labelled 
hepatocytes did increase (range 0.5-2.1% to 0.1-4.2%) (Figure 5.10B and C). This increased 





Figure 5.10: Wnt inhibition did not result in a change in lineage-labelled hepatocytes 
using the CDE-STOP regimen: (A) Schematic of experimental strategy for assessing the 
effect on generation of biliary lineage-derived hepatocytes of Wnt inhibition with ICG001 
using OPN-iCreERT2;R26RYFP strain. (B) Representative images of YFP positive cells generated 
from the experiment. (C) Quantification of resultant YFP-positive hepatocytes after Wnt 
inhibition and serum ALT levels (D). (n=6 for vehicle group, n=8 for ICG001 group). For 
proliferation rates of labelled ductular cells during the recovery period see Figure 4.12E. 
Data are presented as mean ± SEM. Mann Whitney test was used for experiments with two 




Careful temporal regulation of Wnt signalling is crucial for proper liver development (254, 
333, 350, 351). In the adult it remains crucial for maintaining liver zonation and 
homeostasis (20, 150). In HPCs a role for Wnt in proliferation after biliary injury has been 
demonstrated (262, 263, 355) and a role for Wnt in expansion after hepatocellular injury is 
strongly suggested (77, 262), along with a role in hepatocytic differentiation (77, 78, 123, 
269). In this chapter I establish a time-sensitive role for Wnt signalling in controlling the 
proliferation of HPCs in response to hepatocellular injury. 
First using HPC lines I demonstrated that their proliferation is Wnt sensitive. By designing 
experiments to coincide administering Wnt inhibition with the dynamic changes in Wnt 
expression seen in the AhCre MDM2fl/fl model shown in chapter 3, I have confirmed that 
these changes reflect functionality of the Wnt pathway and control of DR proliferation after 
hepatocellular injury. When expression of Wnt target effectors and Wnt pathway reporter 
was low, inhibition had no effect on size or proliferation of the DR. When Wnt target gene 
expression was rising and ductular cells reported Wnt activity, administration of Wnt 
inhibitor prevented their proliferation.  
Previous work by Hu et al also demonstrated that in response to Wnt3a, HPCs isolated from 
DDC treated livers would enter cell cycle and luciferase assays confirmed transcriptional 
activation via TCF/LEF (263). Apte et al studied Wnt in a classic model of potent HPC 
activation – 2AAF + partial hepatectomy (PH). They demonstrated increased expression of 
Wnt1 and beta-catenin on day 5 post PH which was lost by day 10 (262). Knockout of beta-
catenin within both hepatocytes and biliary cells of mice resulted in a diminished HPC 
response after DDC diet; however these animals were not subject to a hepatocellular injury 
regimen. Williams et al also demonstrated increased expression of Wnt1 and beta-catenin 
in the rat 2AAF/PH model (269). They went on to propose that silencing Wnt1 resulted in 
failure of HPC differentiation and instead remained as atypical hyperplastic ducts. I have 
demonstrated that proliferation of HPCs after hepatocellular injury is Wnt-sensitive, and in 
addition that this sensitivity is temporally regulated. Use of a second Wnt inhibitor, 
inhibitor of Wnt secretion C59, confirmed this was not an effect specific to ICG001. 
Benhamouche determined Wnt signalling antagonist APC maintains appropriate liver 
zonation, expressed in periportal hepatocytes preventing Wnt signalling, while zone 3 
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hepatocytes express Wnt target genes including GS. Their work also demonstrates active 
(dephosphorylated) beta-catenin in ductal cells (20). Wnt-responsive Axin2 and GS-
expressing pericentral hepatocytes have been identified as the cell responsible for 
homeostatic renewal of the liver, further supporting a critical role for Wnt in liver 
homeostasis (150). Recently detailed histological analysis of human tissue has described the 
origin and maturation of ‘liver buds’ derived from the stem/progenitor pathway in chronic 
liver disease (51). This study provides further support for the importance of this 
regenerative mechanism in human disease and of note they describe the first feature 
distinguishing a ductal cell capable of generating hepatocytes within a liver bud as 
expression of GS. This would strongly suggest Wnt signalling is involved in this process. 
I went on to demonstrate using a lineage tracing approach that loss of DRs after treatment 
with Wnt inhibitor ICG001 was due to a loss of proliferation capacity. Lineage tracing of DRs 
using the Krt19-CreERT;RCL-tdT strain demonstrated a reduction in cell number after Wnt 
inhibition due to reduced proliferation rate with no unexpected effect on differentiation – 
lineage labelled hepatocytes remained negligible in treated and control animals. 
In order for stem or progenitor cell mediated regeneration to proceed, cells must stop 
expanding, exit cell cycle, and initiate the process of differentiation. Evidence suggests 
CBP/beta-catenin-mediated transcription is essential for stem and/or progenitor cell 
maintenance and proliferation, whereas a switch to p300/beta-catenin mediated 
transcription is the critical step to initiate differentiation and a decrease in cellular potency 
(348, 362-364). Conversely p300 has been shown to promote cell cycle progression and 
prevent apoptosis in malignancy including prostate cancer and multiple myeloma (365, 
366). It remains both possible and plausible that the ability of Wnt to promote both 
proliferation and hepatocytic differentiation of HPCs could be mediated through changes in 
underlying equilibrium between CBP/beta-catenin and p300/beta-catenin. This could 
potentially explain why when OPN-iCreERT2;R26RYFP mice were treated with CBP inhibitor 
ICG001 during the recovery/differentiation phase of the CDE-STOP protocol, the number of 
lineage labelled hepatocytes did not fall but instead trended towards an increase, 
potentially mediated by a relative increase in p300 activity. Alternatively reduction in Wnt-
dependent production of Notch inhibitor Numb may result in increased Notch activity, 
increasing the number of HPCs available to differentiate. The role of p300/beta-catenin 
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both in HPC proliferation and differentiation would be an interesting area for future 
research. Use of p300 inhibitors, or more interestingly, should they be developed, p300 
agonists during CDE-recovery would be interesting and may specifically promote 
differentiation, and potentially of use in situations where there is a robust DR but poor or 
inadequate hepatocyte differentiation. 
As Wnt signalling can induce cell migration, and migration into the parenchyma is key 
feature of HPCs after hepatocellular injury, I examined the effect of Wnt inhibition with CBP 
inhibitor ICG001. Using the same migration assay as described in Chapter 4.3, proliferation 
was prevented and then the migration of HPCs into the centre of a well was measured with 
and without ICG001. Assessing the role for Wnt in migration of HPCs in vivo is beset by the 
same pitfalls as discussed in chapter 4. Notch inhibition in vitro did not limit migration, but 
Wnt inhibition resulted in a failure to migrate. Notch and Wnt signalling can both cause cell 
migration but the differential actions of the two signalling pathways on HPCs may help 
explain how their temporal regulation may permit an effective and orderly regenerative 
response involving HPC activation, proliferation, migration and differentiation. 
 
Figure 5.11: Notch and Wnt are required for an effective regenerative response: The early 
stage of activation and proliferation of the ductular reaction after hepatocellular injury is 
driven by Notch. For a period the Wnt pathway also becomes active and subsequently takes 
over control of proliferation and supports migration and differentiation of HPCs. 
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In summary, after hepatocellular injury there is temporally regulated activity of Notch and 
Wnt signalling that directs proliferation of HPCs (Figure 5.11). Quiescent bile ducts show 
evidence of active Notch signalling. They also show evidence of active Wnt signalling, albeit 
at a lower level than the previously identified Wnt-responsive zone 3 hepatocytes. After 
hepatocellular injury there is marked expansion followed by migration into the parenchyma 
of DRs. This is accompanied by an upregulation of Notch pathway mediated by Notch1 and 
Notch3. This activity directs proliferation of the ductular reaction. The initial burst of Notch 
activity is followed by a rise in Wnt pathway activity, which appears to direct proliferation 
and potentially migration in the later part of the ductular response. As these two distinct 
signalling pathways appear to promote the same function (proliferation) and while one 
dominates the early and the other the late response, this suggests temporal segregation is 
a mechanism which prevents antagonistic activity and permits Notch-driven expansion of 
DRs pending arrival of the post-phagocytic macrophages known to supply Wnt ligand to 
HPCs (123). Notch/Wnt antagonism via Wnt-dependent Numb provides a mechanism to 
switch off Notch signalling ready for Wnt driven differentiation. Intriguingly the data 
presented here suggests Notch and Wnt can act on HPCs at the same time and even in the 
same cell, suggesting the development of a Notch/Wnt permissive state. This may be 
facilitated by the relative resistance of Notch3 to Numb-mediated degradation. In addition 
this suggests these pathways have the potential to be co-operative and agonistic. In the 








In the gut homeostasis requires both Wnt and Notch signal (41, 242, 270). Notch drives 
proliferation within the developing intestine and this requires an intact Wnt signalling 
cascade, making the cells ‘competent’ to respond to the Notch-dependent mitogenic 
stimulus (271). In muscle both Notch and Wnt signal are required for effective regeneration 
after injury from myogenic progenitors with a crucial switch from Notch driven proliferation 
to Wnt driven differentiation with crosstalk occurring via GSK3β. Having established that 
both Notch and Wnt have roles in the proliferation of HPCs after hepatocellular injury, I 
wanted to try and identify if there was a node representing cooperation between the two 
signalling pathways.  
Growth hormone (GH) mediates its effects on growth and development both directly 
through the activation of GH receptors or indirectly by inducing production of insulin-like 
growth factor 1 (IGF1) principally by the liver (290-292). The effects of IGF1 can be 
modulated by IGF binding proteins (IGFBPs) which can regulate its biological actions by 
transporting IGF1 from the circulation to the tissue, maintain a reservoir of IGF1 in the 
circulation which can then potentiate or inhibit IGF1 action (293). IGF1 can be produced by 
many cell types and acts in a paracrine fashion in most tissues (294). Most actions of IGF1 
are mediated through the type 1 IGF receptor (IGF1R), a transmembrane tyrosine kinase 
related to the insulin receptor (IR). Ligand binding causes activation of tyrosine kinase 
activity and autophosphorylation of the receptor. The phosphorylated receptor can bind 
several receptor substrates including the insulin receptor substrates (IRS) initiating 
phosphorylation cascades that transmit the IGF1R signal (see Figure 1.5) (294). This can 
cause activation of phosphatidylinositol 3-kinase (PI-3K) leading to activation of p70 S6K 
kinase which phosphorylates the S6 ribosomal protein and increases the ribosomal pool 
necessary for entry into the cell cycle, and protein kinase B (Akt) (367). Akt phosphorylation 
enhances pro-proliferative protein synthesis through mTOR activation (368, 369). In 
addition to the effects on PI3K, transduction of the IGF1R signal results in recruitment of 
Ras and activation of the Raf-1/MEK/ERK pathway and downstream factors resulting in 
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induction of cellular proliferation (296, 297). In muscle, where a role for both Notch and 
Wnt in regeneration has been described, IGF1 is also of key importance in muscle growth, 
proliferation and differentiation of satellite cells (muscle progenitor cells) (298). Given the 
powerful proliferative effects of IGF1/IGF1R signalling and that the dominant source of IGF1 
is the liver, I was interested in exploring further the relationship between HPC proliferation 
and this axis. 
IGF1 is principally produced by mature hepatocytes (302, 370) however production has 
been identified in ductular cells after biliary injury (295). The IGF1-receptor (IGF1R) has 
been identified on ductular cells and been shown to be important in the development of 
DRs (295, 371). Administration or viral-induced expression of IGF1 in rats with carbon 
tetrachloride-induced cirrhosis (hepatocellular injury not associated with DRs) improved 
liver function and reduced fibrosis (372-374). Subsequently targeted overexpression of IGF1 
by activated hepatic stellate cells or hepatocytes attenuated fibrogenesis and accelerated 
liver regeneration through effects on MMPs, HGF and TGFb (375, 376). Overexpression of 
IGF1 in hepatocytes of rats with TAA-induced cirrhosis (a model involving toxic damage to 
hepatocytes and typically DRs and a fibrotic response), resulted in reduction in fibrosis and 
improved liver biochemistry (376). Interestingly however when IGF1 was overexpressed in a 
model of chronic biliary injury, ductular proliferation and fibrosis increased (371). The first 
small scale clinical trial using short-term administration of recombinant IGF-1 in cirrhosis 
showed an improvement in a marker of liver function, albumin (307).  
Several studies have demonstrated interactions between the IGF1 axis and Notch or Wnt 
signalling. The IGF1R is directly induced by Notch1 signalling under hypoxic conditions in 
adenocarcinoma of the lung, leading to activation of pro-survival Akt (299). Similarly in 
human T acute lymphoblastic leukaemia (T-ALL) initiating cells, IGF1R is a Notch1 target 
(300) and further promotes the mitogenic effects of IGF1 signalling through Hes induced 
inhibition of PTEN and thus enhanced PI3K/Akt/mTOR action. The relationship between 
Wnt signalling and the IGF1 axis is complex, but suggests a close connection and a positive 
feedback loop between Wnt/beta-catenin and IGF1 signalling (377). Wnt signalling can 
induce phosphorylation of IGF1 signalling mediators including Akt and ERK in an IGF1R-
dependent manner (301). IGF1 can stimulate TCF/LEF dependent transcription via 
activation of PI-3K and inhibition of negative regulator GSK3b and increasing cytoplasmic 
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levels of beta-catenin (303). In addition IGF1 can regulate the stability and transcriptional 
activity of beta-catenin (302). In some contexts Wnt signalling can induce expression of 
IGF1 (378), and IRS1, a principal intracellular mediator of IGF signalling (379). Thus I sought 
to determine if the IGF1 axis might represent a Notch/Wnt-sensitive node that drives 
proliferation of DRs, and see if this might explain the apparently contradictory results from 
liver based IGF studies. 
 
6.2 The IGF1 axis is active in HPC lines and Wnt/Notch responsive 
There are previous reports of expression of IGF1 and the IGF1 receptor (IGF1R) in ductular 
cells (295, 371). I began by staining my HPC lines for components of the IGF1 axis – IGF1, 
IGF1R and a third antibody raised against IGF1R phosphorylated at tyrosine 1161 (IGR1R 
pY1161). Following auto-phosphorylation, the tyrosine kinase function increases to a more 
active form. Both BMOL and SWA HPC lines stained positive for IGF1, IGF1R (the beta-





Figure 6.1: The IGF1 axis is expressed in HPC lines: Immunocytochemistry for IGF1 ligand 
(top), the beta-subunit of the IGF1 receptor (middle) and phosphorylated (more active) 
IGF1 receptor in HPC lines BMOL (left) and SWA (right). 
 
I next wanted to determine if growth of the HPC lines was sensitive to IGF1 signalling. From 
the family of synthetic protein tyrosine kinase inhibitors known as tyrphostins, I chose a 
small molecule inhibitor AG1024 that is selective to IGF1R over other members of the 
insulin receptor family (380). Using a MTT assay, I performed a dose-response experiment 
with both HPC lines and found a clear drop in cell viability (Figure 6.2A), confirming these 
cells were sensitive to manipulation of the IGF1 axis. Next I added increasing doses of 
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recombinant murine IGF1 (rIGF1) to the media to see if this increased cell number (Figure 
6.2B). There was no change in viable cell number. As the growth media contains serum, I 
wondered if this might be providing sufficient IGF1 to saturate the system, however when I 
repeated the experiment in serum free conditions, while there was a marked fall in growth 
rate, addition of IGF1 did not rescue this. Given my cell lines stained positive for IGF1 
(Figure 6.1), I wondered if they might produce enough IGF1 ligand to drive their own 
growth through this pathway. I cultured cell lines for 48 hours in their usual growth media 
and collected the conditioned media, then the cells. I performed an ELISA test to quantify 
the secreted IGF1 and compared it to serum containing growth media. In both cases 
conditioned media contained far higher concentrations of IGF1 than the regular media 
(Figure 6.2C). In order to compare the production of IGF1 between cell lines, I lysed the 
collected cells and quantified total cellular protein using a Bradford protein assay as a proxy 
for cell number and normalised the secreted IGF1 level to this and found both lines 
produced very similar levels of IGF1 (Figure 6.2D). Production of IGF1 and IGF1R by HPCs 





Figure 6.2: HPC lines are sensitive to manipulation of the IGF1 axis: (A) MTT assay using 
BMOL (left) and SWA (right) cell lines treated with increasing concentrations of small 
molecule IGF1-receptor (IGF1R) inhibitor AG1024 or vehicle. (B) MTT assay using BMOL 
(left) and SWA (right) treated with increasing combinations of recombinant murine IGF1 
(rIGF1) in ordinary growth media (red) and serum free (blue) media, normalised to lowest 
concentration. (C) Absolute quantification of secreted IGF1 from BMOL and SWA cells 
compared to growth media (p<0.0001). (D) Secreted IGF1 concentration normalised to total 
cell protein as a surrogate for cell number (n=6 per group). Data are presented as mean ± 
SEM. Dose-response experiments were analysed by 2-way ANOVA. Kruskal-Wallis test was 
used for comparison of multiple groups (p value shown in legend above) with Dunn’s 
multiple comparison post-test analysis included in the figure; Mann Whitney test was used 
for experiments with two groups. **p<0.01; ***p<0.001.  
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In order to determine if Wnt signalling might be driving IGF1 production in HPCs, I treated 
cells with ICG001 or vehicle for 48 hours, collected the conditioned media and then the 
cells. Gene expression of Igf1 was reduced in treated cells (Figure 6.3A). Using ELISA, I 
established the concentration of IGF1 in the conditioned media and confirmed a marked 
reduction in IGF1 secretion (Figure 6.3B). In order to determine if this Wnt mediated effect 
was specific to IGF1, I quantified gene expression of Igf1R in the same samples and found 
no effect (Figure 6.3C). 
To identify if Notch signalling might be driving IGF1R expression in HPCs, I treated cells with 
DAPT or vehicle for 48 hours and collected the cells. Gene expression of Igf1R was reduced 
in treated cells (Figure 6.4A). Protein expression was determined using western blotting. 
Using cell lysates from the experiment I performed, Ben Dwyer (a post-doc in the lab) 
performed the blot and I analysed the results. Expression of IGF1R was reduced in BMOL 
cells treated with Notch inhibitor DAPT (Figure 6.4B). There was no reduction in detectable 
IGF1R pY1161 in SWA cells (Figure 6.4C). The range of densitometry was 24.3-52.4 for SWA 
and 53.7-63.07 for BMOLs, and discrepancy remained even after correction for protein 
loading (beta-actin). This difference in expression and detection may reflect a difference in 
auto-phosphorylation in this cell line. Repeating the blot with a less specific antibody may 
help resolve this. Again I confirmed the effect of Notch on IGF1R expression was specific by 
quantifying gene expression of Igf1 in the same samples and found no change in either cell 
line (Figure 6.4D). 
I have established that Notch and Wnt both drive proliferation of HPC lines. Notch-driven 
production of IGF1 receptor in the BMOL line and Wnt-driven production of IGF1 ligand in 
both cell lines sets up a node for cooperation between signalling systems and the capacity 







Figure 6.3: Wnt inhibition reduces expression of IGF1 but not IGF1 receptor in HPC lines: 
(A) Gene expression of Igf1 relative to Gapdh in BMOL (upper panel) and SWA (lower panel) 
cell lines treated with ICG001. (B) Quantification of absolute levels of IGF1 protein secretion 
per ml of media from BMOL (upper panel) and SWA (lower panel) cell lines treated with 
ICG001 (n=6 per group). (C) Gene expression of Igf1-receptor relative to Gapdh in BMOL 
(upper panel) and SWA (lower panel) cell lines treated with with ICG001 (right). n=6 per 
group. Data are presented as mean ± SEM. Mann Whitney test was used for experiments 








Figure 6.4: Notch inhibition reduces expression of IGF1 receptor but not IGF1: (A) Gene 
expression of Igf1-receptor relative to Gapdh in BMOL (left) and SWA (right) cell lines 
treated with DAPT. (B) Expression of IGF1 receptor phosphorylated at tyrosine position 
1161 (IGF1R pY1161) in BMOL cells treated with DAPT or vehicle by western blot (left) and 
quantification of densitometry normalised to beta actin expression (right). (C) Expression of 
IGF1 receptor phosphorylated at tyrosine position 1161 (IGF1R pY1161) in SWA cells 
treated with DAPT or vehicle by western blot (left) and quantification of densitometry 
normalised to beta actin expression (right). (D) Gene expression of Igf1 relative to Gapdh in 
BMOL (left) and SWA (right) cell lines treated with DAPT. n=6 per group. Data are presented 




6.3 The IGF axis is present in DRs and is Notch/Wnt responsive 
IGF1 production within ducts has previously been reported (295) and I wanted to confirm 
this remained the case in the AhCre MDM2fl/fl model. By performing immunohistochemistry 
for IGF1 I was able to localise its expression with ductular marker CK19 (Figure 6.5A). When 
I analysed gene expression of Igf1 over the AhCre MDM2fl/fl model time-course, the 
expression profile followed the expression dynamics of the Wnt expression ‘signature’, 
suggesting that in vivo IGF1 expression may also be under the control of Wnt signalling 
(Figure 6.5B). 
The DRs in the AhCre MDM2fl/fl model stained positive for IGF1R (Figure 6.6A). The receptor 
was also detected in blood vessels. Gene analysis over the time-course revealed the 
expression profile of Igf1R mirrored that of the Notch expression ‘signature’, again 





Figure 6.5: Ductular cells express IGF1 and the expression profile after hepatocellular 
injury follows the Wnt ‘signature’: (A) Immunohistochemistry for Igf1 (red) and CK19 
(green) in AhCre MDM2fl/fl model. (B) Gene expression of Igf1 following Cre induction 
relative to Gapdh normalised to day 0 levels in AhCre MDM2fl/fl model (n=5-8 per time 





Figure 6.6: Ductular cells express IGF1 receptor and the expression profile after 
hepatocellular injury follows the Notch ‘signature’: (A) Immunohistochemistry for 
phosphorylated Igf1 receptor (Igf1RpY1161) (red), CK19 (green) in day 7 of AhCre MDM2fl/fl 
model. (B) Gene expression of Igf1-receptor following Cre induction relative to Gapdh 
normalised to day 0 levels in AhCre MDM2fl/fl model (n=5-8 per time point). Data are 





Figure 6.7: mTOR signalling is active in the ductular reaction after hepatocellular injury: 
Representative photomicrographs of phospho-mTOR staining of day 7 (left panel) and day 
10 (centre and right panel) AhCre MDM2fl/fl model. Photomicrograph scale bars: 100uM. 
 
Downstream of IGF1 and its receptor are PI3K/Akt/mTOR activation (294, 367). In order to 
confirm downstream pro-proliferative mediators were present within the DRs of the AhCre 
MDM2fl/fl model I performed immunohistochemistry for phosphorylated (active) mTOR 
(Figure 6.7). The staining localised to the DRs. 
To determine if IGF1 an IGF1R remained sensitive to Notch and Wnt signal in vivo and that 
this effect remained specific, I treated mice with Notch inhibitor DAPT and Wnt inhibitor 
ICG001 and analysed expression of Igf1 and Igf1R. Consistent with findings in the HPC lines, 
Wnt inhibition reduced expression of Igf1 but not Igf1R and Notch inhibition reduced 





Figure 6.8: Expression of Igf1 and IGF1 receptor is Notch/Wnt responsive in vivo: (A) Gene 
expression of Igf1 relative to Gapdh in animals treated with ICG001 and DAPT (p=0.0128) 
demonstrates sensitivity of expression of Igf1 to Wnt but not Notch inhibition. (B) Gene 
expression of Igf1-receptor relative to Gapdh in animals treated with ICG001 and DAPT 
demonstrates sensitivity of Igf1R to Notch inhibition but not Wnt inhibition (p=0.0068). 
(n=5 per group). Data are presented as mean ± SEM. Kruskal-Wallis test was used for 
comparison of multiple groups (p value shown in legend above) with Dunn’s multiple 
comparison post-test analysis included in the figure. *p<0.05; **p<0.01.  
 
Having established that a Notch/Wnt responsive IGF1 axis is expressed in DRs after 
hepatocellular injury, I wanted to confirm if it was functionally active in driving DR 
proliferation. Using the AhCre MDM2fl/fl model, I designed an experiment where specific 
IGF1R inhibitor AG1024 was administered by i.p. injection daily for days 6-9 (Figure 6.9A). 
Mice were harvested 24 hours after the final dose. There was a marked reduction in size of 
DRs (Figure 6.9B and C). Analysis of proliferation rate confirmed this loss was due to failure 
of proliferation (Figure 6.9D). Level of initial injury as inferred from serum ALT levels 
remaining constant between groups (Figure 6.9E). 
Further importance of this axis in driving the DR was demonstrated through a second 
experiment where the experimental protocol was repeated but instead of inhibition at the 
point of IGF1R, the mTOR inhibitor rapamycin was administered (Figure 6.10A). As mTOR 
does not mediate proliferation solely due to IGF1/IGF1R signalling, rapamycin could 
potentially reduce proliferation of hepatocytes. As the size of the DR in this model relates 
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to the degree of failure of hepatocyte replication, mTOR inhibition could potentially 
increase the stimulus for the DR. Administration of rapamycin in the AhCre MDM2fl/fl model 
resulted in a reduced DR in terms of both cell number and proliferation therefore any 
increased stimulus relating to an effect on hepatocytes was insufficient to overcome the 





Figure 6.9: The IGF1 axis drives ductular expansion after hepatocellular injury:  (A) 
Schematic (left) demonstrates the experimental design for treatment with Igf1-receptor 
inhibitor AG1024 or vehicle following MDM2-mediated hepatocyte injury. (B) 
Representative images of panCK staining. (C) Quantification of effect on ductular response 
in terms of panCK-positive cell number and (D) Ki67 positive proportion. (E) Serum ALT 
values. (n=5 per group). Data are presented as mean ± SEM. Mann Whitney test was used 





Figure 6.10: Inhibition of the IGF1 axis downstream at mTOR further supports 
functionality of this pathway in generating the ductular reaction:  (A) Schematic 
demonstrates the strategy for treatment with rapamycin or vehicle following MDM2-
mediated hepatocyte injury. (B) Representative images of panCK staining. (C) Quantification 
of effect on ductular response in terms of panCK-positive cell number and Ki67 positive 
proportion (D). (E) Serum ALT values. (n=3 vehicle group, n=6 treatment group). Data are 
presented as mean ± SEM. Mann Whitney test was used for experiments with two groups. 





Positive staining of the DRs for phosphor-mTOR (Figure 6.7), and the data from the HPC 
lines, suggests the DR is a specific site for this active pathway. However it remains possible 
that use of IGF1 axis inhibitors might influence other components of the HPC niche – 
macrophages and myofibroblasts – and changes in their function might result in differences 
in the signals they deliver to the DR and thus indirectly impair DR proliferation. In order to 
determine a direct role for the IGF1 axis in driving DRs in vivo I generated a strain where 
Igf1R could be specifically deleted in ductular cells. I crossed mice with loxP sites flanking 
exon 3 of the Igf1r gene (326) with the OPN-iCreERT2;R26RYFP strain to generate OPN-
iCreERT2;R26RYFP;Igf1rfl/fl and OPN-iCreERT2;R26RYFP;Igf1rwt/wt strains. Following tamoxifen 
administration and a two week tamoxifen ‘washout’ period, mice received 3 weeks of CDE 
diet to induce hepatocellular injury and DRs (Figure 6.11A). There was a marked reduction 
in the number of YFP-positive (and thus conditionally lacking Igf1r) ductular cells in the 
OPN-iCreERT2;R26RYFP;Igf1rfl/fl group (Figure 6.11B and C). Analysis of PCNA expression 
confirmed a reduction in proliferation capacity (Figure 6.11D). The number of lineage 
traced hepatocytes remained negligible in both groups and level of injury (as inferred by 
serum ALT) was consistent (Figure 6.11E-F). 
6.4 Disruption of the IGF axis disrupts proliferation of DRs 
Having established that in the CDE model of hepatocellular injury, conditional loss of Igf1r 
within the biliary compartment resulted in loss of DRs, I wanted to test this in a second 
model to confirm the effect. Further groups of animals received two weeks of MCD diet 
(Figure 6.12A). In this model there was also a reduction in DRs and their proliferation 
(Figure 6.12B-D). The number of lineage labelled hepatocytes remained low in both groups 
except for one animal in the OPN-iCreERT2;R26RYFP;Igf1rwt/wt group which showed 
approximately 12% labelled hepatocytes. This may reflect inadvertent liver injury either at 
time of tamoxifen administration or prior to the initiation of MCD diet thus combining a 
‘recovery’ model with an active injury model and seeing expansion of pre-labelled 












Figure 6.11: Conditional loss of Igf1r leads to loss of expansion of the ductular reaction 
after hepatocellular injury:  (A) Schematic of experimental design to assess effect of loss of 
Igf1-receptor on the ductular response to CDE diet injury using OPN-
iCreERT2;R26RYFP;Igf1rfl/fl (n=5) and OPN-iCreERT2;R26RYFP;Igf1rwt/wt (n=4) strains. (B) 
Representative photomicrographs of YFP staining. (C) Quantification of effect on ductular 
reaction in terms of YFP-positive ductular cell number and (D) PCNA positive proportion. (E) 
The number of lineage traced hepatocytes in both groups remained minimal. (F) Serum ALT 
levels. Data are presented as mean ± SEM. Mann Whitney test was used for experiments 













Figure 6.12: A second model of hepatocellular injury (MCD diet) further confirms Igf1r 
required for expansion of the ductular reaction:  (A) Schematic of experimental design to 
assess effect of loss of Igf1-receptor (IGF1R) on the ductular response to MCD diet injury 
using OPN-iCreERT2;R26RYFP;Igf1rfl/fl (n=8) and OPN-iCreERT2;R26RYFP;Igf1rwt/wt (n=5) strains. 
(B) Representative photomicrographs of YFP staining. (C) Quantification of effect on DR in 
terms of YFP-positive ductular cell number and (D) PCNA positive proportion. (E) The 
number of lineage traced hepatocytes in both groups remained minimal except for one 
animal in the wt/wt group that showed approximately 12% labelled hepatocytes. (F) Serum 
ALT levels. Data are presented as mean ± SEM. Mann Whitney test was used for 
experiments with two groups. *p<0.05; **p<0.01. Photomicrograph scale bars: 100uM. 
 
As this data supports a specific effect on the DR of the IGF1 axis in driving proliferation, I 
wanted to see what the effect was on the DR in vivo of administering additional IGF1. In the 
HPC lines, additional IGF1 did not increase proliferation, however in these spontaneously 
immortalised cell lines the proliferation rate is extremely high and therefore may not be 
amenable to further increases. Even when the growth rate was reduced by enforcing serum 
free conditions, additional IGF1 did not enhance growth. IGF1 production in both cell lines 
was extremely high and the system may have been saturated. The AhCre MDM2fl/fl model 
results in generation of robust DRs that have a high proliferation rate. It was not clear if it 
would be possible to influence this with additional IGF1. I designed an experiment where 
recombinant murine IGF1 (rIGF1) or vehicle was administered daily days 6-9 after Cre 
induction (Figure 6.13A). At this time-point post Cre-induction while the absolute number 
of ductular cells is rising rapidly, their proliferation rate is falling. Despite the high number 
of ductular cells in the vehicle group, there was a small increase in number in the animals 
receiving rIGF1 (Figure 6.13B and C). When I assessed the proliferation rate of the cells 
however there was a marked increase from 6.5% to 21.3%, restoring proliferation rate to 
peal levels seen in the first few days of the ductular response (Figure 6.13D). If the animals 
had been left longer it is reasonable to predict the expansion of the DR would have 
continued. 
Given the conflicting evidence from previous studies regarding the effect of IGF1 on causing 
fibrosis (371, 373, 375, 376) and the debate regarding whether HPCs drive fibrosis (86) I 
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went on to examine fibrosis in this model. Picrosirius red (PSR) stains collagen I and III 
deposited during the fibrotic response. PSR stain in this experiment showed collagen 
deposition in fact fell in the IGF1 treated animals, supporting that enhancing HPC function 











Figure 6.13: Administration of recombinant IGF1 enhances the ductular reaction without 
causing fibrosis:  (A) Schematic demonstrates the strategy for administration of 
recombinant murine Igf1 or vehicle following MDM2-mediated hepatocyte injury. (B) 
Representative images of panCK staining. (C) Quantification of effect on ductular response 
in terms of panCK-positive cell number and (D) Ki67 positive proportion. (E) Representative 
photomicrographs of picosirius red (PSR) staining from this experiment. (F) Quantification 
of PSR staining. (G) Serum ALT levels. n=5 per group. Data are presented as mean ± SEM. 
Mann Whitney test was used for experiments with two groups. **p<0.01. Photomicrograph 





In this chapter I have examined the IGF1 axis as a driver for DRs and a potential node for 
cooperation between Notch and Wnt signalling after hepatocellular injury. Synergy 
between Notch signalling and the IGF1 axis has been demonstrated with Notch1 directly 
driving expression of IGF1R and via Hes1 enhancing action of IGF1 axis signalling 
intermediaries (299, 300). Wnt and IGF1 cooperate in a positive feedback loop with IGF1 
stimulating TCF/LEF dependent transcription and both increasing the stability and 
transcriptional activity of beta-catenin (377). In addition Wnt signalling can drive expression 
of both IGF1 and the principal intracellular mediator of IGF signalling IRS1 (378, 379).  
I have demonstrated that two independent HPC lines express both IGF1 ligand and 
receptor. I went on to show growth of both these lines is sensitive to disruption of IGF1 
signalling. I have demonstrated that both cell lines are the dominant source of IGF1 ligand 
that governs their growth. In both cell lines production of IGF1 at the gene and protein level 
was Wnt-sensitive. In both cell lines expression of IGF1R was Notch sensitive at the gene 
level, although I could not detect a reduction at the protein level of IGF1R with a specific 
phosphorylation status. I confirmed this Notch-Wnt sensitivity was a specific effect as 
Notch inhibition had no effect on IGF1 ligand production and Wnt inhibition had no effect 
on receptor production. 
IGF1 production by ductular cells after biliary injury has been previously demonstrated 
(295). The IGF1-receptor (IGF1R) has also been identified on ductular cells (295, 371). I 
confirmed that both ligand and receptor were expressed in the ductular reactions after 
MDM2-mediated hepatocellular injury. I also confirmed downstream signalling was active 
by localising (active) phosphorylated mTOR within DRs. I have shown that expression of 
IGF1 in the AhCre MDM2fl/fl model time-course follows the Wnt target gene expression 
‘signature’ and that IGF1R expression follows the Notch target gene expression ‘signature’, 
suggesting that in vivo too IGF1 axis expression is Notch/Wnt sensitive. This was further 
confirmed as specific by identifying reduced expression of Igf1 but not Igf1R in animals 
treated with Wnt inhibitor ICG001. Animals treated with Notch inhibitor DAPT had reduced 
expression of Igf1R but not Igf1. 
I consistently found that disrupting the IGF1 axis after hepatocellular injury diminished DRs. 
Using the AhCre MDM2fl/fl model I inhibited the IGF1R with a small molecule AG1024 
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resulting in failure of DR proliferation. A previous study demonstrated that cholagniocytes 
isolated from rats undergoing bile duct ligation (BDL) to induce liver injury expressed both 
IGF1 and IGF1R and their proliferation could be inhibited with a IGF1R blocking antibody or 
downstream inhibition of PI3K activity (295). Similarly I found inhibiting the IGF1 axis 
downstream at the point of mTOR resulted in a similar effect on proliferation as blocking 
IGF1R. Using Cre-lox technology to target IGF1 axis disruption to the biliary compartment I 
generated OPN-iCreERT2;R26RYFP;Igf1rfl/fl and OPN-iCreERT2;R26RYFP;Igf1rwt/wt strains and put 
these animals through two different hepatocellular injury models, CDE and MCD diet. In 
both cases there was a marked reduction in generation of labelled (and thus Igf1R lacking) 
ductular cells, and failure of their proliferation. 
I went on to assess the effects of administering an excess of IGF1 to animals after 
hepatocellular injury. Using the AhCre MDM2fl/fl model I administered recombinant IGF1 at 
a similar time to previous inhibitory experiments. At this point DRs are well established and 
while total ductular cell number is still increasing, their proliferation rate is falling. In this 
experiment administration of IGF1 was able to increase cell number and restore 
proliferation rate to maximal levels. Fibrosis in these animals also decreased.  
Several studies have examined the link between IGF1 and CCl4-induced fibrosis in the liver. 
Administration of recombinant IGF1, viral-mediated gene transfer and genetic over 
expression have been used. Recombinant IGF1 administered to rats with CCl4 induced 
cirrhosis showed a number of beneficial effects. Hepatocellular function (serum albumin 
and clotting factors) and hepatocyte proliferation improved and oxidative stress and 
fibrosis were reduced. Livers showed lower hydroxyproline content and activity, fewer 
activated stellate cells and reduced expression of collagen I and III (372, 373, 381). In 
addition there were positive effects on the extrahepatic manifestations of cirrhosis with 
increased food intake, muscle mass and bone density (382). Transgenic mice that expressed 
IGF1 under an aSMA promotor (i.e. overexpress IGF1 on activation of stellate cells) were 
shown to recover more rapidly from acute liver injury caused by administration of CCl4. 
Accompanying improved transaminases and reduced area of necrosis was an enhanced 
expression of HGF, and reduced expression of TGFb1 and collagen Ia (375). Administration 
of a recombinant simian viral vector encoding IGF1 (rSVIGF-1) was found to prevent 
progression of CCl4-induced cirrhosis in rats (376) and mice (374). This was associated with 
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reduced serum bilirubin, improved transaminases, an increase in expression of matrix 
metalloproteinases (MMPs) and HGF and reduced tissue inhibitors of MMPs (TIMPs) and 
TGFb. The CCl4 injury model is not associated with DRs, and has not been shown to involve 
HPC-mediated hepatocellular regeneration, and therefore it is difficult to infer an effect on 
generation of DRs. 
Sokolovic and colleagues investigated the effect of overexpression of IGF1 in a model of 
biliary injury (371). They used the genetic Abcb4-/- model (also known as Mdr2-/-) in which 
excretion of phospholipids into bile, a requirement to neutralise bile acid toxicity, is limited. 
This strain was crossed with the model described above where IGF1 overexpression is 
driven by an aSMA promotor. Contrary to the observed positive effects in animals with 
hepatocyte injury, these animals showed increased fibrosis. Collagen staining increased, as 
did the expression of TGFb and TIMPs. DRs were also larger. Only one previous study has 
looked at the effects of IGF1 administration after hepatocellular injury associated with DRs. 
In this study rSVIGF-1 was administered to rats with thioacetamide (TAA)-induced cirrhosis. 
Oral administration of thioacetamide results in formation of toxic metabolites within zone 3 
(pericentral) hepatocytes (112, 113). Prolonged administration results in ductular reaction, 
hepatic fibrosis and cirrhosis in mice and ultimately dysplasia and biliary carcinoma in rats 
(114). In this rSVIGF-1 TAA study fibrosis also fell, HGF and MMPs increased and TIMPs fell 
(376). Interestingly Irvine et al have recently demonstrated that when the secretion of Wnt 
from macrophages was prevented, fibrosis was increased in mice receiving TAA (383). DRs 
continued to expand (presumably via Notch and other signals such as TWEAK) but they 
were unable to demonstrate any direct effect on fibroblasts numbers or rate of collagen 
deposition. There was however an associated reduction in expression of MMPs and 
increase in expression of TIMPs. IGF1 was not examined but reduced Wnt-driven IGF1 
expression could explain their findings. 
In this chapter I propose a model for cooperation of Notch and Wnt in controlling 
proliferation of DRs in which Notch signalling can drive proliferation via induction of pro-
proliferative genes or direct interaction with PI3K/Akt signalling. It can also drive expression 
of IGF1R, upstream of Akt and mTOR. Wnt signalling can drive proliferation via induction of 
pro-proliferative genes including IGF1. This can then in turn re-inforce Wnt signalling and 
cement the Wnt programme within HPCs to favour differentiation into hepatocytes (Figure 
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6.14). It may be that apparently contradictory effects of IGF1 demonstrated in previous 
studies can be explained when considered in the context of Notch and Wnt signalling. In 
chronic biliary injury where there is a high and persistent level of Notch signalling governing 
DR proliferation (58, 384), cholangiocytic differentiation (123) and transformation of 
hepatic stellate cells into myofibroblasts and resultant fibrosis (283), the addition of IGF1 
results in further over-activity of this system and fibrosis ensues. In situations where there 
is hepatocyte injury, fibrosis and no DR, such as CCl4-induced injury, IGF1 can be 
hepatoprotective and pro-regenerative via induction of HGF, and limiting fibrosis through a 
direct or indirect effect on myofibroblasts. In contexts where there is the potential for DRs 
to generate HPCs capable of hepatocyte differentiation, then increased IGF1, promotion of 
the ‘Wnt program’, including potentially anti-fibrotic pathways, HPC migration and 
subsequent differentiation, may improve regeneration. This further highlights the 
importance of understanding the mechanisms involved in disease development in order for 










Figure 6.14: Proposed model for cooperation of Notch and Wnt in controlling HPC 
response to hepatocellular injury: Notch ligand produced by activated myofibroblasts and 
potentially bile ducts/HPCs themselves can drive HPC expansion via induction of pro-
proliferative genes or direct interaction with PI3K/Akt signalling. In addition, Notch can 
drive expression of type 1 IGF receptor, upstream of Akt and mTOR. Wnt ligands produced 
by macrophages in response to engulfment of dead hepatocyte material and potentially 
endothelial-derived ligand can drive HPC proliferation via induction of pro-proliferative 
genes, including IGF1. IGF1 then further reinforces the Wnt program within HPCs resulting 





In a pilot randomised clinical trial IGF1 was administered to individuals with cirrhosis (307). 
The trial was limited to those with alcoholic liver disease (ALD) or primary biliary cirrhosis 
(PBC) as their aetiology because of reports of growth promoting and anti-apoptotic 
properties of IGF1 and may be associated with the development certain tumours and/or 
their progression (385). Therefore those with a higher risk of developing hepatocellular 
carcinoma (HCC) such as haemochromatosis or chronic viral hepatitis were excluded. The 
level of IGF1 replacement was low and serum levels remained below normal values in 
treated patients. There was a significant increase in serum albumin concentration in the 
IGF1 treated group, consistent with improved liver function. There was also a trend towards 
improvement of Child-Pugh score which assesses the prognosis of liver disease. The 
benefits were most evident in patients with alcoholic liver disease (where injury is 
predominantly hepatocellular in nature and DRs can be seen (61, 386)) compared with 
individuals with biliary injury. 
While IGF-II has been associated with HCC (387-390), a link between IGF1 and HCC is not 
established and low serum IGF1 may in fact predict risk of developing HCC, probably serving 
as a biomarker for severity of liver disease (391). Patients with non-alcoholic fatty liver 
disease have insulin resistance and chronic hyperinsulinaemia which in turn results in 
upregulation of IGF1 and potential involvement in hepatocarcinogenesis, (392) although 
which part of this cascade is directly or principally responsible is yet to be clarified, as is any 
deleterious effect of raising IGF1 levels in this setting. If serum levels of IGF1 were increased 
to supra-physiological levels, this could potentially increase the risk of non-liver 
malignancies associated with IGF1, particularly breast (393) and prostate cancer (394). In 
addition recombinant IGF1 is extremely costly and the dose and duration required for 
cirrhotic patients would render this an unrealistic therapeutic solution at present (395). 
Studies in animals with hepatocellular injury using gene transfer of IGF1 have shown 
encouraging results in terms of slowing the development of cirrhosis and even regression 
(374, 376). IGF1 levels were shown to increase in the liver without circulating levels rising 
above normal. Development of gene transfer or targeted cell therapies in humans may 




7 Conclusions and future perspectives 
 
The importance of Notch and Wnt in liver regeneration is well recognised but remains 
incompletely understood. Differences in expression of Notch and Wnt have been 
documented in end liver stage disease and key roles for Notch in biliary and Wnt in 
hepatocellular fate determination have been demonstrated. However the roles of Notch 
and Wnt in driving the regenerative response, particular after hepatocellular injury, are not 
known. 
Establishing how the liver regenerates, from which cell types and the potency of those cells 
has been hotly debated in recent years (33). The development of inducible, tissue specific 
Cre-lox labelling systems has not conclusively settled the matter (95). Potential reasons 
behind contradictory results include unexpected effects of tamoxifen on hepatocyte biology 
and difficulty in labelling lineages which share common ancestry due to transient 
expression of adult fate-specific genes such as albumin in developmental precursors as well 
as adult progenitors. In addition there is limited ability of our available models to 
meaningfully recapitulate the human disease picture of gross hepatocyte turnover, 
exhaustion and senescence. Rodent dietary models attempt to mirror human chronic 
hepatocellular damage, however age and background strain sensitivity, along with further 
variability related to individual animal units’ pathogen levels, make reproducibility of 
findings between groups a further challenge. Further controversy regarding liver 
regeneration likely relates to consideration of only a single key recovery mechanism – 
either mature hepatocytes or a stem or progenitor cell – and further by the degree of 
rigidity of definitions of stemness applied. In an organ if one mature cell type can 
regenerate itself as well as another cell type can it be a stem cell? Is it transdifferentiation? 
And if this process involves transition through an intermediate bipotential progenitor cell 
then is this de-differentiation of a mature cell, or an apparently terminally differentiated 
cell acting as a facultative (stem) cell of origin for progenitor cells? As an organ whose key 
role is detoxification of both expected and unknown insults, high plasticity and multiple 
potential regenerative strategies for the liver would seem an evolutionary necessity. In 
order to develop new treatments for advanced liver disease, where prognosis is dismal and 
therapies are limited, all potential regenerative avenues must be considered for 
exploitation. Multiple studies have now demonstrated that cells from the biliary 
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compartment can generate hepatocytes after liver injury in the zebrafish, rat and mouse 
(52, 53, 56-58, 262, 396), behaving as facultative stem cells, and there is recent supportive 
evidence of this process occurring in human disease (51). The challenge remains to fully 
understand this process and identify ways of enhancing an important endogenous repair 
pathway. 
The best characterised models of liver regeneration are 2/3 partial hepatectomy and 
acetaminophen poisoning whereby a single insult is applied and the dynamics of the 
response studied, however these injuries are not typically associated with regenerative 
DRs. Combining administration of 2 acetylaminofluorene (AAF), which causes DNA damage 
and increased expression of p21 leading to hepatocyte cell-cycle arrest, with partial 
hepatectomy in rats (2AAF/PH model) has provided compelling evidence of a biliary origin 
for hepatocyte-regenerating DRs. While this model permits time-sensitive study of the 
regenerative response (262, 269), current genetic technology does not however permit 
robust lineage tagging, signalling pathway reporter gene expression or cell type specific 
genetic loss or gain of function. A mouse model has the potential to overcome some of 
these limitations. Classic murine dietary injury models can induce a ductular reaction in 
which lineage labelling has confirmed a biliary origin of both HPCs and a proportion of new 
hepatocytes generated after injury (56-58). The disadvantage of these models is that the 
continuous nature of the injury means our ability to study what signals may drive a DR over 
time are limited and real-time analysis of regenerative pathways is not possible. The 
AhCreMDM2fl/fl strain, through Cre-mediated deletion of MDM2, results in high levels of 
hepatocyte p53 expression and subsequent senescence with p21 expression (59). Cells 
from the DRs of these animals are able to differentiate down either the hepatocyte or 
biliary route, be isolated, expanded, transplanted and then functionally repopulate the 
parenchyma. When the ability of these animals to generate DRs is lost, the animals die, 
confirming both the importance and potency of ductular derived HPCs. Crucially, as injury is 
administered as a ‘single hit’, this model has the potential for scrutiny to be applied to the 
temporal dynamics of injury and regeneration.  
I have demonstrated that after severe hepatocyte injury and induction of senescence using 
the AhCreMDM2fl/fl model, a robust DR develops that can be studied over time. There is 
highly predictable activation, expansion and migration of DRs. I also studied the 
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proliferation dynamics, confirming a highly proliferative cell type. I used this system to 
study Notch and Wnt signalling, but clearly this model has potential for the study of many 
other signalling systems. Isolation of cellular components – hepatocytes, HPCs, fibroblasts 
or macrophages would enable relative contribution of cell populations to expression 
profiles and also assist in the identification of further therapeutic targets. 
The major limitation of this system is that the biliary compartment is not lineage tagged. 
This means direct positive lineage tracing evidence of large scale contribution to 
hepatocyte replacement cannot be demonstrated. This would require a method to induce 
similar hepatocyte injury not using Cre-lox technology, enabling Cre-mediated lineage 
labelling of the biliary compartment. Viral induced overexpression of p21 in hepatocytes 
may be an effective strategy and is currently being developed in the Forbes laboratory. In 
addition to permitting positive lineage tracing of ductular cells, Cre-mediated excision of 
key components of the signalling pathways could be used to determine the effects on 
generation of DRs and subsequent hepatocyte differentiation. 
Using the AhCreMDM2fl/fl strain, complemented by biliary Cre lineage tracing systems, I 
went on to characterise the expression and activity of Notch and Wnt signalling pathways 
after hepatocellular injury. I identified changes in expression of Notch ligands and receptors 
after injury. Receptor expression localised to the DR. I measured the expression of a range 
of Notch target genes and identified a time-sensitive Notch expression ‘signature’. By 
generating the AhCreMDM2fl/fl; CBF:H2B-venus strain I was able to confirm ductular cells 
were in receipt of, and were acting on, canonical Notch signal. By evaluating changes in 
Notch reporter expression over time, I also confirmed that Notch pathway activity was 
dynamic after injury and lost as regeneration progressed. Experiments designed to reflect 
this dynamic expression revealed a time-sensitive role for Notch in driving the proliferation 
of DRs. I went on to demonstrate that this phenotype was driven by the dynamically 
expressed Notch receptors, Notch1 and Notch3. Using Krt19 and OPN Cre strains I was 
further able to further prove Notch-dependent proliferation of DRs in more traditional diet 
based liver injury models. 
I have demonstrated changes in Wnt pathway activity over time after MDM2-mediated 
hepatocyte injury. Similar to Notch effector expression, I identified a characteristic time-
sensitive expression profile or ‘signature’ for Wnt target genes. After injury I observed a 
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loss of expression of Wnt target genes and Wnt pathway activity reporter, which was 
subsequently restored as the DR developed. Using additional experiments designed to 
reflect this dynamic expression profile I went on to demonstrate that proliferation of DRs in 
this later phase was Wnt driven. Furthermore, using the Krt19 Cre strain I was able to prove 
Wnt-dependent proliferation of DRs in diet based liver injury models. 
Having identified roles for both Notch and Wnt in controlling proliferation of DRs, I went on 
to investigate if there was a node of cooperation between the two pathways. I identified 
Notch driven expression of IGF1 receptor and Wnt driven expression of IGF1 ligand,. I went 
on to demonstrate the significance of this axis in proliferation of the DR in multiple mouse 
models, including genetic disruption of this axis specific to the biliary compartment. 
Importantly I demonstrated that administration of additional IGF1 could both enhance 
proliferation of the DR and reduce fibrosis, thus potentially enhancing HPC mediated 
regeneration without negative effects.  
Previous studies in livers from mice with CDE-induced injury in which macrophages (and 
therefore secreted factors such as Wnt ligands and TWEAK) were depleted there was no 
change in expansion of ductular cells, but these HPCs did not migrate into the parenchyma 
instead forming periportal aggregates akin to bile ducts (342). Similarly silencing of Wnt1 
resulted in expanded proliferating atypical ducts in the rat 2AAF/PH model (269). The 
persisting ability of DRs to expand suggests alternative signals are also involved in their 
proliferation. Important signals identified to date in HPC activation and proliferation include 
HGF/c-met, EGFR, Shh, TWEAK and TGF-β (343-345). Notch is a key signal in biliary 
specification of the hepatoblast. It is required for effective arborisation of the developing 
biliary tree and when over-expressed in hepatocytes has the potential to convert their fate 
to cholangiocytes with roles proposed for both Notch1 and Notch2 (156, 170, 171, 211, 
213, 222, 397). I found no dynamic changes in expression of Notch2 after hepatocellular 
injury. In addition blockade of Notch2 did not affect DR proliferation. This may reflect 
functional redundancy, however recent work identified specific Jagged1-Notch1 interaction 
as important for proliferation of DRs after injury by bile duct injury, further supporting 




The functions of Notch3 are less well characterised. It may have a role in activation of 
stellate cells (226) and is expressed by the vasculature (398) and therefore could have 
indirect actions to the ductular proliferation phenotype I observed. My in vivo data, 
combined with the effect of Notch3 knock down in my HPC line, is highly supportive of a 
direct effect upon biliary proliferation. As the Notch receptors are not equivalent targets for 
Numb inhibition with structural differences rendering Notch3 relatively resistant (197, 284), 
this paralog is ideally placed to permit persisting Notch activity in HPCs at a time of rising 
Wnt; a ‘permitted’ Notch. I have not examined the relative roles of the different paralog on 
the production of IGF1R and this would be interesting to pursue. 
A particularly interesting finding in the section of work describing Wnt pathway expression 
was the identification of Axin2 and TCF/LEF:H2B-GFP in the ducts of uninjured animals. 
Previous studies have reported Axin2 RNA expression to be restricted to zone 3 
hepatocytes (20, 150) however in these studies images suggest there may be some ductular 
expression. Similarly a beta-galactosidase (beta-gal) TCF/LEF reporter system has reported 
hepatocyte zone 3 beta-gal activity, with minimal (but detectable) reporter activity in the 
portal region of non-injured animals. The sensitivity of the RNAScope system I employed to 
identify Axin2 is high and may explain apparently differing results. Similarly the 
TCF/LEF:H2B-GFP construct is both highly sensitive (with six TCF/LEF binding sites) and 
encodes a very bright fluorescent reporter permitting high resolution reporting. This also 
enabled co-staining of TCF/LEF:H2B-GFP reporting cells to confirm they were ductular. 
Demonstrating Wnt activity in the uninjured biliary tree may reflect a basal ‘stem potential’ 
of ductular cells consistent with a ‘Wnt responsive’ stem cell model as present in tissues 
such as the intestine, stomach, skin and mammary gland (233) and most recently in 
pericentral hepatocytes (150).  
I saw gross upregulation of Ascl2 accompanying DR activation after hepatocellular injury, 
preceding Lgr5 upregulation, reflecting both a Wnt program but also potentially further 
interaction between Notch and Wnt. Transcription factor Ascl2 occupies an interesting 
position between the two signalling pathways. In epidermal development, Notch signalling 
can both induce Ascl2 expression and repress it via Hes-1 (289). As a direct target of 
canonical Wnt signalling, Ascl2 is required for maintenance of the Lgr5 stem cell pool in 
adult intestinal epithelium (286, 287). I did not give Wnt inhibitor to AhCreMDM2fl/fl animals 
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at the time of Cre-induction or pre-treat them with Wnt inhibitor. This would help 
determine if the low level of Wnt signalling reported in uninjured ducts was required for 
subsequent cell activation and generation of the DR and if in this system Ascl2 expression 
was dependent on Wnt, Notch or both signals. I have not investigated the source of Wnt 
ligand providing Wnt signal to ductular cell in the absence or after injury. Infiltrating bone 
marrow derived macrophages have been demonstrated to be a source of Wnt ligand in 
mice after CDE diet (123) and in mice and rats after chronic thioacetamide (TAA) 
administration (115). Hepatocytes were found to be a source of Wnt1, providing paracrine 
signal to DRs in the 2AAF/PH hepatectomy rat model (262, 269). Central vein endothelial 
cells have been shown to provide Wnt signals to maintain the Wnt-responsive pericentral 
Axin2 positive hepatocytes responsible for homeostatic renewal (150). It may be that zone 
1 hepatocytes or portal tract vessels provide local tonic Wnt signal to ductal cells in the 
resting state and after injury infiltrating macrophages, injured or peri-injury hepatocytes, or 
even sinusoidal endothelilal cells in response to pressure changes related to hepatocyte 
damage can provide Wnt ligand as the DR develops. Changing sources and patterns of Wnt 
ligand expression and the factors controlling this would be an interesting area for further 
study. 
As mentioned above the requirement for induction of Cre to prompt loss of MDM2 in 
hepatocytes makes further tissue-specific genetic alterations difficult. Should viral 
mediated overexpression of p21 in hepatocytes produce a similar phenotype to the 
AhCreMDM2fl/fl strain, then future work could focus on functional effects of deletion of 
specific Notch receptors or Wnt receptors or mediators such as beta-catenin from the 
biliary compartment, or potential ligand expression targeted to biliary cells or other niche 
components such as fibroblasts, endothelia or macrophages. 
The output of Notch signalling is context-dependent, and the proper timing and spatial 
regulation of activation is crucial for normal embryonic developmental processes and often 
involves cross-talk with other developmental signals Wnt and Shh (155). In the adult, 
experiments on damaged muscle identified that the correct sequence of Notch and Wnt 
signal was essential for effective regeneration with this ‘molecular switch’ achieved by 
changes in phosphorylation status of GSK3b (279). I identified a similar paradigm with both 
signals influencing HPC proliferation. It is likely that Wnt is in addition responsible for the 
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migration of HPCs in vivo given the phenotypic change accompanying onset of Wnt 
signalling and the previous finding of loss of HPC migration when macrophages (and their 
secreted Wnt) are obliterated (342). This would be further supported by my observation of 
loss of migration of HPC lines exposed to Wnt but not Notch inhibition.  
Improving the generation of hepatocytes from ductular derived HPCs represents a key 
therapeutic goal. Previous work would suggest inhibiting Notch signalling in favour of Wnt 
would promote hepatocytic differentiation (123). Jors et al performed elegant experiments 
to see if conditional knock out of canonical Notch intermediary Rbpjk and over expression 
of beta-catenin could fate switch DRs during biliary injury, an injury model that normally 
does not result in generation of ductular-derived hepatocytes (58). They found no fate 
switch by altering these alleles, either alone or simultaneously, however did observe in all 
cases a loss of proliferation of affected cells, most marked in the tandem allele strain. There 
are a number of possible reasons why inhibiting Notch at the same time as over-expressing 
the Wnt pathway may result in a loss of proliferation: it may reflect a requirement for both 
these signals to be received in the correct sequence, over expression of Wnt might result in 
an excess of Notch antagonism by Numb, or even an imbalance in the IGF1/IGF1R axis.  
A previous study found Notch pathway was active in the rat 2AAF/PH model and 
administering a gamma secretase inhibitor during peak HPC response demonstrated a 
requirement for Notch in the proper regulation of differentiation of HPCs, albeit in the 
absence of direct lineage tracing (399). I also found that inhibiting Notch in a model where 
HPCs are known to differentiate into hepatocytes resulted in a significantly reduced 
number of lineage labelled HPC derived hepatocytes, rather than enhanced differentiation 
as might have been expected. This is likely to be secondary to a failure of HPC proliferation. 
This suggests that viewing only differentiation related actions of Notch would be short-
sighted and attempting to improve hepatocyte regeneration by Notch inhibition would be 
unsuccessful.   
In addition I found inhibiting Wnt in the same model did not reduce the number of HPC-
derived hepatocytes, which might have been expected if it is important for hepatocytic 
differentiation. Again this is potentially explained by interference with carefully controlled 
HPC proliferation or alternatively differing proliferation versus differentiation outputs of 
Wnt signalling. Given the experience from ex vivo differentiation protocols, it remains 
182 
 
highly likely that Wnt is required for hepatocytic differentiation (75, 77, 78). Resolving this 
may ultimately require unpicking of the differential functions of Wnt signalling and how this 
might be mediated. Previous work has suggested CBP/beta-catenin mediated transcription 
is essential for stem and/or progenitor maintenance and proliferation, whereas a switch to 
p300/beta-catenin mediated transcription is a critical step to initiate differentiation (348, 
362-364). Future work could focus on exploring the differential actions of beta-
catenin/TCF/LEF dependent transcriptional co-activators CBP versus p300 in HPCs. Using 
CBP inhibitor ICG001 I have demonstrated CBP-dependent roles in proliferation and 
migration. It may be differentiation of HPCs relates to p300 activity and permits use of the 
same signal to promote multiple phases in the regenerative response. This would be of 
particular benefit in chronic injury where newly activated DRs could be directed to 
proliferate and migrate while mature DRs are directed to differentiate. This could be 
further explored using specific p300 inhibitors, and should they be identified, p300 agonists 
may promote differentiation. 
I have demonstrated that CBP inhibition reduces IGF1 expression in HPCs but I have not 
explored any effect related to p300 activity. Wnt and IGF1 cooperate in a positive feedback 
loop with IGF1 stimulating TCF/LEF dependent transcription and both increasing the 
stability and transcriptional activity of beta-catenin (377), acting to ‘wind up’ and reinforce 
the Wnt programme. Whether this influences the balance of CBP/p300 activity has not 
been established.  
The data presented here combined with that from previous studies suggest IGF1 therapy is 
potentially beneficial to individuals with hepatocellular liver disease. Delivery of IGF1 to the 
HPC niche however is not without difficulty. Recombinant IGF1 is prohibitively expensive, 
especially when the dose and duration of therapy is considered. Systemic administration 
also carries a theoretical risk of malignancy; especially should supra-physiological levels be 
reached. Delivering direct gene transfer to the liver is another therapeutic option for future 
study, as is ex vivo manipulation of isolated HPCs to enhance IGF1 production, which could 
then be transplanted to exert a positive local effect on the endogenous response. I have 
principally examined autologous Wnt-responsive IGF1 expression of IGF1 by HPCs and 
biliary cells, however the major non-liver source of IGF1 is believed to be macrophages 
where its production is stimulated in response to colony stimulating factor (CSF)-1 (400). As 
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infiltrating macrophages have already been demonstrated to provide Wnt ligand to HPCs 
after hepatocellular injury, clearly they could also provide IGF1 and thus further promote 
the Wnt programme. This also suggests an alternative future therapeutic strategy involving 
cell therapy with engineered macrophages as an alternative to enhancing hepatocyte or 
HPC IGF1 production or systemic administration. As macrophages do not produce IGF 
binding partners the effect of secreted IGF1 is likely to be local with little systemic activity 
and so potentially carrying lower risk of inducing tumorigenesis.  
In conclusion this work describes the identification of temporally regulated Notch and Wnt 
signalling after hepatocellular injury. Following injury the DR is associated with a marked 
increase in Notch activity and inhibition of this pathway attenuates this response by 
affecting ductular proliferation. Once the reaction has developed, ductular Wnt signalling 
becomes dominant and further drives proliferation, as the effects of Notch diminish. I 
demonstrate that these signalling pathways can operate independently and cooperatively 
to drive proliferation of regenerative DRs. This work supports the paradigm of a Notch/Wnt 
permissive state within HPCs and one where both functional antagonism (for example with 
relation to differentiation via Numb) and agonism (for example proliferation via the IGF1 
axis and relative Numb resistance of Notch3) can occur. Exploration of the roles and 
interactions of these signalling systems helps identify the complex networks at play and 
identify key target pathways for the rational design of novel disease and context-specific 
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